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Mastitis is the most common and expensive health problem of dairy cattle. Its control 
and management are the main reasons for antimicrobial usage (AMU) in dairy cattle with the 
potential for the development of antimicrobial resistance (AMR), as introduced in Chapter 1. 
To limit AMU, farmers are increasingly encouraged to adopt targeted treatment decisions based 
on knowledge of the pathogens causing clinical mastitis (CM), whereby treatment of non-severe 
CM is generally recommended for gram-positive mastitis but not for gram-negative or culture-
negative mastitis. In Chapter 2 the current knowledge of mastitis pathogens and their 
management is discussed with a specific focus on treatment, and host, farm or pathogen factors 
that influence the probability of treatment success. Such knowledge, combined with the use of 
on-farm diagnostics, could contribute to reduced AMU for mastitis control. In addition, a review 
of currently available on-farm diagnostics is provided. This is followed by original research to 
investigate the performance of different tools to support targeted treatment based on the 
differentiation of gram-positive CM from other cases of CM using two different approaches.  
In the first approach, presented in Chapter 3 the aims were to conduct a laboratory-
based evaluation of the performance of a simplified slide test as a tool to differentiate gram-
positive CM from other cases of CM, and to compare its performance against a commercially 
available on-farm test that is commonly used in my area (VétoRapid). Test outcomes were 
compared to results from bacteriological culture and matrix-assisted laser desorption/ionisation 
time-of-flight mass spectrometry (MALDI-ToF MS). Milk samples (n = 156) were obtained 
from cases of severe and non-severe CM on seven farms and collected by farm personnel. After 
removal of contaminated samples (n = 23) and organisms with unknown species identity (n = 
3), the simplified slide test showed high sensitivity and accuracy (> 80%), similar to the 
comparator test. For most outcomes of interest (culture positive, Escherichia coli, or gram-
positive growth), the specificity of the slide test (85.7, 97.5 and 76.8% respectively) was higher 
than the specificity of the comparator test (57.1, 92.4 and 58% respectively). When considering 
non-severe cases of CM only and interpreting detection of gram-positive organisms as an 





the comparator (77.4% vs 60.4%) and similar sensitivity (83.9% vs 87.5%). The proportion of 
sampled CM cases, contaminated samples and gram-positive mastitis cases differed between 
farms, which affects the positive and negative predictive value, the economic value of diagnostic 
testing and its potential to reduce AMU.  
Culture-based tests have the inherent limitation of long turn-around time. Culture-
independent tests based on biomarkers of inflammation are used as a proxy for infection. If 
results of biomarker tests were pathogen-specific they could potentially be used to inform 
targeted treatment decisions with shorter turn-around times than culture. Therefore, a second 
approach presented in Chapter 4, investigated if a recognised mastitis biomarker could be used 
to differentiate mild-to-moderate gram-positive CM from other forms of CM. To detect 
cathelicidin presence two Western blot techniques (A and B) were performed using CM samples 
and healthy quarter milk samples obtained by farm personnel. As for the first approach, 
outcomes were compared to results from bacteriological culture and MALDI-ToF MS. To detect 
gram-positive bacteria technique A showed variable sensitivity (31.6-68.4%) and specificity 
(55.6-81.5%), with moderate accuracies (< 67.4%). Agreement between gels was slight (κ = 
0.109) and moderate (κ = 0.572) using exposures of 30 seconds and 5 minutes, respectively, 
demonstrating poor repeatability of technique A. Technique B showed variable sensitivity (37.5-
87.5%), low specificity (15.4-38.5%) and moderate accuracies (< 73.5%). The agreement 
between gels was almost perfect (κ = 0.9) and perfect (κ = 1) using exposures of 5 minutes and 
30 seconds, respectively, showing high repeatability of this method. When considering non-
severe cases of CM and interpreting detection of cathelicidin presence as an indicator of the 
need for antimicrobial treatment, i.e. as a marker of gram-positive mastitis, the biomarker had 
moderate-high sensitivity (75%), low specificity (30%) and low accuracy (42.9%) using the 
technique B. In healthy quarter milk samples, cathelicidin was not detected (n = 9). This 
approach showed that the biomarker failed to support targeted treatment decisions based on 
differentiation of gram-positive CM but supports its use as a general mastitis biomarker. 
Refinement of cathelicidin testing through detection of cathelicidin subtypes may improve its 
usefulness as indicator for gram-positive mastitis and treatment. Farmer needs, attitudes and 
behaviour are crucial for on-farm test uptake, as discussed in the final Chapter. Farmers want 





make it an attractive tool to target antimicrobial treatment of non-severe clinical mastitis with 
good accuracy. The short turn-around time of biomarker-based tests, allowing farmers to 
generate results and make treatment decisions between two rounds of milking, warrants further 
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1. Chapter 1. General Introduction 
Food demand is estimated to increase by half between 2012 and 2050. This demand is a 
result of population growth, increased urbanization, and per capita increase in incomes (FAO, 
2017). At the same time, we are living in an environment where natural constraints, such as 
natural resource degradation and climate change are of growing concern and putting the limited 
natural resources under increased pressure. However, satisfying these extra demands with the 
farming practices of today is likely to lead to higher competition for natural resources, increase 
greenhouse gas emissions, increase deforestation, and land degradation. There is a critical need 
to stop and reverse these environmental issues, allowing at the same time to produce food 
efficiently to meet the world needs (FAO, 2017). To respond to this increase in demand and 
address these constraints “we need to produce more with less” (Foresight, 2011). Technological 
advances allow better use of resources and higher production of extra outputs with an 
improvement in food safety. 
Mastitis, an inflammation of the mammary gland mostly caused by bacterial infection, 
is the most common and expensive health problem of dairy cattle (Ruegg, 2003). The presence 
of mastitis in dairy herds is an example of production inefficiency (Halasa et al., 2007), and 
controlling mastitis is an important way to “produce more with less”. Also, mastitis can be a 
painful disease and may affect cow welfare (Leslie and Petersson-Wolfe, 2012). Finally, mastitis 
control and management is also the main reason for antimicrobial usage (AMU) in dairy cattle 
(Pol and Ruegg, 2007b), with several consequences, including discarded milk (Ruegg, 2003), 
presence of antimicrobial residues in milk (Garcia et al., 2019) and potential for the 
development of antimicrobial resistance (AMR) (Pol and Ruegg, 2007a; Oliver and Murinda, 
2012). 
AMR is currently a critical public health issue. Today, approximately 700 000 humans 
die per year as a result of infections caused by multi-resistant bacteria (O’Neill, 2014). The 
predictions suggest that by 2050 around 10 million people will die from bacterial infections 
caused by multi-resistant bacteria if no actions are taken to reverse behaviours that are leading 





the World Health Organization (WHO) is already taking specific initiatives to prevent AMR 
(WHO, 2015). WHO identified priority pathogens that need extra caution and new strategies to 
control them, as well as antimicrobials that are considered of critical importance in human 
medicine (WHO, 2017). In 2019, WHO identified Highest-Priority Critically Important 
Antimicrobials (HP-CIA) for human medicine and discouraged usage of HP-CIA in livestock 
production (WHO, 2019; Responsible Use of Medicines in Agriculture Alliance (RUMA), 
2020). Examples of priority pathogens are Escherichia coli, Klebsiella spp., and Staphylococcus 
aureus and HP-CIA include quinolones, macrolides and ketolides, polymyxins and 3rd and 4th 
generation cephalosporins. Those pathogens and antimicrobials have all been linked with bovine 
mastitis (Klaas and Zadoks, 2017).  
Veterinarians have the role to preserve bovine udder health, guarantee animal welfare 
and prevent economic losses. In addition, veterinarians must assume their responsibility to 
combat AMR emergence and preserve antimicrobial efficacy for the time to come. There is an 
imperative for the reduction in AMU in the dairy industry. Mastitis management relies too much 
on antimicrobials (Klaas and Zadoks, 2017). Regarding mastitis treatment, there is an 
opportunity to reduce AMU and stop using HP-CIA (Turner et al., 2018; Doehring and 
Sundrum, 2019; Nobrega et al., 2020). Societal pressure to reduce AMU in farming forces us to 
improve our knowledge and to develop new mastitis management approaches that promote 
prudent AMU (OIE, 2016). This involves appropriate prescription and avoiding inappropriate 
AMU to preserve antimicrobial efficacy for as long as possible (Centers for Disease Control 
and Prevention, 2007). 
In some countries quota to reduce AMU has been implemented (Dorado-García et al., 
2016). In the United Kingdom (UK) there are no government-mandated restrictions relative to 
AMU in livestock production yet. However, to meet the requirement of food standard schemes 
dairy farmers in the UK need to undertake an annual review of AMU with their veterinarian. 
And from the 1st of June 2018, the use of HP-CIAs must be the last option and restricted to cases 
where evidence of sensitivity or diagnostic testing justifies its use (Red Tractor Assurance, 
2018). Policies like these or targets for AMU set in the Netherlands (Bos et al., 2015) are needed 





The use of selective treatment in lactating and non-lactating animals, respectively, is a 
practice that restricts AMU to cases that are more likely than others to benefit from treatment 
(Lago and Godden, 2018), or to cases most likely to have an intramammary infection at dry-off 
(Vanhoudt et al., 2018). It aims to maximize treatment efficacy, animal health and welfare, 
while at the same time promoting prudent AMU and minimizing potential selection for AMR. 
This approach is often described as selective treatment or targeted treatment. “Selective 
treatment” recommends blanket treatment to be the default option, which is modified by 
selecting cows for treatment. “Targeted treatment” suggests no treatment to be the default 
option, with the targeting of treatment to those cows that are most likely to benefit from it 
(Malcata et al., 2020). Selective dry cow treatment (DCT) is adopted in many countries 
(Vanhoudt et al., 2018), selective treatment of clinical mastitis (CM) in lactating animals is still 
a recent practice (Lago and Godden, 2018) and requires a deep understanding of different 
manifestations of mastitis and its epidemiology. Ideally, this would include knowledge of 
severity, causative agent and prognosis, so that treatment with anti-inflammatory, antimicrobial 
or supportive products are adapted to each CM case. In Chapter 2, I will review the biological 
aspects of mastitis and current treatment modalities and explore potential opportunities for 
improvements in CM treatment with less AMU. Diagnostics play an important role in such 
improvements.  
In Chapter 3, I describe a new diagnostic test that is based on culture, like most current 
assays, but which may have advantages in terms of simplicity and user-friendliness. Culture-
based tests have a long turn-around time, which is a major limitation. This limitation could be 
overcome with the use of biomarkers, which are not culture dependent. In Chapter 4, I explore 
the potential of a biomarker as a diagnostic indicator. Finally, in Chapter 5, I discuss results 
from the previous chapters with an emphasis on non-technical aspects of test uptake, such as 






2. Chapter 2. Literature review 
 
2.1 Types of mastitis 
Mastitis is an inflammation of the mammary gland, frequently caused by intramammary 
infections (IMI). Most IMI are caused by bacteria, although they can be caused by yeasts or 
algae. In rare cases, mastitis can be caused by mechanical or chemical trauma, e.g. through teat 
or udder trampling, or when cleaning liquids are mistaken for teat disinfectants. On some 
occasions, the cause of mastitis is not detected. These situations can be frustrating because of 
the difficulty to manage the disease when its aetiology is not known, or frustration about costs 
of diagnostic tests that yield negative results.  
Mastitis is characterized by physical and chemical changes in milk and, in some cases, 
by pathological changes in the mammary gland tissue or at a systemic level. The magnitude of 
the inflammatory response and the degree of change depends on the cause of mastitis and host 
factors. Clinical mastitis occurs when physical changes in milk or in the quarters can be detected 
using human senses (vision, touch, and taste, although the latter is no longer recommended 
because of health and safety concerns), whereas detection of subclinical mastitis (SCM) requires 
the use of additional tools. Most cells in milk are white blood cells, normally referred to as 
somatic cells, and somatic cell count (SCC) is used as an indicator of mastitis in cows. When 
the milk appears physically normal as judged by the naked eye, but is high in SCC, this is 
considered an indicator of SCM. 
A cow can develop CM immediately after an intramammary challenge or after a 
prolonged period of subclinical infection. After resolution of a CM episode (clinical cure), a 
quarter can return to the uninfected state or to a state of SCM and persistent IMI, which can 
flare up again in CM later on (Bradley and Green, 2001; Zadoks et al., 2003). There are three 
clinical forms of CM. In mild CM, only altered milk is detected (Wenz et al., 2001; Pinzón-
Sánchez and Ruegg, 2011). These represent between 40% and 50% of CM cases (Oliveira et al. 
Ruegg, 2013; Levison et al., 2016). Moderate CM is characterized by abnormalities in milk and 





abnormal milk, with abnormalities of the gland, and with the cow presenting systemic signs of 
illness (e.g. fever, tachycardia, tachypnoea, dehydration, decreased ruminal function or 
anorexia) (Wenz et al., 2001; Lago et al., 2011; Pinzón-Sánchez and Ruegg, 2011). IMI can 
occur in the dry period or during lactation and may manifest as SCM or CM in either phase of 
the lactation cycle. 
In the past, based on pathophysiology and epidemiology, mastitis pathogens have been 
classified as contagious, environmental or teat skin opportunists (Radostits et al., 2007). 
Contagious bacteria primarily exist within the mammary gland and are transmitted from cow to 
cow during the milking process. They are associated with persistent infections normally 
reflected by a raised SCC. This type of mastitis was a major problem in the past, however 
standard prevention programmes allowed for a reduction in their prevalence (Royster and 
Wagner, 2015). The pathogen distribution varies between countries, but Staph. aureus, 
Mycoplasma spp. and Streptococcus agalactiae are normally important contagious bacteria 
(Royster and Wagner, 2015), whereas Streptococcus dysgalactiae and Streptococcus uberis can 
be contagious as well as environmental, depending on herd management and environmental 
conditions. Environmental mastitis is caused by pathogens derived from the environment. They 
can be acquired during milking, between milkings, or without milking (e.g. by heifers and dry 
cows). The bacteria most likely to infect cows from the environment include coliforms and S. 
uberis. The cause of mastitis, particularly when caused by IMI, can rarely be detected without 
further testing. Even severe CM, often called “toxic mastitis” and attributed to E. coli, can be 
caused by S. uberis or Staph. aureus (Zadoks et al., 2000; Tassi et al., 2013). Conversely, 
coliform species can be responsible for moderate or mild CM or even SCM (Bradley and Green, 
2000). Mild-to-moderate forms of CM can also be caused by Strep. agalactiae (Simões 
Cortinhas et al., 2016). Thus, there is no absolute rule regarding different causative agents of 
mastitis and clinical severity. 
The most common outcomes when culturing milk from CM are no growth, E. coli and 
“environmental streptococci” (Bradley et al., 2007; Oliveira et al., 2013). The latter, however, 
should be referred to as “gram-positive, catalase-negative cocci”, as the genus of the organism 





and other genera (Klaas and Zadoks, 2017). Opportunistic mastitis pathogens are normally 
commensal bacteria from the teat skin that can cause mastitis after entering the udder through 
the streak canal. Non-aureus Staphylococci (NAS) are the most common bacteria from this 
group. Today, we know that the distinction between contagious and environmental pathogens 
at the species level may be misleading, instead, it should be applied at the strain level (Zadoks 
et al., 2011). Correct differentiation of epidemiology and modes of transmission as contagious 
or environmental pathogens would allow the implementation of mastitis control methods 
tailored to the farm’s situation (Klaas and Zadoks, 2017). 
Other type of mastitis, with distinct characteristics are Summer mastitis. This form of 
mastitis affects essentially dry cows and heifers in pasture, but it can also affect calves and bulls. 
This type of mastitis occurs mostly in Summer months and in temperate climates of North 
Hemisphere. In England and Wales, it has been reported to affect 39-54% of the herds with 2.1 
to 4.1 cases per affected herd (Berry, 1998). Several pathogens have been associated to this type 
of mastitis, such as Truepurella pyogenes, Peptococcus indolicus, Streptococcus dysgalactiae, 
Fusobacterium necrophorum. In acute phase animals with Summer mastitis have pyrexia, 
anorexia, with enlarged and swollen udder and teat, that may cause discomfort and altered 
mobility score. A watery secretion with clots may be recovered if the quarter is stripped. In some 
cases, animals may develop septicaemia or toxaemia. In severe cases, the quarter can become 
gangrenous or an abscess may develop, that can burst at the surface of the udder (Ahmad et al., 
2015; Blowey and Edmondson, 2010). One of the most important risk factor for this type of 
mastitis is the seasonal activity of the sheep head fly, Hydrotea irritans, a non-biting fly, that 
feeds on secretions, and is known as a vector for transmission of the main bacteria T. pyogenes 
in the teat end. Other important risk factors are trauma or damage of the teat due to poor milk 
settings, the presence of spiky plants on pasture that can cause irritation to the udder skin and 








2.2 Mastitis pathogens 
Mastitis-causing pathogens can be classified in major and minor pathogens according to 
their severity, virulence, and capacity to damage the udder. The most common major mastitis 
pathogens are Strep. agalactiae, S. uberis, Strep. dysgalactiae, Staph. aureus, Mycoplasma spp. 
and gram-negative coliforms, such as E. coli and Klebsiella spp. By contrast, Corynebacterium 
bovis and NAS are considered minor pathogens as they lack the ability to cause severe CM 
(Schepers et al., 1997; Reyher et al., 2012a), and their pathogenicity is limited to moderate 
increase in the SCC, up to mild CM, in rare occasions (Djabri et al., 2002; Pyörälä and Taponen, 
2009a). 
This distinction between major and minor pathogens is particularly important because 
SCM and mild CM caused by NAS may be left untreated (Pyörälä and Taponen, 2009a), as 
spontaneous cure rates are around 70% (McDougall, 1998; Wilson et al., 1999). 
 
2.2.1 Major Pathogens  
2.2.1.1 Gram-negative coliforms  
Coliform mastitis has been commonly associated with “environmental mastitis” and in 
practice, there is the perception that they are commonly responsible for severe CM cases. IMI 
caused by coliforms may start in the dry period as SCM and can develop into CM in early 
lactation  (Bradley and Green, 2000). Severe CM can cause bacteraemia with mastitis pathogens 
or bacteria from lungs and gut origin (Wenz et al., 2001). 
 
2.2.1.1.1 Escherichia coli    
Mastitis caused by E. coli is mostly transient with clinical presentation dependent on 
host factors (see 2.4.2.1 Host factors section), environmental hygiene (Klaas and Zadoks, 2017) 
and different strains. E. coli strains are generally commensals, but they can also be pathogenic. 
To date, the ability to cause mastitis has not been linked to specific virulence traits (Keane, 
2019), supporting that E. coli mastitis is mostly related to host factors. Mild and moderate CM 





1994; Roberson, 2012). Severe cases can develop bacteraemia (Suojala et al., 2013). On some 
occasions, E. coli IMI can be persistent with multiple episodes of CM alternated with SCM. 
Clinical mastitis caused by this pathogen is responsible for a significant decrease in milk yield 
that may last until the end of lactation (Heikkilä et al., 2018) and important negative effects on 
fertility, especially for severe cases (Lavon et al., 2019; Dalanezi et al., 2020).  
 
2.2.1.1.2 Klebsiella spp.     
 Klebsiella spp. IMI causes generally more severe clinical signs than E. coli, is 
characterized by a stronger immune response, with higher lethality (Schukken et al., 2012), 
greater risk of culling (Fuenzalida and Ruegg, 2019a), reduced rate of spontaneous cure (Pinzón-
Sánchez et al., 2011), and a tendency to become chronic (Fuenzalida and Ruegg, 2019b). Milk 
production losses due to CM caused by this genus are substantial. Multiparous cows, in 
particular, produced 4.9 Kg less milk per day in comparison with unaffected cows (Hertl et al., 
2014). Pathogenicity of Klebsiella pneumoniae bacteria in the udder is not well understood, but 
some virulence factors such as capsular serotypes, mucoviscosity-associated gene have been 
identified, and can explain some of the severity caused by IMI of this pathogen (Osman et al., 
2014). 
 
2.2.1.2. Staphylococcus aureus 
Most Staph. aureus behave as contagious organisms, however, some strains can be 
environmental (Klaas and Zadoks, 2017). Cows can become infected with their own or 
environmental strains of this pathogen (Zadoks et al., 2011). The pathogenicity of this pathogen 
and its ability to colonize the skin and mucosal epithelia, and its poor response to treatment in 
some cases (Barkema et al., 2006), make IMI caused by this pathogen a problem in the dairy 
industry (Rainard et al., 2018). Mastitis cases caused by this pathogen are commonly SCM, 
manifested with increased SCC. Most of the IMI are chronic and can persist for the entire or 
even the following lactation, with CM flare-ups with variable severity. CM cases can manifest 
with a sudden rise in SCC and acute signs of pyrexia and anorexia, even before detectable 





for few days, then the infection becomes subclinical. In some IMI, it remains as SCM and can 
spread widely among the herd mates. But on other occasions, it can be severe CM, manifested 
with per acute systemic signs and ischaemic gangrene in the quarter and teat. The severity of 
the disease is associated with host (see 2.4.2.1 Host factors section) and pathogen factors (see 
2.4.2.4 Pathogen factors section) and the spread of infections is associated with strains’ 
contagiousness and husbandry practices (Rainard et al., 2018). Chronically infected mammary 
glands are the main reservoir of Staph. aureus in herds, but it also can colonise teat and inguinal 
skin, nares and hocks (Capurro et al., 2010; Rainard et al., 2018). The bacteria are mainly spread 
by teat cup liners during the milking process, milkers’ hands and washcloths. Infections in 
heifers that did not come in contact with any milking machine can be due to flies (Anderson et 
al., 2012). Cows diagnosed with CM with this pathogen suffered a significant and long-term 
loss in milk production. The milk yield decrease is larger when the IMI occurred in early 
lactation but was similar in both CM and SCM (Heikkilä et al., 2018).  
There are generally multiple strains of this pathogen within a herd, often but not 
necessarily, with a predominance of one strain, reflecting whether its transmission is contagious 
or environmental (Sommerhäuser et al., 2003). Strains can differ in their ability to spread, cause 
CM, increase SCC, cause persistent IMM or affect milk production (Barkema et al., 2006).  
2.2.1.3 Gram-positive catalase-negative cocci 
These are commonly referred to as “environmental streptococci” or “Streptococcus 
spp.”, although this is a misnomer because the group includes several bacterial genera, including 
streptococci, enterococci and lactococci, among other pathogens. The major pathogens of this 
group are S. uberis, Strep. dysgalactiae and Strep. agalactiae. The major enterococci are 
Enterococcus faecium and Enterococcus faecalis, and the main lactococci are Lactococcus 
lactis and Lactococcus garvieae (Klaas and Zadoks, 2018). Little is known about shedding 
patterns and pathogenesis of these pathogens except for S. uberis and Strep. dysgalactiae. 
 
2.2.1.3.1 Streptococcus uberis 
 S. uberis is a common udder pathogen able to cause both SCM and mild to severe CM. 





(Pedersen et al., 2003; Milne et al., 2005; Keane, 2019). There is some evidence of strain-
associated virulence (Zadoks et al., 2003; Keane, 2019). This pathogen has both contagious and 
environmental modes of transmission (Zadoks et al., 2001; Wente et al., 2019), subject to 
geographic variations, and in the UK, most are contagious (Davies et al., 2016). It can be found 
in other sites than the mammary gland, e.g. the gastro-intestinal tract, soil, water, forage and 
insects. However, faecal shedding is needed to maintain it in the environment (Zadoks, 2007). 
New IMI may occur in lactating cows through the milking parlour, or from the environment and 
all the animals in the herd are susceptible to this form of transmission (Zadoks et al., 2003). 
There is a different ability of S. uberis strains to cause disease (Tassi et al., 2013, 2015).  
 
2.2.1.3.2 Streptococcus dysgalactiae 
Strep. dysgalactiae has been described as both contagious and environmental pathogen 
responsible for SCM and CM cases. This pathogen has been identified in the rumen, faeces, 
muzzle, tonsils, vagina, bedding and barn environment (Cobirka et al. 2020), or associated with 
teat lesions (Ericsson Unnerstad et al., 2009). Infection rates in some countries are higher during 
the summer pasture season (Lundberg et al., 2016), in other countries in the housing season 
(Olde Riekerink et al., 2007). Despite being a common mastitis pathogen, few studies have 
focused on this pathogen.  
 
2.2.1.3.3 Streptococcus agalactiae  
 Strep. agalactiae IMI is usually chronic and subclinical, with intermittent episodes of 
CM. Infections are characterized by an increase in SCC and a decrease in milk yield (Keefe, 
1997). This pathogen is highly contagious and easily transmitted from cow to cow during 
milking. With infected cows acting as a reservoir of infection and contaminating milking 
equipment and milkers’ hands (Keefe, 2012). It was considered an obligate IMM pathogen 
(Keefe, 1997), but it was found in environmental reservoirs, such as water throughs and stalls, 
or in the rectum of the cows (Jørgensen et al., 2016), and is also carried by a significant 
proportion of people (Skov Sørensen et al., 2019). Historically this pathogen has been eradicated 





regardless of the number of infected quarters – “Blitz therapy” (Erskine et al. 2003). 
Implementation of mastitis control practices resulted in elimination of this bacteria from several 
herds is western countries, but it re-emerged recently in northern Europe, probably due to 
changes in herd size, housing and milking systems, as well as the emergence of new strains with 
new epidemiological characteristics. For example, faecal, environmental, or human reservoirs 
of Strep. agalactiae may exist in some herds (Jørgensen et al., 2016; Skov Sørensen et al., 
2019).  
 
2.2.1.4 Mycoplasma spp. 
Mycoplasma spp. has been known as a mastitis pathogen since the 1960s in the US (Hale 
et al., 1962) and since then it has emerged as an important pathogen worldwide (Nicholas and 
Ayling, 2003). Because of its difficult detection through bacterial culture and the need to use 
specific culture media, its prevalence is probably underestimated (De Vliegher et al., 2012). 
Mycoplasma bovis is the most pathogenic species of the genus Mycoplasma. This organism is 
associated with mastitis and other diseases (Calcutt et al., 2018). Infected animals can become 
asymptomatic carriers and shed the organism through nasal discharge and milk for months to 
years and diagnosing these animals can be challenging. Regarding udder health, it has been 
associated with SCM, CM or chronic mastitis. In acute CM cases, the mammary gland of a 
single quarter or multiple quarters can be severely compromised, showing a serous or purulent 
exudate. CM is characterized by hard quarters, with a sudden drop in milk and failure to respond 
to antimicrobial treatment (Calcutt et al., 2018). In other cases, there are no systemic signs of 
disease, and clinical presentation is limited to a mucoid discharge or signs of arthritis or even 
abortion. M. bovis is very contagious and transmission is generally by aerosols. Transmission 
can occur at milking time from a reservoir, the infected udder; via fomites, hands of a milker, 
milking unit liners, or udder washcloths (Fox, 2012). Calves can also be infected by ingesting 
milk from infected cows or during foetal development if the dam was infected. Semen can also 
transmit the organism, via artificial insemination (Haapala et al., 2018) or using an infected 
breeding bull (Gille et al., 2018). Bedding can also be a source of infection (Piccinini et al., 





from external herds are risk factors for outbreaks of this disease (Punyapornwithaya et al., 2011; 
Calcutt et al., 2018).  
2.2.2 Minor Pathogens 
IMI by minor pathogens result in minor or absent damage to the bovine mammary gland 
with a minor inflammation, detectable by low increase in SCC (Reyher et al., 2012a). However, 
milk production losses by these pathogens should not be neglected (Heikkilä et al., 2018). The 
relative importance of minor pathogens depends on the prevalence of major pathogens, and milk 
quality standards in the region or country (Schukken et al., 2009). An important aspect is that 
the presence of these pathogens (NAS and corynebacteria) at the teat end may protect against 
infection with major pathogens (Reyher et al., 2012b). 
 
2.2.2.1 Corynebacterium bovis 
Corynebacterium bovis is regarded as a minor pathogen that causes a mild increase of 
SCC, rarely associated with CM, and if CM occurs, cases are normally mild (Hiitiö et al., 2016; 
Heikkilä et al., 2018) and with limited decreased yield (Heikkilä et al., 2018). This pathogen 
has been considered as a colonizer of the teat canal (Bexiga et al., 2011) but was detected in 
similar numbers when milk samples were collected via the teat canal or directly from the udder 
cistern (Heikkilä et al., 2018). Some authors reported that this pathogen can have an important 
protective role against IMI caused by other pathogens (Rainard and Poutrel, 1988), whereas 
other authors report an association with an increased risk of mastitis (Berry and Hillerton, 2002). 
Conflicting results may be due to differences between experimental studies and field 
observations (Reyher et al., 2012b). Another possible explanation for this polarization of 
opinions is that the protective effects of this pathogen are probably masked because glands with 
IMI are innately susceptible to repeat infections irrespective of the protective effect of 






2.2.2.2 Non-aureus staphylococci 
Non-aureus staphylococci are the most frequently isolated bacteria that cause IMI, but 
they also colonize the teat-ends and can be detected in cows’ faeces (Wuytack et al., 2020). 
They are generally considered a group of minor pathogens that may include more than 20 
different species. The most commonly detected species include Staphylococcus chromogenes, 
Staphylococcus simulans, Staphylococcus xylosus, Staphylococcus haemolyticus, 
Staphylococcus epidermidis and Staphylococcus hyicus. There are conflicting results regarding 
their importance, and there are variations in virulence among species and strain (Vanderhaeghen 
et al., 2014). Some might be due to identification issues because identification of these bacteria 
at the group level rather than species level has been a standard procedure in both diagnostics 
and research (Supré et al., 2011). IMI by these pathogens generally results in SCM with 
moderate SCC increase or mild CM. This might be related to a low bacterial load in the milk 
probably illustrative of the low colonization level of the mammary gland. Clinical signs differ 
among different NAS species and among studies, which is partly due to different study designs, 
species under investigation and methods for species identification (Vanderhaeghen et al., 2014). 
In an experimental study, Staph. simulans infection caused higher SCC than infections by Staph. 
epidermis (Simojoki et al., 2011). Staph. simulans and Staph. chromogenes caused SCM and 
CM in approximately equal proportions and no species was noted to be significantly different 
in terms of severity or clinical presentation (Taponen et al., 2006). Staph. chromogenes was the 
most prevalent species in CM (Zadoks and Watts, 2009; De Visscher et al., 2016; Condas et al., 
2017). Staph. hyicus has been more commonly associated with CM than SCM (Persson Waller 
et al., 2011). An important aspect is that IMI or teat apex colonization by NAS may have a 
protective effect on udder health, although the protective effect varied among studies. In 
observational studies, the IMI with these minor pathogens had no protective effects against 
major pathogens. Contrary to that, in challenge studies, their protective effect was significant 
and particularly when major pathogens were introduced into the mammary gland via methods 
bypassing the teat end (Reyher et al., 2012b). These effects were higher for IMI by NAS than 
for C. bovis IMI (Reyher et al., 2012b). The protective effect of teat apex colonization by NAS 
was shown in heifers, specifically against IMI caused by major pathogens in early lactation 





quarters at the beginning of lactation from having SCC above 200.000 cells/ml, and  influence 
the entry of major pathogens (Vliegher et al., 2003) There is a knowledge gap in how these 
bacteria cause IMI and disease. A recent study of more than 190 genes in 25 NAS species 
demonstrated that suspected virulence factors are generally not associated with disease severity. 
The severity of mastitis caused by these bacteria is associated with an increased number of toxin 
that these bacteria produce and host immune evasion genes (Naushad et al., 2019). 
Mastitis management approaches to decrease mastitis incidence by improving measures 
to prevent infection can help to reduce AMU in dairy production (Klaas and Zadoks, 2017). 
 
2.2.3 Other pathogens 
Prototheca spp. is an environmental alga, that causes mastitis and is associated to poor 
milking hygiene and contaminated water. It has been recognized in multiple countries and its 
incidence in dairy herds is increasing Worldwide. Prototheca spp. can spread from cow to cow 
like contagious pathogens if there are chronic infected animals in the herd (Jagielski et al., 2019). 
They are refractory to antibiotic treatment (Roberson, 2012). 
Yeasts are organisms ubiquitous in the environment which are considered opportunistic 
pathogens of the mammary gland, causing mastitis when immunity is impaired. Sources of 
infection include the skin of the udder, udder secretion, milkers’ hands, milking machines, 
treatment instruments, floor, straw, feed, dust, soil and sanitizing solutions. Mastitis caused by 
yeasts can become persistent and subsequently culling of these animals is the only option 






2.3. Mastitis prevention 
In a context of societal pressure to reduce AMU and to maximize production in dairy 
farms, the adoption of preventive practices targeting the host and the environment to reduce the 
emergence of new IMI and the transmission of mastitis-causing bacteria (MCB) are becoming 
more common. 
 
2.3.1 Host  
A way to prevent mastitis is to select cows with characteristics that offer them more 
resistance to mastitis. Cows’ teats are the first barrier against the entry of bacteria and selecting 
for characteristics such as the amount of keratin present (Capuco et al., 1992), lower peak flow 
rate (Rupp and Boichard, 2003), or longer teat canal length (Hillerton and Lacy-Hulbert, 1995) 
reduce the risk of mastitis. Some of those characteristics, e.g. low peak flow rate, may not fit 
well in modern milking practices. Another way to prevent mastitis is to select sires with high 
breeding values for mastitis characteristics, such as udder conformation, SCC data and CM data. 
This means that the progeny of this animal will be more resistant to mastitis (Rupp and Boichard, 
2003). 
Another strategy to prevent mastitis is to increase cows’ immunity. This can be done 
using an effective vaccination. Regarding Staph. aureus vaccine, several studies have been 
conducted and there is no commercially available vaccine for which there is convincing 
evidence of sufficient protection to justify its use (Rainard et al., 2021). Some evidence showed 
that a commercial vaccine reduces the chances of transmission (mostly in first lactation animals) 
and improves the chances of cure (Schukken et al., 2014), however other studies did not reach 
the same conclusion (Landin et al., 2015). E. coli vaccine has also shown good results and is 
capable of reducing CM severity and milk yield losses. This vaccine even offers some protection 
against culling in cows with Klebsiella spp. mastitis (Bradley et al., 2015). Recently, a S. uberis 
mastitis vaccine was launched, and this vaccine administered in the pre-calving period was able 
to reduce CM severity and milk yield losses in an experimental challenge. Further studies are 





To adopt more specific strategies targeting the host, particularly for environmental 
mastitis, it is important to determine whether CM that occurs in early lactation is due to IMI that 
occurs during the dry period or during lactation. If IMI occurs in early lactation, nutrition may 
be inadequate. Good nutrition management can give cows more resistance to mastitis, allowing 
their immune system to combat better any IMI. It is important to have feed composition 
consistency, supply enough vitamin E and selenium, particularly when feedstuffs are grown in 
soils deficient in these elements or when animals are consuming stored forages (Smith et al., 
1997). Body condition score at calving is also important to avoid important negative energy 
balance and clinical or subclinical ketosis, which impairs udder defences (Suriyasathaporn et 
al., 2000). If IMI has dry period origin, it is important to review DCT protocols and dry cow 
nutrition and hygiene. DCT was initially developed to allow long-term treatment of existing IMI 
without the need to discard milk (Neave et al., 1969) and has subsequently been recommended 
as a tool to prevent new dry period infections in herds with low IMI prevalence (Schukken et 
al., 1993). 
However, this practice has high AMU and, although the relationship between AMU and 
the development of AMR in mastitis bacteria is complex and unclear, there is a potential 
selection for AMR. Therefore AMU in non-infected quarters is not necessarily a prudent use of 
antimicrobials (Scherpenzeel, 2017). In non-infected quarters usage of internal teat sealants 
(ITS) at dry-off prevents IMI during the dry period and has a protective effect on the incidence 
of new CM cases (Rabiee and Lean, 2013). In some studies, the use of ITS was as effective as 
DCT with antimicrobials in preventing new IMI (Huxley et al., 2002). Is important to make it 
clear that if there are any existing IMI, ITS alone would not resolve them. 
 
2.3.2 Environment  
Environmental mastitis has become relatively more prevalent, whereas contagious 
mastitis has become relatively less important in dairy herds in the last decades due to the 
implementation of mastitis prevention programs. Cows’ skin has Staph. aureus and NAS. Cows’ 
faeces can contain S. uberis (Zadoks et al., 2005), E. coli and Klebsiella spp. (Munoz et al., 
2006) and, occasionally, Staph. agalactiae (Jørgensen et al., 2016; Cobo-Ángel et al., 2018). 





Zadoks, 2017). Alleys, traffic lanes, water troughs, outdoor environments, and bedding, when 
contaminated with faeces are sources of MCB. Barns and milking parlours for lactating cows as 
well as heifer or dry-cow barns should be kept as clean and as “free” as possible from MCB. 
Improving hygiene, however, requires time and effort, and the economic margins in dairy 
production are often so narrow that such effort is compromised. 
Measures such as flies control using pour-on synthetic pyrethroids directly on the udder 
and teats in high risk period and high risk areas, use of teat sealant and good pasture management 
are important to control and prevent Summer mastitis (Ahmad et al., 2015; Blowey and 
Edmondson, 2010). 
 
2.3.3 Milking parlour 
In the milking parlour, the contagious transmission of MCB can be controlled through 
good milking parlour hygiene, early identification, and segregation of animals with IMI, 
treatment or culling of infected animals, and application of products or tools that reduce the 
probability of transmission, such as teat disinfectants. 
Milking machine settings can account for up to 20% of new IMI (Mein, 2012). It is 
important to have a regular service of the milking machine, make sure that the vacuum is set 
correctly, avoiding liner slips, air suction and overmilking. Overmilking, which can be due to 
machine or operator error, can be responsible for teat-end hyperkeratosis which depletes cows’ 
teat end defences and increases the incidence of mastitis (Pantoja et al., 2020). Vacuum 
conditions may vary between clusters and liners, if not correctly adapted (Pyörälä, 2002) may 
be responsible for liners slips and air suction, which affects milking performance and teat 
condition (Besier and Bruckmaier, 2016).  
Using teat-dips before and after milking reduces the incidence of IMI caused by 
environmental mastitis pathogens, and the incidence of IMI caused by opportunistic and 
contagious mastitis pathogens, respectively (Enger et al., 2016). In Europe, the use of pre-dips 
containing disinfectants to reduce bacterial load prior to milking is rare or prohibited because of 





pre-milking routine is adopted, it is important to monitor the efficacy of the procedure. If 
disinfectants are applied to dirty teats, they won’t work (Munoz et al., 2008). Milkers’ hands, 
udder cloths and teat-dips can be sources of MCB (Klaas and Zadoks, 2017). Serratia spp. 
outbreaks have been associated with unhygienic handling of teat-dip (Muellner et al., 2011) and 
unhygienic teat wipes have been a source of Pasteurella spp. (Klaas and Zadoks, 2017). Post-
milking teat dips can reduce new IMI by 50%, however, it should be done every milking and 
must have a disinfectant with effective germicide action (Pankey et al., 1984). Another indirect 
benefit of teat dips is that they can help to maintain and preserve a healthy teat skin. 
Nevertheless, in some parts of the world, in winter conditions post-dips should be carefully 
managed, as they can do more harm than good if there is a risk that they can cause frostbite. In 
this context, some powder-based teat dips or temporary discontinuation of teat dip use may be 
a preferred management option. However, there are no one-fits-all solution, as a change in 
dipping routine can result in a decrease in mastitis prevention against some type of pathogens 
but may result in an increase in others (Morrill et al., 2019).    
Automated milking systems are becoming more common worldwide; they are replacing 
traditional milking in the parlour due to labour shortages and have the potential to increase milk 
production by increasing milking frequency. Regarding mastitis control, automatic milking 
systems can have limitations with mastitis detection and teat cleaning procedures, which have 
been improved in recent years, through the improvement of equipment and operational settings. 
Automatic detection using sensors and machines also offer some advantages because they check 
every cow, every quarter and the milk produced. People often do not do that, and generally, 
machines are better than people at detecting changes in colour, milk temperature, and 
conductivity. Furthermore, these systems milk at quarter level avoiding overmilking or reducing 
the risk of cross-contamination among quarters of the same cow during the milking process and  
record a large amount of data that can be used to adopt strategic interventions (Hogenboom et 
al., 2019). Shifting from conventional milking to automatic milking is generally associated with 
a deterioration of udder health performance, however careful interpretation of the origin of these 
problems is needed because the changes that occur are often broader than the milking system, 
and often include housing and laneway changes which can also affect udder health (Penry, 





udder hair, correct machine settings and cleaning, and milking intervals adapted to each animal’s 
stage of production, can help to mitigate these challenges. Is important to not forget that despite 




Used and unused bedding can be an important reservoir for environmental pathogens 
when contaminated with bovine faeces (Klaas and Zadoks, 2017). Different types of bedding 
are associated with different bacterial growth. Sawdust can be a source of Klebsiella spp. 
mastitis, but this type of mastitis can occur with any bedding material after faecal contamination 
has occurred (Ericsson Unnerstad et al., 2009; Verbist et al., 2011). Straw and peat can be a risk 
factor for S. uberis mastitis (Ericsson Unnerstad et al., 2009). Composted bedded packs were 
associated with Klebsiella spp. outbreaks (Klaas and Zadoks, 2017). Recent research indicates 
that if this bedding is well managed by keeping the pack dry and the cows clean, and with the 
use of excellent teat preparation, it can be used with minimal effects on udder health (Leso et 
al., 2020). Recycled manure solids are a rich source of nutrition for bacteria, even if they were 
free from coliforms before use. There is some concern that the use of recycled manure solids 
may contribute to AMR, and this may need further investigation (Leach et al., 2015; Klaas and 
Zadoks, 2017). Inorganic bedding like sand can be a good option to reduce the environmental 
load of opportunistic pathogens, although faecal contamination will turn sand into a partially 
organic bedding material. Frequent cleaning of barn alley floor helps to improve cow hygiene 
(DeVries et al., 2012), and proper alley scraping can make a difference between clean and dirty 
udders (Magnusson et al., 2008). 
  
If these preventive measures fail, an animal can develop IMI and CM, and to ensure 
animal welfare and reduce the economic impact of this disease, mastitis treatment options need 






2.4. Mastitis treatment 
Mastitis is the most common reason for AMU in dairy farms (Pol and Ruegg, 2007b), 
as it is the most common bacterial disease and farmers believe that antimicrobials are important 
for the success of the treatment (Swinkels et al., 2015). However, AMU may lead to AMR, and 
high antimicrobial usage in livestock production has been critically questioned (WHO, 2015). 
Some countries, particularly in Northern Europe adopted regulations and restrictions on AMU 
several decades ago, e.g. a veterinarian must be consulted before starting a mastitis treatment 
(Wolff et al., 2012). In other countries, e.g. The Netherlands, a reduction in AMU was enforced 
in recent years (Bos et al., 2015). In the UK, antimicrobials are prescribed by veterinarians, but 
in mild and moderate CM cases farmers make their own treatment decisions. However, there 
are food standard schemes where the farmer is required to have an annual review of AMU with 
his or her veterinarian to provide guidance for responsible AMU (Red Tractor Assurance, 2018).  
To preserve antimicrobial efficacy and safeguard human health, strategies that promote 
and ensure prudent use of antimicrobials in animal agriculture, including dairy production, are 
needed (Trevisi et al., 2014; O’Neill, 2016). To reduce AMU, selective or targeted treatment 
can be used in lactating cows with CM (Lago et al., 2011a,b; Vasquez et al., 2017; McDougall 
et al., 2018).  
Treatment of CM during lactation differs between countries and farms. Ideally, it should 
be based on CM severity, and knowledge of causative pathogens and susceptibility profiles at 
cow or herd level. Mild and moderate CM treatment generally consists of the application of 
intramammary (IMM) antimicrobial ointment through the teat canal (Steeneveld et al., 2011), 
possibly with concomitant administration of non-steroidal anti-inflammatory drug (NSAID) 
(McDougall et al., 2009). IMM antimicrobial treatments are prescribed to eliminate the 
pathogen from the cow or at least from the quarter, whilst NSAIDs are administered to control 
inflammation and manage pain. Parenteral antimicrobial are generally recommended in severe 






Despite all the protocols and treatments available, there is no panacea regarding CM 
treatment. However, it is known that some cases are more likely to cure than others, and in some 
cases, probability of cure is so low that antimicrobial treatment may not be justified. Before 
developing this argument, is important to understand how CM cure can be defined and assessed.  
 
2.4.1 Measures of cure 
Treatment success and “cure” are often used interchangeably, although they do not mean 
the same. Cure does not necessarily need to be preceded by treatment as it can occur 
spontaneously. Clinical cure is based on CM detection and it occurs when milk and udder return 
to their normal aspect (Oliveira et al., 2013). This type of cure is often used by farmers as the 
perceived treatment success, but it has limitations as CM can revert to SCM, detectable by 
elevated SCC or the presence of MCB in milk samples taken after treatment (Pinzón-Sánchez 
and Ruegg, 2011). Another measure of cure is the bacteriological cure (Degen et al., 2015), 
which is associated with IMI detection and is defined as the absence of MCB in the milk sample 
taken 14 to 21 days after a previous milk sample where a MCB was detected, although different 
authors may use different test numbers or intervals for evaluation of bacteriological cure 
(Barkema et al., 2006). Clinical cure and bacteriological cure are thus different outcome 
measurements, focussing on clinical signs and IMI, respectively. They can occur as a result of 
treatment or spontaneously and occur simultaneously or not. The bacteriological cure is 
probably harder to measure objectively, and not practical or economically viable to evaluate as 
an outcome measure of cure on-farm. However, bacteriological cure is often very important in 
research and used as the gold standard test. Another relevant measure in mastitis management 
is treatment success. In contrast to cure, this must be preceded by treatment. Examples of 
measures of treatment outcome are bacteriological and clinical cures, number of days milk is 
not saleable, recurrence of CM, retention of the animal within the herd, SCC, milk production 
(Pinzón-Sánchez and Ruegg, 2011).  
Another important aspect to take into consideration is that dairy farming is an economic 
business. This has led to the concept of “economic cure”, which is when the benefit of treatment 





treatment decisions from the economic perspective of the business (Barkema et al., 2006). 
Understanding these outcomes is important to make adequate management decisions and better 
understand the factors that influence treatment success. 
 
2.4.2 Mastitis Management 
Mastitis can be managed in multiple different ways which will depend on farmers’ 
desired outcomes and may differ between countries and production systems. Selective CM 
treatment based on information from factors that affect treatment efficacy (host, herd, treatment 
and pathogen) will help to inform which CM are more likely to benefit from treatment. In other 
words, there is an opportunity to restrict AMU to CM cases where the spontaneous cure is 
significantly less than the expected treatment cure rate. Management of CM with protocols helps 
to simplify this task. In the following section, management recommendations to reduce AMU 
and increase treatment efficacy, without jeopardizing animal welfare and animal health, while 
trying to minimize costs will be presented based on literature. Management protocols should 
include the best evidence-based practice and adapted to each farm’s characteristics. They should 
be periodically monitored, reassessed and modified as needed (Roberson, 2003).  
After detecting a CM case, it is important to severity score each CM case, because severe 
and non-severe CM, which encompasses mild and moderate CM, are managed differently. If 
possible, information on the host and the pathogen should be considered to implement targeted 
or selective treatment (Roberson, 2012). When is not possible to adopt treatment decisions based 
on knowledge of the causative pathogen, treatment should be supported with available 
information from the cow (see section: 2.4.2.1 Host factors), and from the herd (see section: 
2.4.2.2 Herd factors). This knowledge would help to choose the treatment approach adapted to 
cases that are most likely to benefit from treatment and reduce AMU by minimizing non-
essential AMU. If antimicrobial treatment is not indicated, other cost-effective management 
options (as seen in previous section:2.3.1 Host) should be considered to minimize unnecessary 






2.4.2.1 Host factors  
There are several factors at the host or quarter level that can affect the probability of a 
CM case to cure. This knowledge can be used in the decision-making process of CM treatment. 
After detecting CM in an individual animal, severity scoring must be used to differentiate CM 
cases in mild, moderate and severe (see section: 2.1 Types of mastitis), because severe cases are 
emergencies and should be treated immediately using the supportive treatment and parenteral 
antimicrobial (Roberson, 2012; Suojala et al., 2013; Ruegg, 2017). By contrast, mild and 
moderate CM are not emergencies, and antimicrobial should not be administered until a cow’s 
medical history and characteristics are reviewed, to identify animals that are likely to benefit 
from antimicrobial treatment. Questions and information regarding the cow need to be 
considered, such as “Is it a new case of CM or relapse?”, “How many quarters are affected?”, 
“What is the cow’s stage of lactation, pregnancy status, and production value?”, “Are there any 
other concomitant health problems?”  
Increasing parity has been described in several studies to be associated with a low 
probability of cure. Studies on mastitis caused by Staph. aureus reported chances of cure in 
heifers and in older animals between 57-92% and between 27-67%, respectively (Pyörälä and 
Pyörälä, 1998; Taponen et al., 2003a). Pinzón-Sánchez and Ruegg, (2011) reported a higher 
cure proportion in cows with low parities (≤ 3) (between 81-89.5%) than in cows with higher 
parities (60.7%). Adult cows, in third or greater lactation, are also 15.4 times more likely to have 
CM recurrence in any quarter than heifers (Pinzón-Sánchez and Ruegg, 2011). Parity affects the 
probability of cure from S. uberis CM in a similar manner (Samson et al., 2016). A possible 
explanation for low cure rates in older animals includes a larger mammary gland size and larger 
volume of tissue to be cleared out, whilst a standard antimicrobial dose that is used for any udder 
size, and thus lower dose of antimicrobial per unit of udder volume in these animals (Barkema 
et al., 2006). Another possible explanation, albeit without scientific evidence, is that older 
animals’ immunity decreases with the age, a phenomenon known as immunosenescence, the 
gradual deterioration of the immune system brought on by natural age advancement  (Samson 
et al., 2016). Increased parity has also been described to be a risk factor for new dry period IMI, 





4 or greater had 4.2 times higher risk to have a CM within 120 days in milk (DIM) of the 
following lactation than quarters from cows of parity 2 (Pantoja et al., 2009).   
Higher SCC before the development of CM is also associated with lower chances of cure 
(Bradley and Green, 2000; Pinzón-Sánchez and Ruegg, 2011), reported in specific studies on 
Staph. aureus (Owens et al., 1988) and on S. uberis mastitis (Samson et al., 2016). According 
to Bradley and Green (2009), the mean predicted probability of bacteriological cure after 
treatment when SCC before treatment was < 200.000 cells/ml is 40%; this value can decrease 
to 27 and 22%, if the SCC before treatment was between 200.000 to 800.000 cells/ml or above 
800.000 cells/ml, respectively. History of high SCC is also associated with a probability of cure. 
Animals with 2 monthly milk recordings with SCC below 200.000 before treatment have a 
higher probability of cure than animals with multiple monthly milk recordings with high SCC 
for Staph. aureus (Barkema et al., 2006) and S. uberis (Samson et al., 2016). In situations with 
chronically elevated SCC in the previous lactation or more than four consecutive monthly milk 
recordings with high SCC in the current lactation, antimicrobial treatment may not be justifiable 
(Ruegg, 2017). The periods of increase in SCC may indicate that cows are chronically infected 
before the development of the CM, and generally, chronically infected cows have a lower 
response to treatment (Melchior et al., 2006). Similarly, a longer duration of IMI for Staph. 
aureus as shown by consecutive culture-positive samples has been proven to influence cure rate 
(Sol et al., 1994, 1997). This might be explained by fibrosis formation in udders with S. uberis 
IMI (Thomas et al., 1994) and fibrosis and micro abscess formation in cases of Staph. aureus 
IMI (Erskine et al., 2003).  
Animals with a history of previous CM cases in the same lactation are less likely to 
experience bacteriological cure than those without prior CM (Pinzón-Sánchez and Ruegg, 2011; 
Samson et al., 2016). In Pinzón-Sánchez and Ruegg, (2011) study the proportion of the first 
case of CM that resulted in cure were higher (86.5%) than the proportion of cases that were 
preceded by a previous CM case (51.9%). Therefore, animals that have a history of repeated 
treatments (more than 3) in the same lactation or animals that are concomitantly affected with 
other chronic diseases may not benefit from additional antimicrobial treatment (Ruegg, 2017). 





for the development of CM at the beginning of the following lactation and also was associated 
with SCC status at the dry period (Pantoja et al., 2009). That study followed several multiparous 
cows that experienced at least 1 case of CM in the previous lactation. It found that these animals 
were 4.2 times more likely to experience a CM case in the first 120 DIM of the following 
lactation than cows that completed the previous lactation without CM cases. This same study 
also reported that quarters that have high SCC at dry-off  (SCC ≥ 200.000 cells/ml) were 2.7 
times more likely to have a CM case in the first 120 DIM of the following lactation that quarters 
with low SCC at dry-off  (SCC < 200.000 cells/ml) (Pantoja et al., 2009). 
Probability of cure from Staph. aureus IMI is reduced when multiple quarters are 
infected (Sol et al., 1994; Osterås, Edge and Martin, 1999). Factors contributing to this may be 
the duration of infection, which is probably longer when multiple quarters are infected, the need 
to achieve cure in each quarter before the cow is cured, and the risk of within-cow transmission 
of the pathogen resulting in re-infection (Zadoks et al., 2001). Mastitis in hind quarters is less 
likely to cure than front quarters, possible due to the volume of the gland, similar to the situation 
in older versus younger cows (Barkema, Schukken and Zadoks, 2006).  
Several aspects will influence the economic benefit of a treatment, e.g. regulatory limits 
for bulk milk SCC, milk price, quality premium payments and penalties, labour costs, and quota 
systems for milk production or AMU. To optimise economic cure, such factors should be 
combined with cow history and cow characteristics that influence the probability of cure and 
information regarding animal’s value. Milk yield (Pinzón-Sánchez and Ruegg, 2011a), 
reproduction status (Lehenbauer and Oltjen, 1998), milk quota situation of the farm, availability 
of replacement heifers (Steeneveld et al., 2011) and retention pay-off value (Groenendaal, et 
al., 2004) are important measures to inform decision making. Animals that are not expected to 
benefit from antimicrobial treatments based on their history or based on milk culture results and 
information of mastitis causing-pathogen (see 2.4.2.4 Pathogen factors section) can be managed 
with different options, which are culling, watchful waiting, dry-off of the affected quarter, early 
dry-off the cow, or segregation of the cow. Culling the cow is another approach, and the animal 
is removed from the herd because of sale, slaughter or salvage (Fetrow et al., 2006). Watchful 





given to manage cow comfort. In this approach, milk is discarded until it returns to normal and 
animals’ clinical progression is monitored. The watchful waiting should be applied for animals 
where the probability of spontaneous cure is high e.g., no history of previous CM, three 
consecutive milking records with SCC below 200.000, low parity, and non-severe CM (Ruegg, 
2017).  
In animals that have a single quarter with CM, with consecutive repetitive treatment 
failures, but still good milk yield in the other quarters, the affected quarter can be dried-off. 
With this approach, animals keep producing milk, normally 15% less (Steeneveld et al., 2011). 
This might be a good approach when the economic and vital prognosis of the animal is not 
compromised, or for animals with high breeding value. With this approach, there is a decreased 
risk for the development of AMR and the animal can finish its lactation.  
Early dry-off of the cow rather than the quarter is another option, particularly in a high-
value pregnant cow with chronic SCM or CM. Early dry-off occurs when a pregnant animal is 
dried off more than 60 days before its due date. This approach is normally indicated for high 
value and high merit pregnant cows that have chronic CM or chronic SCM. Especially when 
segregation is not an option, which would reduce the risk of transmission within the herd, these 
animals can be dried-off earlier than usual. Segregation, i.e. separation of chronically infected 
animals from healthy animals is another option, particularly in farms where culling is not 
feasible due to economical constraints. These animals should be milked last, and milk should 
be discarded. They are candidates for future culling and should not be eligible for breeding 
(Ruegg, 2017). 
For animals that are late in lactation and not pregnant, or lame, or that have other health 
problems or with low yield, culling may be considered (Royster and Wagner, 2015). In these 
animals, vital and/or economic prognostics are reduced and culling instead of treating CM may 
be a profitable option.  
Culling is a decision that requires a balance in the herd to have economic animal health 
benefits. Poor culling management would allow the retention of older animals, lower producing 





and therefore retention of animals more likely to require extra AMU. However, if culling rates 
are too high this will shift the balance towards a greater number of younger, and healthier 
animals (De Vries, 2017). This can be positive in terms of reduction in AMU and managing 
udder health as an example of animal welfare. However, it raises societal concerns and ethical 
issues regarding environmental sustainability, climate change and animal welfare by decreasing 
animal longevity. Mature cows have higher milk yield, and heifers emit considerable amounts 
of greenhouse gases during the 2 first years of life when they are unproductive. Thus, decreasing 
culling rates by increasing the longevity of the herd increases environmental sustainability and 
is also associated with improved animal welfare and improved consumer perceptions of the 
dairy industry. This latter aspect is of extreme importance for the dairy sector. The market is 
regulated by consumer demands, and if there is a considerable shift away from the consumption 
of dairy products this may have ruinous consequences in the sector (Schuster et al., 2020). In 
heifers, culling decisions are more difficult to make and treatment of CM is often recommended, 
because treatment in these animals has higher probability of cure, and the return on the 
investment in raising these animals is still to come (Barkema et al., 2006). 
 
2.4.2.2 Herd factors 
The biology of CM in dairy cattle has not changed much over recent decades, although 
developments in genetics and at husbandry levels have led to significant changes in the 
predominant pathogen populations in developed countries (Barkema et al., 2015). This has led 
to a decrease in the prevalence of contagious mastitis and a relative or absolute increase in the 
incidence of environmental mastitis (Klaas and Zadoks, 2017). In response udder health control 
programs need to focus more on the prevention of mastitis caused by opportunistic bacteria that 
reside in the environment often recognized as more complex than the control of mastitis caused 
by contagious pathogens. Herd data such as previous cases of CM, bulk tank SCC, individual 
test-day SCC, incidence, and prevalence of SCM, etc. continue to be a valuable parameter to 
measure, monitor and adopt strategies to manage and control mastitis at the herd level, based on 
simple epidemiological principles. They enable the identification of the predominant bacteria, 
to understand the most common modes of transmission and to categorize the herds as 





or lactating period origin. They allow to identify risk factors for transmission, offer an 
opportunity to reduce AMU, by allowing earlier review of the efficacy of treatment and control 
plans, and adoption of specific measures to prevent infection, or even to establish a prognosis 
before treatment decision. Usage of these records on the farm is still far from optimum, and in 
this section, some opportunities to improve record collection and assessment, as well some herd 
management changes to reduce AMU will be discussed. 
Environmental mastitis problems often manifest as an increased number of cases of CM, 
rather than an increase in bulk milk SCC. CM data are of particular importance in herds where 
BTSCC are below 200.000 cells/ml, and if CM data is not recorded or available, just relying on 
bulk tank SCC may lead to the false impression that there are no udder health problems, as it is 
a good indication of SCM prevalence but not for CM because milk from animals with CM must 
be withheld from the tank.  
CM records are often incomplete, as CM detection and recording can be difficult and 
subject to multiple barriers. Detection often requires milking personnel to modify their routines, 
it may slow down the milking process, or it may require employing an extra person in the 
parlour. Detection of an excessive number of CM in some circumstances can result in negative 
consequences for the milking staff, discouraging them from reporting CM cases that they have 
observed, and definitions may vary among farms and farm staff. Also, there can be confusion 
about the time between observations and when to consider a case to be a new case rather than 
the continuation of a previously observed CM case (Ruegg, 2003). 
Information regarding the stage of lactation of each CM or SCM identifies high-risk 
period for infection and gives guidance in therapeutic decisions. Half of the enterobacterial CM 
cases that occur within the first 100 DIM arise in quarters that were already infected during the 
dry period (Bradley and Green, 2000). Thus, the association between dry-period IMI and 
lactational CM suggests that prevention of IMI during dry-period by reducing exposure to 
pathogens is important. The severity of CM is rarely recorded but such data can offer value in 
monitoring pathogen shifts. In a herd where most cases are caused by Gram-negative pathogens, 
a greater proportion of severe cases are expected. Mild cases have value in assessing the 





SCC records can help to reduce AMU in the herd is in their usage to support treatment decision 
of SDCT (Scherpenzeel et al., 2014).  
 Monitoring SCM is important because mastitis often fluctuates between SCM and CM. 
A cow with SCM is more likely to develop CM than uninfected cows (Pantoja et al., 2009). 
Information about lactation-average SCC and bulk tank SCC is used in mastitis control 
programs to improve milk quality related to SCM and is frequently available through milk 
collection. Individual test-day SCC patterns offer multiple advantages over bulk tank SCC. They 
can be used to monitor SCM in different cohorts (by lactation, DIM, age, and location of the 
dairy). Analysing monthly patterns of these selected cohorts can offer insight into areas needing 
investigation. Examples of such indices include the prevalence of SCM for first lactation and 
older cows; dynamics of intramammary infections across the dry period; the rate of new 
infections during lactation; and proportion of animals that are chronically infected. They are 
also very useful to monitor cure, assess CM, SCM and dry cow treatment (Rhoda and Pantoja, 
2012), which can be used to identify and target specific management decisions to each animal 
such as segregation, culling, and treatment. Periodical milk recording offers the opportunity to 
capture long-term outcomes of mastitis treatment in a convenient and affordable way (Samson 
et al., 2016). For CM and SCM treatment during lactation, monitoring SCC patterns is important 
to observe whether the current treatment protocols are adequate. This data can also be used to 
assess prognosis (see host factors), e.g. a review of SCC history that precedes a CM episode can 
inform the probability of cure for CM. It also can be used to inform treatment-decision, by 
providing some insight into the most likely aetiology that is causing the IMI and the CM episode. 
A CM case that is preceded by a long history of SCM is more likely to be caused by gram-
positive bacteria, and normal milking records followed by a sudden case of CM is more likely 
to be caused by gram-negative bacteria (Ruegg and Pantoja, 2013). 
Treatment of SCM may reduce the risk of cow-to-cow transmission, and the associated 
risk of new CM cases. The reduction in AMU for CM may offset the costs of treating SCM, 
depending on prevalence and transmission in a herd (Barlow et al., 2013). Cost benefit analysis 
showed that the benefit of antimicrobial treatment in SCM caused by Staph. aureus was herd, 





antimicrobial treatment of cows is often profitable if the right cows are selected based on risk 
factors for cure (see section:2.3.1 Host). When the contagious transmission of Staph. aureus is 
unlikely the treatment can be beneficial if it is of short duration and in animals that are more 
likely to cure, young and penicillin-sensitive animals (see section: 2.4.2.4 Pathogen factors). 
When the probability of transmission is low, the low intensity treatment regimens are profitable 
when appropriate cows are chosen (Swinkels et al., 2005). 
 
2.4.2.3 Treatment factors 
Antimicrobial treatment of non-severe mastitis is justified when the predicted 
probability of cure is higher with antimicrobial treatment than without (Ruegg, 2018). This is 
generally the case for gram-positive organisms such as staphylococci and streptococci but not 
for gram-negative organisms (Roberson, 2012; Suojala et al.,  2013; Lago and Godden, 2018). 
Because E. coli infections are generally limited to the superficial mucosal surfaces and have 
high spontaneous cure rates, antimicrobial treatment of mild and moderate cases is not needed 
(Suojala et al.,  2013). For streptococci and staphylococci, the probability of cure is significantly 
enhanced by antimicrobial treatment when compared to no treatment, although cow-factors and 
pathogen factors such as antimicrobial resistance also affect the probability of cure, as described 
respectively in sections 2.4.2.1 Host factors and 2.4.2.4 Pathogen factors. It is also common that 
some proportion of CM cases are culture negative, with variations between different studies and 
regions, but this can be responsible for 10 to 40% of CM (Roberson, 2003; Pinzón-Sánchez and 
Ruegg, 2011b; Oliveira and Ruegg, 2014). Other CM cases, can also be caused by organisms 
that are not susceptible to the antimicrobial approved, such as Mycoplasma spp., Prototheca 
spp. or yeast (Ruegg, 2018). Therefore, it has been estimated that in 50 to 80% of the CM cases, 
antimicrobial treatment might not be justifiable (Roberson, 2003), which supports that treatment 
decisions should be according to the mastitis-causing pathogen. And some studies, in North 
America and in Europe, evaluated the use of targeted treatment in CM, based on the 
differentiation between gram-positive pathogens and other causes of mastitis, showing that this 
approach has the potential to reduce AMU significantly without negative influence on udder 
health, production or culling (Lago et al., 2011a,b; Mansion-de Vries et al., 2014). 





effects in the treatment of non-severe coliform mastitis (Schukken et al., 2011a; Schukken et 
al., 2013; Suojala et al., 2013) but this evidence is not consistent (Pyörälä et al., 1994; Ganda 
et al., 2016; Fuenzalida and Ruegg, 2019). Moreover, 3rd and 4th generation cephalosporins and 
fluoroquinolones are HP-CIA and should not be used in animals (RUMA, 2020). 
In severe cases, parenteral treatment is preferred and should be tailored to manage 
cardiovascular shock, reduce pain, inflammation and prevent bacteraemia. In these cases, 
priority should be given to correct dehydration, with hypertonic or isotonic intravenous fluids 
and oral fluids (Roberson, 2012). Parenteral antimicrobial are recommended to prevent bacteria 
spread in the bloodstream, and fluoroquinolones and 3rd and 4th generation cephalosporins are 
the recommended antimicrobial based on efficacy (Suojala et al., 2013), although this 
contravenes WHO and RUMA recommendations. 
In the past, the selection of the route of administration of antimicrobial was 
recommended according to the localization of the causative pathogen. For pathogens that 
remained in milk or ducts, such as Strep. agalactiae, Strep. dysgalactiae and NAS, IMM route 
was preferred. For pathogens that were recognised to penetrate the udder tissues, such as Staph. 
aureus, Trueperella pyogenes or S. uberis parenteral antimicrobial was recommended (Erskine 
et al., 2003). However, in a randomized clinical control trial in mastitis caused by S. uberis 
parenteral treatment for 3 days achieved similar bacteriological cure rates to an aggressive IMM 
treatment (2 tubes per day) and higher than IMM treatment at labelled rates (1 tube per day) 
(80% vs 80% vs 64) (Hillerton and Kliem, 2002). This suggests that parenteral treatment is not 
better than IMM treatment. Parenteral antimicrobial and aggressive IMM used 14 times and 4 
times more antimicrobial than the labelled dosage, and aggressive IMM use may be seen as the 
preferred balance between reducing AMU and achieving treatment efficacy (Hillerton and 
Kliem, 2002).  
In a perspective of prudent AMU, parenteral antimicrobial should be limited to severe 
CM cases. IMM aggressive antimicrobial treatment should not be use, or only to cows that are 
carefully selected based on host factors. Likewise, extended treatments in mild and moderate 
CM should be limited to specific cases based on host or pathogen factors (Oliver et al., 2003; 





result in benefits, such as fewer follow-up treatments, less milk production loss and lower 
culling rates. These benefits sometimes do not outweigh the extra treatment costs (Steeneveld 
et al., 2011), increased discarded milk, and increased risk of milk residues, with also potential 
selection for AMR (Barkema et al., 2006). In addition to this, if not done properly, repeated 
infusions via the teat canal have higher risk for potential IMI (Gillespie et al., 2002; Swinkels 
et al., 2005).  
 
2.4.2.3.1 Gram-negative coliforms 
Escherichia coli  
The clinical signs are mainly a consequence of lipopolysaccharides (LPS), therefore, 
treatment should target LPS effects. In mild and moderate CM caused by E. coli, antimicrobial 
treatment is not needed, and administration of NSAIDs, frequent milking and fluid therapy 
should be the best approach. However, in severe CM cases there may be unlimited growth of 
bacteria or bacteraemia (Wenz et al., 2001), and in these cases, antimicrobial treatment 
administered parenterally is recommended in order to control the infection and to increase cow 
survival. There are numerous antimicrobial molecules for systemic treatment, with variations in 
availability and its authorized usage among countries. These molecules include trimethoprim–
sulphonamides, oxytetracycline, fluoroquinolones, cefquinome, and ceftiofur (Wenz et al., 
2001; Suojala et al., 2013). Trimethoprim–sulphonamide combination at a high dose (48 mg/kg 
at 12-h intervals) has been recommended for treating coliform mastitis (Erskine et al., 2003). 
However, concerns exist about the activity of these molecules in milk and the capacity to achieve 
therapeutic dosage following label dosage. Oxytetracycline efficacy in milk is also known to be 
decreased, due to strong chelate formation with casein, and dosage to achieve and maintain 
therapeutic concentrations are much higher than the label dosage; but no field studies were 
found in the literature to test this effect. A third-generation cephalosporin is authorized for 
systemic usage in both the USA and Europe. It diffuses poorly in milk, having zero milk 
withdrawal, and its usage for mastitis treatment in Europe is unauthorised. The key question 
here is whether parenteral treatment of cows with severe CM is interpreted as mastitis treatment 
(not permitted, not likely to work because there is no penetration of the mammary gland) or as 





treatment in some EU countries. A clinical trial that used this molecule systemically, alone or 
combined with IMM infusion, in comparison with a treatment group using IMM infusion with 
ampicillin-cloxacillin found that this cephalosporin improved clinical recovery and limited milk 
yield losses (Shpigel et al., 1997). Systemic enrofloxacin resulted in faster bacteriological cure 
and significantly limited the milk loss and clinical cure of the affected quarter 24 hours post-
treatment as compared with no treatment (Hoeben et al., 2000), but enrofloxacin is a 
fluoroquinolone and hence a HP-CIA that should not be used in animals. Regarding treatment 
with ceftiofur administered in IMM infusions in mild and moderate CM caused by E. coli there 
is some evidence that this treatment increased bacteriological cure but had no benefits in milk 
production (Schukken et al., 2011a). Thus, there is some evidence of the beneficial effects of 
treating E. coli CM with fluoroquinolones and cephalosporins, but this evidence is not consistent 
in other studies (Pyörälä et al., 1994; Ganda et al., 2016; Fuenzalida and Ruegg, 2019). As it 
has seen previously, these antimicrobials are HP-CIA and their usage in livestock should be 
avoided.  Non-steroidal anti-inflammatory drug treatment showed evidence of improved 
treatment efficacy in all E. coli CM, and their use in CM caused by these pathogens is 
recommended (Suojala et al., 2013; McDougall et al., 2016).  
 
Klebsiella spp.  
The reported spontaneous bacteriologic cure rates for this bacteria varied from 18 to 
60% (Schukken et al., 2011a; Ruegg, 2018; Fuenzalida and Ruegg, 2019a). In a recent study 
that evaluated the efficacy of IMM treatment in non-severe CM caused by gram-negative 
bacteria spontaneous bacteriologic cure rates of Klebsiella pneumoniae were lower than for E. 
coli CM (18 vs 97%). In this same study, non-severe CM caused by Klebsiella pneumoniae 
treated with IMM infusion of ceftiofur had higher bacteriological cure rates than CM cases 
caused by the same bacteria that did not receive any IMM treatment (78 vs 18%) (Fuenzalida 
and Ruegg, 2019a). Cases of non-severe CM caused by Klebsiella spp. and treated with a 5-day 
course of IMM ceftiofur were 8.5 times more likely to result in bacteriological cure than cases 
without treatment, with bacteriological cure similar to the previous study (57 vs 19%, 





may benefit from antimicrobial treatment in some situations and due to the poor prognosis, other 
management situations according to cow value may need to be considered.  
 
2.4.2.3.2 Staphylococcus aureus  
Spontaneous bacteriological cure for this pathogen can be as low as 0-11% (Ruegg, 
2018), although estimated cure rates will depend on inclusion criteria. This pathogen is 
susceptible to multiple antimicrobials in vitro. However, in vivo cure rates can be variable. Cure 
rates can be very high, and treatment can be rewarding if the right cow is chosen and the 
infection is detected early. Treatment failure often occurs when the infection becomes chronic 
(Barkema et al., 2006). Multiple reasons contribute to the poor response to treatment in chronic 
IMI caused by Staph. aureus, including its ability to survive inside neutrophils, the capacity to 
induce fibrosis and to form micro abscess (Erskine et al., 2003), and the fact that it can adhere 
to the mammary gland epithelium and cause deep infection in the udder tissues (Schukken et 
al., 2011b). To improve treatment response, several studies with different antimicrobial classes, 
combinations of drugs, routes of administration and treatment duration have been conducted. 
However, comparisons between studies require caution, because definitions of cure, study 
designs, sample size, treatment length, molecules and formulations used, route of 
administration, animals’ characteristics, etc. will vary among studies and often multiple 
different variables can be studied in a single study. When treating prepartum heifers cure rates 
were close to 100% for all the different molecules studied (penicillin-novobiocin, penicillin-
streptomycin, cephapirin, tilmycosin, or a cephalonium-based products) (Owens et al., 2001). 
For CM caused by penicillin-resistant isolates, both amoxicillin-clavulanic acid and spiramycin 
were equally ineffective with only 31% cure (Taponen et al., 2003a). In another study of CM 
caused by Staph. aureus, the use of a 2nd generation cephalosporin resulted in a higher 
bacteriological cure rate than the use of cloxacillin (52.4 vs 12.5%) (Wraight, 2003). A study 
that investigated the same compound under different formulations of penicillin G, methicillin, 
and their esthers demonstrated that penethamate treatment (esther of penicillin G) for 4 days in 
SCM had higher cure rates (68.8 vs 56.5%) (Ziv and Storper, 1985). Drug combinations can 
have a synergistic effect, for example, penicillin and neomycin acted synergistically against 





penicillin G alone or combined with neomycin (Taponen et al., 2003b). Some drug 
combinations are registered for use in mastitis, whereas other drug combinations may constitute 
extra-label usage, and require justification balancing benefit and risk. 
Longer treatment is generally associated with higher probability of cure. For example in 
a small-scale study, SCM treated for 2-, 5- or 8-days had 13, 31, or 83% probability of cure, 
respectively (Gillespie et al., 2002). Others reported  6, 56 and 86% cure for, no treatment, 2-
day and 8-day treatment, respectively (Deluyker et al., 2005). However, in another study of 
SCM, a 6-day extended treatment, with 3 cloxacillin tubes administered every 48h, had similar 
cure rates to no treatment (Shephard et al., 2000). For CM, the evidence that extended treatment 
results in increased chances of cure is stronger than for SCM. In one study that compared a 
standard treatment of 3 IMM tubes administered every 12 hours with treatment that was 
extended for an additional 48 hours, the extended treatment was 2.3 times more likely to result 
in bacteriological cure than the standard treatment (Sol et al., 2000). In another study of CM, 5-
day treatment had a numerically higher chance of bacteriological cure than a 3 or4 day treatment 
(42 vs 29%) (Pyörälä and Pyörälä, 1998). The benefits of extended therapy protocols, such as 
higher proportions of cure, resulting in decreasing SCC, less risk of transmission (see section: 
2.4.2.2 Herd factors), and improved saleability of milk, must be weighed against several 
disadvantages, among them are antimicrobial cost, discarded milk, increased risk for residues 
in the milk, and the potential increased risk of infecting the cow through repeated IMM 
infusions. Evidence regarding the route of antimicrobial treatment is not unanimous and 
sometimes difficult to interpret, as it includes different routes of administration, as well the 
presence of a second active molecule, or they often compare different molecules that are 
administered via different routes rather than the same molecule administered through a different 
route. Also, when comparing different routes of antimicrobial administration, the amounts of 
antimicrobial for parenteral use may be larger than for IMM, which has economical and 
potential public health implications regarding different cost-benefit and potential for the 






2.4.2.3.3 Gram-positive catalase negative cocci 
Streptococcus uberis  
S. uberis treatment recommendations should be animal specific (see section: 2.4.2.1 Host 
factors) rather than pathogen specific because we have information on cow-level risk factors for 
cure (Samson et al., 2016) but not on pathogen-level risk factors. Treatment should include 
antimicrobial as the probability of spontaneous bacteriological cure of these organisms is low 
with high recurrence if IMM antimicrobial infusions are not administered (Ruegg, 2018). When 
ceftiofur was administered for 2 days, in CM cases caused by S. uberis bacteriological cure rates 
were 43%. If treatment duration was extended to 5 or 8 days, bacteriological cure rates were 
88% and 100%, respectively (Oliver et al., 2004). Similar results were found for SCM caused 
by S. uberis, i.e. extended treatment was responsible for an increase in bacteriological cure 
(Oliver et al., 2004). Pathogen factors, such as fibrosis and the ability to invade subepithelial 
and septal tissue, and lymphatic vessels and lymph nodes (Thomas et al., 1994), may explain 
why the response of S. uberis mastitis to treatment can be low, even after extended therapy 
(Milne et al., 2005). As for Staph. aureus, the benefits of it must be considered relative to the 
increased costs of antimicrobial and discarded milk, and the increased risk of residues in milk 







Streptococcus dysgalactiae  
Strep. dysgalactiae, showed variable bacteriological cure rates that were lower than for 
S. uberis mastitis in CM studies from New Zealand (64.7-73.3% vs 87.7-89.8%) (McDougall, 
Agnew, et al., 2007) and (73.7-100% vs 90.6-95.7%) (McDougall et al., 2007), but higher in 
studies from SCM from United States (80 vs 67%) (Oliver et al., 2004) and from Europe (7-
26% vs 9-20%) (Deluyker et al., 2005). Therefore these streptococci CM generally respond well 
to treatment but spontaneous bacteriological cure rates are generally poor (28-30%) (Ruegg, 
2018). The differences between countries may be related to management differences, which is 
likely to be the case for S. uberis in New Zealand, or to strain differences, but little is known 
about Strep. dysgalactiae in this regard. 
 
Streptococcus agalactiae 
In the past, the prevalence of Strep. agalactiae IMI was reduced rapidly through “blitz” 
treatment. With this method, an entire herd or, more economically, all the infected cows in a 
herd are treated with antimicrobial. This was seen as an effective practice with cure rates from 
70-90% (Erskine et al., 2003). The success of this practice relied on bacteriological cure rates 
and the fact the bacteria was believed to be an obligate udder pathogen. However, as seen 
previously (see section: 2.1 Types of mastitis) this pathogen is found in environmental reservoirs 
and is also carried by a significant proportion of people (Skov Sørensen et al., 2019). “Blitz” 
strategy has important costs, which are AMU, discarded milk and increased labour, as well as 
increased risk of milk residues, and the possibility IMI while infusing IMM treatment. 
Regarding the context of today where there are calls to reduce AMU because it potentially leads 
to AMR, this is not judicious or effective practice if not accompanied by other management 
changes to reduce prevalence and incidence of the infection e.g. good milk hygiene, good 
biosecurity and re-testing the treated, and if refractory to treatment, culling should be considered 
according to other host factors (Keefe, 2012). 
 
2.4.2.3.4 Mycoplasma spp. 
Treatment with antimicrobial is generally inadequate. Mycoplasma lacks a cell wall, 





action of these molecules (Calcutt et al., 2018). In vitro studies demonstrated that mycoplasmas 
were also resistant to all the main antimicrobial groups, including macrolides, tetracyclines, 
lincosamides, aminoglycosides, chloramphenicols and fluoroquinolones. Some of the resistance 
mechanisms are of the same nature as those described in cell-walled bacteria species, largely 
based on genetic point mutations (Lysnyansky and Ayling, 2016). As explained in the pathogen 
section (see section: 2.4.2.3.4 Mycoplasma spp.) these organisms have the capacity to 
disseminate in different body sites and to produce biofilms, meaning that treatment is rarely 
sufficiently thorough, or ineffective (Nicholas et al., 2016). Therefore, antimicrobial treatment 
for mastitis caused by Mycoplasma is not justifiable economically or in terms of prudent AMU. 
 
2.4.2.3.5 Minor pathogens 
Bacteriological cure rates with penicillin for NAS range from 80-90%. However, for 
penicillin-resistant isolates it was shown that cure rates decrease by 20% compared to penicillin-
sensitive isolates, which might indicate that spontaneous cure occurs commonly. Treatment 
duration was between 2 and 4 days and is recommended that 2-3 days of treatment can be used 
to treat NAS mastitis (Pyörälä and Taponen, 2009b). The authors of the cited review defend that 
antimicrobial treatment is not economically justifiable when a quarter has single isolation of 
NAS, particularly, if it also yields low numbers of bacteria in the milk sample, as these bacteria 
can have their origin in the teat skin and their detection may not constitute clear evidence of 
IMI. Spontaneous bacteriological cure for NAS has been reported to be as high as 70% 
(McDougall, 1998; Wilson et al., 1999), and IMI by these bacteria have limited severity (see 
section 2.2.2.2 Non-aureus Staphyloccocci). It is recommended to limit antimicrobial usage for 
treating moderate-severe CM and quarters with persistent IMI (Pyörälä and Taponen, 2009b). 
In the same review, authors recommend that the antimicrobial chosen should be based on 
susceptibility testing accompanied by beta-lactamase testing, because resistance profiles of 
NAS can be quite variable, and some may even be methicillin-resistant (Sampimon et al., 2011). 
In persistent infections, DCT at dry-off remains a good tool as cure rates at this stage are 
generally higher than in lactation (Pyörälä and Taponen, 2009b). 





2.4.2.4 Pathogen factors 
Apart from penicillin-resistance in Staph. aureus, relatively little is known about 
pathogen factors that affect treatment outcome. Existing knowledge is largely limited to AMR, 
capacity for adherence and invasion of the mammary gland tissues, and ability to form biofilms, 
as summarized in this section. 
 
2.4.2.4.1 Antimicrobial resistance 
 Antimicrobial resistance of MCB can vary among countries and studies and often there 
is a lack of homogeneity of criteria to evaluate them, limiting the feasibility and the value of 
comparisons. For Staph. aureus, for example, resistance to β-lactam antimicrobials is well 
understood, and it is known that penicillin-resistant strains are far less likely to respond to any 
treatment than penicillin-sensitive strains (Barkema et al., 2006). The mechanisms behind it, 
however, are not clear. A possible explanation is that penicillin-resistant genes are in 
pathogenicity islands that also encode virulence genes that affect the probability of cure. 
Another relevant aspect is that antimicrobials, specifically fluoroquinolones, can stimulate the 
dissemination of these genes. Thus, testing for β-lactamase production or penicillin sensitivity 
in Staph. aureus samples should be a prerequisite for treatment and done routinely (Taponen et 
al., 2003a). Among these genes encoding β-lactamase, blaZ is the most common and is 
responsible for resistance to penicillin (Olsen et al., 2006). Phenotypic testing for penicillin 
resistance is part of the diagnostic routine in some laboratories, and genotypic detection of blaZ 
is part of commercially available PCR-based mastitis diagnostics (Koskinen et al., 2009). 
For E. coli, a recent study demonstrated that differences in AMR can occur among 
different E. coli phylogenetic groups, although they may be uncommon or limited (Tomazi et 
al., 2018). However, there are reports that some E. coli bacteria developed resistance to 
molecules that have been used for many years in dairies (ampicillin, streptomycin, 
sulphonamide, and oxytetracycline), but resistance to fluoroquinolones and cephalosporines is 
still uncommon (Suojala et al., 2013). Other study using shows the opposite, that despite some 





MCB, including E. coli, did not show increased resistance to these antimicrobials (Erskine et 
al., 2002). 
In a recent study in Canada of Klebsiella spp. isolates from CM milk samples just 42% 
of the isolates showed some AMR, with streptomycin and tetracyclines being the AB that 
showed some degree of resistance (Massé et al.,  2020) 
 
2.4.2.4.2 Adherence/invasion 
Host-adapted strains of Staph. aureus grouped in the clonal complex 97 are believed to 
be more unlikely to cure, possibly because they have a better capacity to survive in bovine 
mammary tissue (Rainard et al., 2018). In vitro, Staph. aureus showed the capacity to evade 
neutrophils and to form capsules, able to adhere to mammary gland epithelial cells, capacity to 
evade macrophage killing and to resist to phagocytosis (Barkema et al., 2006; Tassi et al., 2015). 
For Strep. agalactiae host-adapted clade, CC61 strain showed several virulence factors 
involved in adhesion, invasion of the pathogen in host cells and evasion of the immune system 
defences. Likewise, Strep. dysgalactiae and S. uberis, showed the ability to survive within 
mammary epithelial cell for extended periods without losing its viability in vitro (Calvinho et 
al., 1998; Tamilselvam et al., 2006). Adherence and invasion may protect bacteria from the 
effect of antimicrobials and the effect of the immune system, although some antimicrobials, e.g. 
penethamate iodide, can penetrate intracellularly (Almeida et al., 2007). Intracellular invasion 




Biofilm formation has been demonstrated in vitro for some pathogens, including S. 
uberis and Staph. aureus, but results are highly dependent on the test system used. For example, 
S. uberis O140J was used as the negative control in one study and whereas it was considered to 





spp. isolates from bovine mastitis have been reported that up to 84% produced biofilm 
(Schönborn et al., 2017), probably explaining its low and variable response to treatment. 
 For Staph. aureus the ability to form biofilm varied between different strains, with 
strains isolated from the mammary gland having better capacity to form biofilm in vitro than 
strains isolated from teat skin and milking unit liners, suggesting a potential risk factor for 
infection (Fox et al., 2005). For both pathogens, the existence and the potential role of biofilm 
in vivo is a matter of debate (Fontaine and Smith, 2006). 
 
2.5 Tests available in clinical mastitis 
To implement targeted treatment in lactational mastitis it is important that a diagnostic 
test can differentiate mild-to-moderate gram-positive mastitis from other types of mastitis, that 
the test has the potential to be used as a point-of-care test, i.e. either on-farm as a cow side test 
or with turn-around time or service of 24 hours, which still can be achieved by some commercial 
diagnostic laboratories or veterinary practices (Malcata et al., 2020). Milk samples must be 
collected aseptically to have meaningful culture results, otherwise, contaminants might indicate 
that treatment is needed and result in a poor reduction of AMU. Current diagnostic tests can 
detect mastitis, i.e. inflammation, based for example on biomarkers, and diagnostic tests that 
can detect the presence of a pathogen, based on bacteriological culture or molecular methods. 
The first can be an indirect measure of infection as most mastitis cases are due to IMI (Adkins 
and Middleton, 2018), while the latter is a direct measure for infection. Inflammation 
information without any pathogen-specific information and the presence of infection without 
evidence of inflammation may not be sufficient evidence to support treatment (Nyman et al., 
2016).  
Currently, diagnostics tests for on-farm use are based on bacterial culture, whereas 






2.5.1 Culture-dependent tests for pathogen identification 
The conventional microbiological laboratory cultures have been the “gold standard” for 
mastitis testing (National Mastitis Council (NMC), 2017), though there is no consensus on how 
to interpret culture results (Dohoo et al., 2011). This may lead to difficulties in interpreting 
studies where point-of-care tests have been evaluated using this test as the gold standard or 
reference test. Furthermore, routine culture may yield false bacterial identifications (Koskinen 
et al., 2009), with an overall rate of erroneously identified bacteria between 7 and 37% across 
different laboratories (Pitkälä et al., 2005). These numbers can increase if performed by persons 
with less diagnosis expertise. Another drawback of this system is the delay between the 
submission of milk samples and reporting the results (Lago et al., 2011a,b). To address these 
limitations and societal calls to reduce AMU, many point-of-care tests or on-farm diagnostics 
have been developed. Multiple diagnostic tests with different characteristics for the 
classification of mastitis bacteria are commercially available. Performance of diagnostic assays 
can be evaluated based in scientific characteristics such as sensitivity, specificity and accuracy, 
and convenience aspects such as cost, ease of use and turn-around time. 
There are currently on the market an array of distinct diagnostics (reviewed by Malcata 
et al., 2020). They can be based on Petrifilm (McCarron et al., 2009a; Mansion-de Vries et al., 
2014b), agar plates (Royster et al., 2014a; Viora et al., 2014), tube-test based systems 
(Leimbach and Krömker, 2018), or dip-slide plastic paddles (Malcata et al., submitted). Some 
identify bacteria in broad diagnostic categories such as gram-positive and gram-negative e.g. 
VétoSlide (Malcata et al., submitted), MastDecide (Leimbach and Krömker, 2018), Petrifilm 
(Mansion-de Vries et al., 2014b), or the Minnesota easy culture-biplate (Royster et al., 2014a). 
Other tests allow to identify bacteria to genus or species-level, e.g. VétoRapid (Viora et al., 
2014), or the Minnesota easy culture-triplate (Royster et al., 2014a). Most novel tests include 
AB susceptibility testing (Jones et al., 2019). Despite their distinct characteristics, all tests are 
more reliable when used to classify more broad categories, such as growth, gram-positive and 
gram-negative than when they identify bacteria at the genus or species level (Lago and Godden, 
2018). Peer-reviewed studies reported sensitivities for detecting gram-positive bacteria that 
could range from 58.6% (Leimbach and Krömker, 2018) to 98% (McCarron et al., 2009a), 





accuracies from 58.6% to 85.3% (Leimbach and Krömker, 2018). The inherent trade-off 
between sensitivity and specificity may limit the accuracy of the test, and pathogen prevalence 
in test-evaluations may influence the confidence intervals around the point estimate. Most early 
tests based on Petrifilm or agar were cheap but readings and outcomes were subject to users 
experience (McCarron et al., 2009b). Recent market introductions, such as Mastatest (Jones et 
al., 2019), include automatic reading to increase ease of use, in exchange for a higher cost. All 
current assays are based on bacterial growth, resulting in turn-around times of more than 16 
hours. This may be enough to inform treatment decisions, but farmers would prefer a result with 
a turn-around time between less than 12 hours (Griffioen et al., 2016). The use of on-farm testing 
raises concerns regarding health and safety or environmental impact. In some countries, these 
tests require a specialized laboratory and must not be used by laypeople (Kerwat, et al., 2020). 
They are potential ways to propagate hazardous pathogens. Besides the biological hazard, these 
tests are often made of plastic and their usage can generate non-biodegradable waste. 
The cost of the test does not seem to be a priority of dairy farmers (Griffioen et al., 
2016), despite very low-profit margins that often affects the sector. There is some controversy 
regarding the economic benefit of on-farm testing, which may be herd and pathogen dependent 
(Cha et al., 2013; Down et al., 2017), and also regarding animal welfare impacts resulting from 
postponing treatment until having the results (Down et al., 2017). Despite that, on-farm testing 
is recognized as a suitable opportunity to support targeted treatment of CM and reduce AMU. 
A recent study also showed that delaying treatment had no detriment to animal health (Bates et 
al., 2020). 
Most tests were designed to identify pathogens to genus or species level, but farmers 
may be more interested in advice on which antimicrobial to use (Griffioen et al., 2016), and 
information at gram-level might be enough to implement targeted treatment decisions according 
to farmers expectations. Data on uptake of on-farm testing are scarce, but in a study from the 
Netherlands performed a few years ago, only 2% of farmers based treatment decisions on culture 






2.5.2. Culture-independent tests for pathogen identification 
Culture-independent methods as the name indicate do not need culture and could have a 
faster turn-around time. They are not available on-farm yet, and currently cost more than culture. 
 
2.5.2.1 DNA based methods 
Polymerase chain reaction (PCR) can be used for the identification of MCB directly 
from milk. The PathoProof mastitis PCR assay was the first commercially available DNA-based 
method for pathogen detection directly from milk, and additional assays have become available 
since then. The initial version was a multiplex real-time test kit that can detect up to 11 different 
bacteria in the milk along with the β-lactamase gene (the blaZ gene) responsible for 
staphylococcal penicillin resistance (Koskinen et al., 2009). It is important to associate detection 
of this gene with another test as the presence of the gene alone is not sufficient to determine 
whether is associated with Staph. aureus or NAS (Koskinen et al., 2009). These real-time tests 
do not require a culture step and the total analysis can be done within 3-4 hours, which can be 
used to support targeted treatment CM. The use of PCR allows the detection of growth-inhibited, 
dead bacteria, which is often presented as an improvement in sensitivity compared to culture. 
However, whether the detection of DNA bacteria in culture negative samples requires 
antimicrobial treatment is questionable (Nyman et al., 2016). 
Another DNA-based test that has been evaluated for direct detection of mastitis 
pathogens in milk is loop-mediated isothermal amplification (LAMP). This test uses different 
chemistry than Polymerase chain reaction (PCR) and requires less sample preparation. It is less 
sensitive to inhibitory substances present in biological samples and may be applicable under 
field conditions (Bosward et al., 2016). In research studies, this test can give fast, cost-effective 
pathogen identification. It can be converted into a pregnancy test-like a lateral flow device, 
which could be a rapid on-farm diagnostics option (Cornelissen et al., 2016). A major challenge 
for on-farm molecular diagnostics is the existence of many pathogens species and AMR genes 
that may be present in milk or in mastitis pathogens, and it is difficult to design tests that 






2.5.2.2 Diagnostic tests to detect inflammation 
Current tests to detect inflammation for on-farm use include California mastitis tests, 
other measurements of SCC, measurement of the electrical conductivity, or the lactate 
dehydrogenase activity. Acute-phase proteins may also serve as mastitis biomarkers, such as 
haptoglobin (Åkerstedt et al., 2009), serum amyloid A (Eckersall et al., 2006), N-acetyl-β-D-
glucosaminidase (Pyörälä et al., 2011), lipopolysaccharide-binding protein (Schroedl et al., 
2001) and cathelicidins (Addis et al., 2016, 2017). SCC and electrical conductivity are widely 
used on-farm whereas the use of acute-phase proteins is limited to veterinary or research 
laboratories. Markers of inflammation have limited value to support targeted treatment of CM 
because they lack pathogen-specificity. If biomarkers indicative of causative agents could be 
identified, this could form the basis of a test that is more rapid than culture and with the ability 
to differentiate between the need for treatment (mild-to-moderate CM due to gram-positive 






2.6. Aims and objectives 
The aim of the original research described in this thesis is to investigate the scientific 
characteristics (sensitivity and specificity) of different tools to support targeted treatment of 
bovine CM, considering a culture-based and a culture-independent approach.  
 
Objectives 
1. Culture-dependent assay 
To evaluate the performance of a simplified test against a reference test consisting of 
bacteriological culture and determination of species identity using matrix-assisted laser 
desorption/ionisation time-of-flight mass spectrometry (MALDI-ToF MS) 
To compare the performance of the simplified test against a commercially available 
comparator test that is commonly in use in author’s practice. 
A. By assessing the difference among both tests 
B. By assessing agreement between tests 
 
2. Culture-independent assay 
To develop a reproducible and consistent western blot protocol for a potentially 
pathogen-associated biomarker of mastitis, cathelicidin. 
To assess if cathelicidin can be used to differentiate mild-to-moderate gram-positive CM 
from other forms of CM. 
 
3. Because uptake of tests is determined by scientific characteristics as well as convenience 
aspects of tests and farmer behaviour, the general discussion will describe those aspects of the 







3. Chapter 3. Laboratory based evaluation of a simplified culture 
system as tool for targeted mastitis treatment 
 
3.1. Introduction 
Presence of mastitis in dairy herds causes production inefficiency (Halasa et al., 2007) 
and animal welfare problems (Byrd et al., 2017). Its control is the most frequent reason for 
AMU in lactating and non-lactating dairy cows (Pol and Ruegg, 2007b) with several 
consequences, including discarded milk (Ruegg, 2003), presence of antimicrobial residues in 
milk (Garcia et al., 2019) and potential for the development of AMR (Pol and Ruegg, 2007a; 
Oliver and Murinda, 2012). High AMU in livestock production has been critically questioned 
(WHO, 2015). In order to preserve antimicrobial efficacy and safeguard human health, strategies 
that promote and ensure prudent use of antimicrobials in animal agriculture, including dairy 
production, are needed  (Trevisi et al., 2014; O’Neill, 2016). 
To reduce antimicrobial use, selective or targeted treatment can be used, both in dry 
cows (Vanhoudt et al., 2018; Vasquez et al., 2018; Lipkens, 2019) and in lactating cows with 
CM (Lago et al., 2011a,b; Vasquez et al., 2017; McDougall et al., 2018). Antimicrobial 
treatment of non-severe mastitis is justified when the predicted probability of cure is higher with 
antimicrobial treatment than without antimicrobial treatment (Ruegg, 2018). This is generally 
the case for gram-positive organisms such as staphylococci and streptococci but not for gram-
negative organisms (Roberson, 2012; Suojala et al., 2013; Lago and Godden, 2018). For 
example, E. coli infections are generally limited to superficial mucosal surfaces with more than 
75% spontaneous cure rates (Suojala et al., 2013). Other CM, caused by Mycoplasma spp., 
Prototheca spp. or yeast are intrinsically resistant to treatment (Ruegg, 2018).  
The use of selective treatment for CM in lactating cows (please see section 2.4.2.3 
Treatment factors), based on the differentiation between gram-positive pathogens and other 
causes of mastitis, has the potential to reduce AMU significantly without negative influence on 





Cephalosporins and fluoroquinolones are the only compounds with some evidence of beneficial 
effects in treatment of non-severe coliform mastitis (Schukken et al., 2011a; Schukken et al., 
2013; Suojala et al., 2013) but this evidence is not consistent (Pyörälä et al., 1994; Ganda et al., 
2016; Fuenzalida and Ruegg, 2019). Moreover, the World Health Organization classified both 
of these antimicrobial classes as HP-CIA for human medicine (WHO, 2019) and their use in 
veterinary medicine is discouraged. Thus, while there may be tension between the imperative to 
protect animal welfare and the need to safeguard public health, the evidence base for the value 
of antimicrobial treatment of mild to moderate gram-negative CM is weak and societal concern 
about such use is getting stronger. This has led to the development of an array of diagnostic 
assays for on-farm classification of mastitis pathogens to support selective treatment. 
Numerous culture-based detection kits for the classification of mastitis pathogens have 
been described and commercialized. The performance of diagnostic assays can be evaluated 
using a range of criteria, such as the ASSURED criteria (Affordable, Sensitive, Specific, User-
friendly, Rapid and robust, Equipment-free and Deliverable to end-users) (Kosack et al., 2017), 
which cover both scientific characteristics such as sensitivity, specificity and accuracy, and 
convenience aspects such as cost, ease of use and turn-around time. For test characteristics 
please see section: 2.5.1 Culture-dependent tests for pathogen identification. 
Data on the uptake of on-farm testing are scarce. In a recent study from The Netherlands, 
only 2% of farmers based treatment decisions on culture results (Griffioen et al., 2016). 
Availability of an affordable, user-friendly and simplified test that can differentiate gram-
positive organisms from other causes of mastitis will potentially improve uptake of on-farm 
testing. The need for reliable and simple testing to differentiate between gram-negative, gram-
positive or culture-negative samples was also recognized for point-of-care diagnosis of 
bacteriuria in pregnant women, leading to the development of the Uricult dip-slide (Van Dorsten 
and Bannister, 1986). The dip-slide is a plastic paddle with two selective media that can be 
dipped in a liquid sample such as urine or milk and allows for subsequent growth of either gram-
positive or gram-negative organisms. The dip-slides can be used in a doctor’s office (Van 
Dorsten and Bannister, 1986) or veterinary practice (Zadoks, personal communication) but I am 






The aim of the current study was to evaluate the laboratory performance of a simplified 
slide test for bovine mastitis against a reference test consisting of bacteriological culture and 
determination of species identity using matrix-assisted laser desorption/ionisation time-of-flight 
mass spectrometry (MALDI-ToF MS). Because assay performance may be influenced by the 
population under study, particularly the proportion of gram-positive and gram-negative 
organisms in the CM case selected for test evaluation, a commercially available plate-based test 
previously evaluated (Viora et al., 2014) was used to benchmark the new simplified slide test. 
 
3.2. Material and Methods 
 
3.2.1 Regulatory compliance 
This research was approved by the Ethics and Welfare Committee of the School of 
Veterinary Medicine of The University of Glasgow, UK (Ref 50a/16). 
 
3.2.2 Sample size calculation 
Sample size for evaluation of Sensitivity and/or Specificity of a diagnostic test was 







According to this formula, n = sample size, P0 = denote the pre-determined value of 
sensitivity or specificity of new diagnostic test, P1 = is the value of sensitivity (or specificity) 
under alternative hypothesis. With (1 - α) % confidence level and (1 - β) % power for detection 
an effect of P1 - P0 using normal approximation as a general rule. Z𝛼𝛼
2
 and Z𝛽𝛽 denote the upper  
𝛼𝛼
2
 and β percentiles of standard normal distribution and α and β are the probabilities of type I 
and type II errors respectively with confidence level (Z = 1.96 for 95% CI) (Hajian-Tilaki, 
2014). Assuming a test sensitivity of 90% compared to the value of 100% for the reference test 





Sample size for estimation of prevalence of gram-positive bacteria was calculated using 
the formula n=(Z^2 P(1-P))/d^2 , where n = sample size, Z = value from a standard normal 
distribution corresponding to a desired confidence level (Z = 1.96 for 95% CI), P = expected 
prevalence or proportion and d = desired precision (Daniel and Cross, 2013) as implemented in 
Excel (Naing, Winn and Rusli, 2016). Based on the range of prevalence’s reported for gram-
positive organisms in mastitis cases in different studies, e.g. 34% (Viora et al., 2014), 44% 
(Lago et al., 2011a,b) and 49% (Milne et al., 2003), a prevalence of 50% was assumed as it is 
the “worst case” scenario for sample size estimation (Naing, Winn and Rusli, 2016). For this 
prevalence and a precision of 0.2, the required sample size was 133. 
 
3.2.3 Sample collection 
Seven dairy farms in Scotland were selected for participation based on herd size, location 
and willingness to cooperate in the study (Table 3-1). Farm staff, including milkers and herd 
managers, were recruited to participate in the study and trained to identify CM cases and to 
classify them as mild (presence of abnormal milk such as milk with clots or flakes or serous 
milk), moderate (presence of signs of udder tissue inflammation: hardness, swelling, redness, 
heat or pain) or severe (animals with additional systemic signs of disease, such as fever, 
tachycardia, tachypnoea, dehydration, anorexia and decreased ruminal function) (Pinzón-
Sánchez et al., 2011a). They were also taught how to collect milk samples aseptically according 
to National Mastitis Council recommendations (NMC, 2017). The trained staff cleaned, pre-
dipped and dried the teat, fore-stripped 2 to 3 times, scrubbed the teat using swabs and surgical 
spirit and collected milk in 30 ml sterile universal containers (Henry Schein, Melville, United 
States of America) held in a diagonal position and without touching the cap to avoid 
contamination. Universal containers are the most used milk sampling vessels in my practice 
area. No preservative was added to the milk samples.  
Quarters with macroscopic changes in milk were sampled regardless of mastitis severity. 
If multiple quarters of a cow were affected simultaneously, all affected quarters were sampled. 
If a second episode of CM occurred in the same cow, she could be included again, regardless of 





same quarter occurring >14 days after the previous episode was considered a new CM case, 
regardless of the pathogen isolated. If the second CM episode occurred in the same quarter 
within 14 days with a different etiologic agent than that of the first episode, it was also 
considered a different CM case (Hertl et al., 2014). Animals were eligible for inclusion in the 
first week after calving but no animals included were within 14 days of administration of 
antimicrobial products. 
Samples were collected from January to May 2018. They were stored frozen on-farm (-
20°C), and once a week, they were transported by me to Glasgow University’s Veterinary 
Diagnostic Services laboratory where they were stored frozen (-20°C) until processing. All 





























1 795 58 140 28 3 52-point rotary sand 
2 549 30 180 30 3 





3 496 33 230 60 3 




4 607 5 145 40 3 






5 304 8 195 45 2 




6 296 12 280 65 2 









3.2.4 Reference test  
Samples were thawed at ambient temperature for up to 8 hours and processed 
simultaneously using the reference test, the simplified slide test, and the commercially available 
plate-based comparator test as described in the following two sections. I was blinded to the 
reference test result. For consistency, all media were inoculated and read by me. Bacteriological 
culture (NMC, 2017) with subsequent determination of species identity using MALDI-ToF MS 
was used as the reference test. Sheep blood agar (5% vol/vol; SBA) and MacConkey agar 
number 3 plates (E&O Laboratories Limited, Bonnybridge, Scotland) were inoculated with 0.01 
ml of milk each using disposable sterile calibrated plastic loops. Plates were incubated at 37°C 





colony-forming unit per mL of milk and was counted for each morphotype. Samples that did 
not yield growth of visible colonies were considered negative for mastitis-associated pathogens. 
Samples that yielded three or more colony types were considered contaminated and excluded 
from data analysis in accordance with NMC guidelines. For the remaining plates, each 
morphotype was identified by standard laboratory methods (NMC, 2017) including colony 
morphology, growth on MacConkey, catalase test, and haemolysis. In these plates, each colony 
type was sub-cultured onto half of an SBA plate for purification. From each pure culture, a 
colony was selected and grown in 2 ml of Brain Heart Infusion broth for 24 hours at 37°C in 
aerobic conditions without shaking. The isolates were preserved with 15% glycerol (v/v) in 
cryovials at -80°C and submitted to an external laboratory (Laboratoire de Microbiologie, 
Vétoquinol SA, Lure, France) for species identification by MALDI-ToF MS analysis, using 
Vitek-MS and V3.1.0 database (bioMérieux, Marcy-l'Étoile, France). 
 
3.2.5 Slide test  
The slide test consists of a double-sided plastic slide with two selective media, i.e. a 
green side selective for gram-negative bacteria and a red side selective for gram-positive 
bacteria (Figure 3-1). 
Media of the simplified slide test (VétoSlide, Vétoquinol, Lure, France) were inoculated 
by applying milk directly to each side using cotton wool swabs (approximate volume 0.1 mL) 
(Lago and Godden, 2018) to moisten the entire surface of the media, as per manufacturer’s 
instructions. The inoculated slides were incubated at 37°C in aerobic conditions and examined 
after approximately 48 hours. When at least one colony was visible, the sample was considered 
positive (Dohoo et al., 2011). Based on the manufacturer’s guidelines, any growth on the green 
media was considered to indicate the presence of gram-negative bacteria and red colonies on 
the green media were considered to be E. coli. Growth on the red media was considered to 
indicate the presence of gram-positive bacteria (Figure 3-1 A-B). When there was growth on 
both media, it was considered to indicate mixed infection with gram-positive and gram-negative 
bacteria. Guidelines for interpretation of results as indicative of contamination were not given 





3.2.6 Comparator test 
Plates for the comparator test (VétoRapid, Vétoquinol, Lure, France) were chosen for 
benchmarking because it is the most commonly used on-farm test in my dairy community and 
was previously evaluated in similar study settings (Viora et al., 2014). These plates contain three 
sectors of selective indicator media, i.e. for gram-negative organisms (sector 1), staphylococci 
(sector 2) and streptococci and enterococci (sector 3) (Viora et al., 2014) (Figure 3-1 E-H). 
Plates were inoculated with 0.01 ml of milk per sector using disposable sterile calibrated plastic 
loops. The inoculated plates were incubated at 37°C in aerobic conditions and examined after 
approximately 48 hours. Based on the manufacturer’s guidelines, it was possible to identify 
eight of the most common mastitis-associated pathogen species or genera: E. coli (dark blue 
colonies on sector 1), Klebsiella spp. (red-purple colonies on sector 1), Staph. aureus (yellow 
or golden colonies and yellow or golden discolouration of agar on sector 2), non-aureus 
staphylococci (NAS; clear colonies and no change in the agar colour on sector 2), S. uberis 
(black colonies and blackened agar on sector 3), Enterococcus spp. (black colonies and agar on 
sector 3 together with pinhead yellow colonies and discolouration of sector 2), Strep. 
dysgalactiae (clear colonies on sector 3 with green coloured corona at 48 hours and red-brown 
agar colouration) or Strep. agalactiae (clear colonies on sector 3 with clear-bright corona at 48 
hours and red-brown agar colouration). Samples that did not yield visible colonies on the 
comparator test were considered negative for mastitis-associated pathogens. As for the slide test, 






Figure 3-1 Test kits. On the left: Slide test. The green media (A) allow for detection of gram-negative bacteria, 
with Escherichia coli growing as red colonies and other species as white colonies (A, B). The red media allows for 
detection of gram-positive bacteria. (D) Bacterial growth on red media. E. Commercially available plate-based 
comparator (VétoRapid, Vétoquinol, Lure, France) with 3 selective indicator media. (F) Growth in the sector 
selective for gram-negative bacteria. (G) Growth in the sector selective for staphylococci. (H) Growth in the sector 




3.2.7 Data analysis 
Samples that were contaminated based on the reference test, or that contained isolates 
that were non-identifiable by MALDI-ToF MS, were excluded from the evaluation of diagnostic 
test performance. All other culture-positive and culture-negative samples (n = 130) were 
included in the calculation of sensitivity, specificity, accuracy and predictive values for growth, 
gram-positives, gram-negatives and E. coli. The reference test was used to classify results from 
the slide test and comparator test as correct or incorrect. For culture-positive samples with gram-
positive or gram-negative species as identified by the reference test, matching results from the 
slide test or the comparator test were considered true positives (TP) and non-matching results 
were considered false negatives (FN). For example, a sample yielding Staphylococcus 
haemolyticus with the reference test, gram-positive growth on the slide test, and NAS on the 
comparator test was considered a true positive (TP) for growth of gram-positive organisms in 





no growth in the reference test, gram-positive results in the slide test and Staph. aureus in the 
comparator test was interpreted as false positive (FP) at growth and gram-positive levels in both 
tests and as true negative (TN) at gram-negative and E. coli levels. Additional examples of 
interpretation of tests results as TP, TN, FP or false negative (FN) are given in Table 3-2. From 
those classifications, sensitivity (Se), specificity (Sp), accuracy (Ac), positive predictive value 
(PPV) and negative predictive value (NPV) were calculated as follows: Se = TP/(TP+FN), Sp 
= TN/(FP+TN), Ac = (TP+TN)/n, PPV = TP/(TP+FP), NPV = TN/(FN+TN).  
  To evaluate the potential of the test kits as treatment decision support tools, the 
calculations were repeated using a subset of samples, originated from non-severe CM cases only 
(n = 109), that were neither contaminated nor contained an organism that could not be identified 
by MALDI-ToF MS and the outcome was expressed as “treatment”. This outcome is equivalent 
to gram-positive growth (one or two colony types) against not gram-positive. The latter category 
includes gram-negative bacteria, non-bacterial growth, and culture-negative results. 
Statistical analysis was performed in Excel (Microsoft Corp., Redmond, USA) using 
tabular methods done by myself, and in R with the guidance of a statistician (R Core Team, 
2019). Epidemiological parameters were expressed as percentages with 95% Wilson type 
confidence intervals (CI), calculated using the Hmisc package in R (Harrel Jr and Dupont, 
2019). Wilson intervals are preferred over exact intervals and Wald (normal approximation) 
type intervals, as they have coverage probability closer to the nominal value (Agresti and Coull, 
1998) and confidence limits that do not exceed the boundaries of the unit interval. The parameter 
estimates for the slide test and the comparator test are not independent because they are derived 
from the same sample. To account for this dependence when considering differences between 
estimates of Se, Sp, Ac, PPV and NPV for the two tests, Wald type confidence intervals were 
calculated using formulae derived from Kosinski (2013). If the 95% confidence interval for the 
difference between tests excluded zero, test performance was considered significantly different. 
Agreement between tests was expressed as Cohen’s kappa coefficient (κ) and considered 
almost perfect (κ > 0.8), substantial (0.61 ≤ κ ≤ 0.8), moderate (0.41 ≤ κ ≤ 0.6), fair (0.2 ≤ κ ≤ 





Table 3-2 Examples of possible results in the reference test and the simplified slide test under evaluation 
(VétoSlide, Vétoquinol, Lure, France) with respective classification as True positive (TP), True Negative (TN), 
False Positive (FP) and False Negative (FN). 
Examples of 
possible results in 
the reference test 
Examples of 














TP TP FP TN, FP1 TP 
1 gram-positive gram-negative1 TP FN FP TN, FP1 FN 
1 gram-positive No growth FN FN TN TN FN 
2 gram-positives gram-negative1 TP FN FP TN, FP1 FN 
























No growth FN FN FN TN, FN1 FN 




FP FP FP TN, FP1 FP 
No growth No growth TN TN TN TN TN 







3.3.1 Reference test 
The number of milk samples collected per farm ranged from 5 to 58 (Table 3-1). Out of 
156 samples, 23 (14.7%) were contaminated. Among 133 non-contaminated samples, 14 
(10.5%) showed no growth, and 116 (87.2%) showed growth of one or two colony types that 
could be identified by the reference method (Table 3-3). Three samples yielded growth of 
organisms that could not be identified by the reference method, and those samples were 
excluded from further analysis.  
Within each farm’s sample set, both gram-positive and gram-negative isolates were 
identified, with a preponderance of gram-positive results for some farms (Farms 3, 4 and 5; 
Figure 3-2), mostly gram-negative results for others (Farms 2 and 6; Figure 3-2) and an even 
balance for the remainder (Farms 1 and 7; Figure 3-2). The proportion of contaminated samples 
per farm ranged from 0 to 33%, indicating considerable differences in sample quality.  
The most identified species were E. coli and S. uberis, followed by other common MCB, 
including Strep. dysgalactiae, Staph. aureus and Klebsiella (Table 3-3). 
 
Figure 3-2 Sampling results for bovine milk samples (n = 130) from quarters with clinical mastitis by participating 
























3.3.2 Slide test 
After excluding contaminated samples and samples that yielded non identifiable 
organisms, 130 milk samples were used to evaluate the performance of the slide test at milk 
sample level. A milk sample could be culture negative or culture positive, contain a single 
colony type or two colony types, i.e. both gram positive, both gram negative, or mixed gram-
positive and gram negative. Mixed cultures were considered gram-positive in the gram-positive 
analysis and gram-negative in the gram-negative analysis. Based on these samples the 
proportion of culture negative results was considerably higher for the slide test (20%) than for 
the reference test (10.8%). Of 26 culture-negative samples in the slide test, 12 (46.2%) were 
correctly classified (Table 3-3). Of the 14 FN slide test results, 7 were from samples with gram-
positive growth in the reference test and 7 from samples with gram-negative growth (Table 
3-3). Mixed gram-positive and gram-negative growth was more common in the slide test 
(12.3%) than in the reference test (5.4%) (Table 3-3). 
Table 3-3 Test results of 130 milk samples from bovine clinical mastitis based on a reference test consisting of 
standard bacteriological culture and species identification by matrix-assisted laser desorption ionisation time-of-
flight mass spectrometry (MALDI-ToF MS) in comparison with the simplified slide test (VétoSlide, Vétoquinol, 







No growth 14 (10.8) 26 (20.0) 17 (13.1) 
Growth 116 (89.2) 104 (80.0) 113 (86.9) 
Gram-positive only 54 (41.5) 50 (38.5) 55 (42.3) 
Gram-negative only 53 (40.8) 38 (29.2) 30 (23.1) 
Mixed (gram-positive & gram-negative) 7 (5.4) 16 (12.3) 28 (21.5) 
Gram-negative 60 (46.2) 54 (41.5) 58 (44.6) 
Escherichia coli 51 (39.2) 45 (34.6) 50 (38.5) 
Klebsiella spp. 6 (4.6) n/a 16 (12.3) 
Other gram-negative 4 (3.1) n/a 2 (1.5) 
Gram-positive 61 (46.9) 66 (50.8) 83 (63.8) 
Staphylococcus spp. 22 (16.9) n/a 56 (43.1) 
Staphylococcus aureus 7 (5.4) n/a 43 (33.1) 
Non-aureus staphylococci 15 (11.5) n/a 21 (16.2) 
Streptococcus spp. 32 (24.6) n/a 50 (38.5) 
Streptococcus dysgalactiae 10 (7.7) n/a 11 (8.5) 
Streptococcus uberis 21 (16.2) n/a 38 (29.2) 
Other Streptococcus spp. 1 (0.8) n/a 6 (4.6) 
Enterococcus spp. 3 (2.3) n/a 2 (1.5) 
Other gram-positive 13 (10.0) n/a 1 (0.8) 
Prototheca zopfii 2 (1.5) n/a n/a 
1The total number of species/genera listed exceeds the number of samples because more than one species/genus was detected in some samples that were not 





The sensitivity of the slide test was similar for gram-positive and gram-negative 
organisms, but specificity was higher for the latter, resulting in higher accuracy for gram-
negative organisms (89.2%) than for gram-positive organisms (79.2%), and higher yet for E. 
coli (accuracy 92.3%; Table 3-4). For the samples from non-severe CM cases (n = 109), the 
potential of the slide test to be used as treatment decision support tool was evaluated. Sensitivity 
and specificity for the subset of non-severe CM cases were similar to those for all CM cases 
(Table 3-4). Positive predictive value of the slide test was high (>92.6%) for growth, gram-
negative results, and E. coli and moderate (between 75 and 80%) for gram-positive results and 
treatment. The negative predictive value was less than 50% for growth, but over 80% for all 






Table 3-4 Performance of the simplified slide test under evaluation (VétoSlide, Vétoquinol, Lure, France) and a 
commercially available plate-based comparator (VétoRapid, Vétoquinol, Lure, France) for identification of mastitis 
pathogens (n = 130 samples). Results are based on comparison with a reference test consisting of culture and 
species identification based on matrix-assisted laser-desorption ionisation time-of-flight mass spectrometry and the 
difference represents the comparison of both tests when correcting for dependence. Values represent point estimates 
expressed as percentage with 95% confidence intervals in brackets. 
 VétoSlide VétoRapid Difference 
Sensitivity 
Growth (n = 116) 87.9 [80.8; 92.7] 92.2 [85.9; 95.9] 4.3 [-2.2; 10.8] 
Gram-negative (n = 60) 83.3 [72.0; 90.7] 83.3 [72.0; 90.7] 0.0 [-9.2; 9.2] 
Gram-positive (n = 61) 82.0 [70.5; 89.6] 88.5 [78.2; 94.3] 6.6 [-3.5; 16.6] 
E. coli (n = 51) 84.3 [72.0; 91.8] 86.3 [74.3; 93.2] 2.0 [-9.6; 13.5] 
Treatment (n = 56) 83.9 [72.2; 91.3] 87.5 [76.4; 93.8] 3.6 [-6.3; 13.4] 
Specificity 
Growth (n = 14) 85.7 [60.1; 96.0] 57.1 [32.6; 78.6] -28.6 [-52.2; -4.9]* 
Gram-negative (n = 70) 94.3 [86.2; 97.8] 88.6 [79.0; 94.1] -5.7 [-13.5; 2.1] 
Gram-positive (n = 69) 76.8 [65.6; 85.2] 58.0 [46.2; 68.9] -18.2 [-30.4; -7.3]* 
E. coli (n = 79) 97.5 [91.2; 99.3] 92.4 [84.4; 96.5] -5.1 [-9.9; -0.2]* 
Treatment (n = 53) 77.4 [64.5; 86.5] 60.4 [46.9; 72.4] -17 [-30.6; -3.4]* 
Accuracy  
Growth (n = 130) 87.7 [80.9; 92.3] 88.5 [81.8; 92.9] 0.8 [-5.8; 7.3] 
Gram-negative (n = 130) 89.2 [82.7; 93.5] 86.2 [79.2; 91.1] -3.1 [-9.1; 2.9] 
Gram-positive (n = 130) 79.2 [71.5; 85.3] 72.3 [64.1; 79.3] -6.9 [-15; 1.1] 
E. coli (n = 130) 92.3 [86.4; 95.8] 90.0 [83.6; 94.1] -2.3 [-7.7; 3.1] 
Treatment (n = 109) 80.7 [72.3; 87.0] 74.3 [65.4; 81.6] -6.4 [-15; 2.1] 
Positive predictive value   
Growth 98.1 [93.3; 99.5] 94.7 [88.9; 97.5] -3.4 [-6.7; -0.03]* 
Gram-negative 92.6 [82.4; 97.1] 86.2 [75.1; 92.8] -6.4 [-15.2; 2.4] 
Gram-positive 75.8 [64.2; 84.5] 65.1 [54.3; 74.4] -10.7 [-18.9; -2.55]* 
E. coli 95.6 [85.2; 98.8] 88.0 [76.2; 94.4] -7.6 [-14.8; -0.3]* 
Treatment  79.7 [67.7; 88.0] 70.0 [58.5; 79.5] -9.7 [-18.5; -0.86]* 
Negative predictive value 
Growth 46.2 [28.8; 64.5] 47.1 [26.2; 69.0] 0.9 [-18.7; 20.5] 
Gram-negative 86.8 [77.4; 92.7] 86.1 [76.3; 92.3] -0.7 [-7.3; 5.8] 
Gram-positive 82.8 [71.8; 90.1] 85.1 [72.3; 92.6] 2.3[-7.3; 11.9] 
E. coli 90.6 [82.5; 95.2] 91.3 [83.0; 95.7] 0.7 [-5.8; 7.2] 
Treatment  82.0 [69.2; 90.2] 82.1 [67.3; 91.0] 0.1 [-10.7; 10.8] 
*Outcomes where VétoSlide and VétoSlide are significantly different. 
The total of samples that yield in the reference test growth, Gram-negative, Gram-positive, E. coli and Treatment 








3.3.3 Agreement between tests 
The agreement between the slide test and the comparator test as expressed in Cohen’s κ 
was only moderate (0.45 to 0.53). This was partly due to the predominance of culture positive 
results among the 130 non-contaminated samples, leaving limited room for agreement beyond 
chance (Figure 3-3). In comparisons against the reference test, the slide test outperformed the 
comparator test for detection of gram-positive organisms in non-severe mastitis cases, with 
substantial (κ = 0.61) and moderate (κ = 0.48) agreement respectively, and for detection of E. 
coli across all non-contaminated samples, with almost perfect (κ = 0.84) and substantial 
agreement (κ = 0.79), respectively. 
 
Figure 3-3 Venn diagrams showing agreement between the reference test (top), simplified slide test (VétoSlide; 
bottom left), and commercially available plate-based comparator (VétoRapid; bottom right). Numbers represent 
the number of samples testing positive for each result, with the position in the Venn diagram showing which test(s) 
yielded that result. Numbers (n) in labels refer to results of the reference test. κ values indicate Cohen’s kappa for 
agreement between two tests (κ1 = agreement between VétoSlide and reference test; κ2 = agreement between 
VétoRapid and reference test; κ3 = agreement between VétoSlide and VétoRapid). The outcomes growth, gram-
positive, gram-negative and Escherichia coli are based on non-contaminated samples with no growth or with 
identifiable pathogens from all cases of mastitis (n = 130). Result for treatment are based on non-contaminated 






3.3.4 Benchmarking against the comparator test 
Despite using a higher inoculum volume than the comparator test, the slide test gave 
more false negative and fewer false positive results in terms of growth and had significantly 
greater specificity but similar sensitivity. Similar results were obtained for the outcomes Gram-
positive, E. coli and treatment when comparing the slide test to the comparator test. The low 
specificity of the comparator test for growth, gram-positive and treatments was partly due to 
poor specificity in the detection of Staph. aureus and S. uberis (70.7% and 82.6%, respectively; 
Table 3-5), which was accompanied by high sensitivity for the same pathogens, as well as E. 
coli (100%, 90.5% and 86.3%, respectively). In terms of sensitivity, there were no statistically 
significant differences among tests for any of the outcomes (Table 3-4). 
Despite the greater specificity of the slide test, overall accuracy of the two tests was not 
significantly different. In my study population, positive predictive value of the slide test was 
significantly greater than for the comparator test for growth, gram-positive, E. coli and 





Table 3-5 Performance of the commercially available plate-based comparator (VétoRapid, Vétoquinol, Lure, France) for identification of mastitis pathogens (n = 130 samples) 
based on comparison of results at species, genus or group level with a reference test consisting of non-selective culture and species identification based on matrix-assisted 






(n = 7) 
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In the current study, I evaluated the laboratory performance of a simplified culture-
based slide test, VétoSlide, which was developed as a potential point-of-care tool to support 
farmers’ CM treatment decisions. The new test was also benchmarked against a 
commercially available plate-based comparator test that is currently used in my practice area. 
The simplified test outperformed the plate-based comparator test in specificity but not in 
sensitivity or overall accuracy. The simplicity of the slide test can make it an attractive tool 
for farmers to target antimicrobial treatment to cows with non-severe CM that yield growth 
or, more specifically, gram-positive culture results from milk samples.  
The test was easy to perform it required only inoculation of a CM milk sample on 
pre-prepared media, making it suitable for use outside of a formal laboratory setting, in line 
with its original design for office-based urine dip-slide testing (Van Dorsten and Bannister, 
1986). Based on the manufacturer’s instructions, slides can be swabbed with milk, as done 
in my study, or dipped in milk. The universal vials that are routinely used for milk sample 
collection on the farms in my practice area are not large enough for the dip method, which 
is why I used the swab method. Alternatively, larger milk sampling containers could be used, 
but this would increase the risk of sample contamination. Even with current sampling 
methods, sample contamination, together with the willingness to collect samples, were 
identified as issues that need to be overcome for routine on-farm uptake of the test. Slide test 
results are easy to interpret based on the qualitative reading of growth on each side of the 
slide, which are differentiated by the colours red and green. For colour blind people this may 
pose a problem, as difficulty distinguishing between red and green is the most common form 
of colour blindness (Neitz and Neitz, 2000). For further evaluation of convenience criteria, 
on-farm studies with end-users should be conducted, as already done for Petrifilm (Mansion-
de Vries et al., 2014a) and the Minnesota easy culture System (Royster et al., 2014a). 
Affordability is also considered part of the convenience criteria for test evaluation but should 
be considered in the context of cost-benefit, particularly in farming, which is an economic 
activity. The economic value of pathogen information in mastitis treatment depends on 
several factors, including the presence of a dominant pathogen species on the farm and the 
risk of pathogen transmission (Cha et al., 2013; Down et al., 2017). Likewise, the ability of 
on-farm diagnostics to reduce antimicrobial use depends on the prevalence of gram-positive 





had a predominant pathogen type whereas others did not. Therefore, the value of information 
would be farm-specific and no blanket statements around cost-benefit or reductions in 
antimicrobial use cannot be made based on my results. It is clear, however, that some farms 
will need further training in sample collection and handling to reduce the number of 
contaminated samples and make investment of time and money into diagnostic testing better 
value for money.  
The accuracy of gram-positive detection in samples from non-severe CM was 80.7% 
with the slide test (VétoSlide), placing it in the same range as commercially available point-
of-care tests, including the comparator test (VétoRapid) (74.3%, this study), the Minnesota 
Easy Culture System-Triplate (81.3%) (Ferreira et al., 2018), Minnesota Easy Culture 
System-biplate (81 to 84%) (Royster et al., 2014a), Petrifilm (80.2%) (Mansion-de Vries et 
al., 2014a) and MastDecide (58.6 to 85.3%) (Leimbach and Krömker, 2018). However, 
when comparing performance results of the present tests to other studies, caution is required 
as study designs (e.g. definitions of intramammary infections and reference standards), study 
populations (animal and pathogen populations), and methods to calculate confidence 
intervals differ. For example, Staph. chromogenes was not detected among the NAS species 
in this study, which is surprising because it is the most common NAS in most other studies 
(Zadoks and Watts, 2009). 
In practice, the positive and negative predictive value of a test are more important 
than the sensitivity, specificity or accuracy, but both depend on pathogen prevalence in the 
population, making them study specific. For that reason, I benchmarked the slide test against 
the comparator test in a single study, allowing for direct comparison of predictive values. 
Positive predictive values were higher for the slide test, implying that it was less likely to 
result in unnecessary treatment than use of the comparator test. Negative predictive values 
for the slide test were similar to those of the comparator test, meaning that the reduced risk 
of over-treating was not accompanied by an increased risk of under-treating. Failure to treat 
based on false negative results for gram-positive organisms may negatively impact cow 
welfare whereas false positive results for gram-positive organisms will lead to a sub-optimal 
reduction of antimicrobial use. Whether positive or negative predictive value is considered 
more important in informing treatment decisions differs between regions. In some areas, 
such as southern Europe (Busani et al., 2004), it is generally assumed that antimicrobial 





working in the area. Conversely, in northern Europe, it is assumed that treatment is not 
needed until proven otherwise (Jørgensen et al., 2016; Persson Waller et al., 2016). Within 
countries, this balance may shift over time, as illustrated by work from The Netherlands on 
selective DCT. Two split-udder trials conducted two decades apart (Schukken et al., 1993; 
Scherpenzeel et al., 2014) in the same country both showed that blanket DCT prevents CM 
when compared to selective DCT. However, the first study concluded that blanket DCT 
should be used to prevent CM despite the need to “eliminate unnecessary use of antibiotics”; 
whereas the second study emphasized the reduction in antimicrobial use that could be 
achieved by abandoning blanket DCT. This illustrates how similar outcomes may be 
presented differently depending on shifts in societal concerns. The number of on-farm 
diagnostics described and available in North America to inform lactational treatment of CM 
suggests a similar shift in attitude away from blanket treatment to targeted or selective 
(McCarron et al., 2009a; Lago et al., 2018).  
In the current study, frozen milk samples thawed under ambient temperature rather 
than fresh milk samples were used. According to some authors, freezing of milk samples 
may increase the frequency of isolation of Strep. agalactiae and Staph. aureus (Villanueva 
et al., 1991; Sol et al., 2002) whereas others report no impact on recovery of Streptococcus 
spp. or Staph. aureus (Schukken et al., 1989) or even a decrease in recovery of Strep. 
agalactiae and Strep. dysgalactiae (Sol et al., 2002). Likewise, some authors report that 
freezing may affect recovery of E. coli (Schukken et al., 1989) whilst others found no effect 
of freezing for 6 weeks on E. coli viability (Murdough et al., 1996). Although freezing may 
have affected the prevalence of certain isolates recovered in this study, it should not have 
affected the comparison of results between the reference test, the slide test, and the 
commercially available comparator plate-based test. 
Thawing of milk samples at room temperature for up to 8 hours may have influenced 
my results by acting as a pre-incubation step. Some authors found that pre-incubation 
enhances the detection of Staph. aureus but not streptococci (Sol et al., 2002), which 
contrasts with results from others, who reported increased detection of streptococci and 
coliforms after pre-incubation (Dinsmore et al., 1992). Published pre-incubation studies 
focus on incubation at 37ºC rather than room temperature. Even at 37ºC, pre-incubation for 
4 hours does not lead to increased detection of contamination (Dinsmore et al., 1992) so the 





during sample collection rather than my culture method. The farm-specific level of 
contamination supports this notion. 
A larger volume of milk was inoculated on the slide test than on the reference test or 
the commercial comparator test. An increase in sample volume enhances bacterial recovery 
(Dinsmore et al., 1992), which could translate into higher sensitivity (fewer false negatives) 
as well as lower specificity (more false positives). In this study, no such effect was observed, 
as sensitivity was not different between slide test and comparator test while specificity was 
higher for the slide test, despite the use of a higher inoculum volume. The reference test used 
in this study include species identification by MALDI-ToF MS and revealed the presence of 
several species that are not recognized as typical mastitis pathogens, e.g. Bacillus and 
Lysinibacillus species. Although both genera are gram-positive, it is debatable whether they 
should be targeted with antimicrobial treatment because little is known about their role as 
pathogenic agents or their response to treatment. None of the currently available point-of-
care tests for mastitis have the ability to differentiate such organisms from recognized 
mastitis pathogens, and conventional microbial diagnostics continue to be important for the 
identification of pathogens to species level (Mansion-de Vries et al., 2014a). For three 
isolates, species identification was not possible, demonstrating the limitations of MALDI-
ToF MS as it only identifies microbial spectra that are available in the database (Cameron et 
al., 2017). 
 Finally, the value of knowledge and diagnostic information depends on their 
implementation. Even if farmers acknowledge the existence of management practices that 
would benefit their farm management, they often do not implement them (Barkema, 
Schukken, et al., 1999). Farmers often experience “insecurity” about how to treat mastitis 
and “uncertainty” about treatment efficacy or cow recovery after treatment (Jansen and Lam, 
2012; Swinkels et al., 2015). Point-of-care tests can reduce this insecurity and allow for the 
implementation of evidence-based treatment approaches. Whilst a detailed result, namely 
pathogen identification, as provided by the comparator test (VétoRapid) and other tests 
comprising three or more selective indicator media, is the preferred outcome for diagnostic 
tests for subclinical mastitis, it is not farmers’ priority for CM diagnostics (Griffioen et al., 






4. Chapter 4. Exploration of a culture-independent biomarker 
as indicator to inform targeted mastitis treatment 
 
4.1 Introduction 
Antimicrobial resistance (AMR) constitutes an important global public health 
problem and, in some parts of the world, also an animal health problem. Antimicrobial use 
(AMU) contributes to the emergence of this problem (O’Neill, 2014). To reduce AMU in 
the dairy sector, several strategies have been proposed. Targeted treatment of CM can 
promote prudent AMU without jeopardizing animal health and welfare. There are multiple 
diagnostic tests to support treatment decisions, with different advantages and limitations 
(Malcata et al., 2020). 
Currently, there are many diagnostic tools that are culture-based. They offer the 
advantage of being able to be used on-farm as point-of-care tests and can identify the 
pathogen. Because they depend on culture, they have long turn-around times. In addition, 
these tests often require user training and experience, with user training needed both for test 
interpretation and sample collection (see: Chapter 3). Otherwise, sample contaminants 
might indicate that treatment is needed and may result in a sub-optimal reduction of AMU. 
In theory, culture-independent tests could offer shorter turn-around times. They can 
identify the pathogen or even target AMR genes based on DNA methods, for example using 
PCR or LAMP. However, these methods have a higher cost than culture when conducted 
off-farm and are not yet available for on-farm use. Other culture-independent tests can detect 
inflammation instead of the pathogen, which is used as a proxy for infection. Advances in 
proteomic techniques allowed the identification of multiple mastitis biomarkers such as 
haptoglobin (Åkerstedt et al., 2009), serum amyloid A (Eckersall et al., 2006), N-acetyl-β-
D-glucosaminidase (Pyörälä et al., 2011), lipopolysaccharide-binding protein (Schroedl et 
al., 2001) and, more recently, cathelicidins (Addis et al., 2016, 2017; Wollowski et al., 






Several pathogen-associated molecular patterns are recognised in the udder by 
pattern recognition receptors that instigate a cascade of events leading to the release and 
expression of antimicrobial molecules and cytokines from host cells in the mammary gland 
(Günther et al., 2017; Petzl et al., 2018). There is evidence that host response is specifically 
adapted to different mastitis-causing pathogens and strains (Bannerman et al., 2004; Blum 
et al., 2017). Therefore, host-response biomarkers that are pathogen-specific could 
potentially be used to inform treatment decisions. In comparison with culture-based tests, 
they would have the advantage that they provide a diagnosis in minutes or hours. There is 
some promising evidence that supports this approach, such as chemokines and cytokines that 
measured different immune response to gram-positive and gram-negative mastitis (Mansor 
et al., 2013; Kusebauch et al., 2018), or gene expression in udder tissue likely to be 
associated with pathogen and duration of infection (Loor et al., 2011; Kościuczuk et al., 
2012). However, it is not always clear whether biomarker profiles reflect the severity of 
inflammation or the causative agents and concerns exist about the sensitivity and specificity 
of acute-phase proteins (Pyörälä et al., 2011) or antimicrobial peptides such as cathelicidins 
(Addis et al., 2016; Pongthaisong et al., 2016; Wollowski et al., 2021).  
Cathelicidins are part of the host defence mechanism and have antimicrobial activity 
against different types of pathogens or potent chemotactic and proinflammatory functions 
that are able to neutralize infectious agents (Zanetti, 2004; Tomasinsig et al., 2010; Young-
Speirs et al., 2018). These peptides are produced locally in mucosal epithelia or produced 
systemically and stored as preformed protein precursor in the leukocyte’s cytoplasm. 
Cathelicidin production and release are triggered by microbial invasion, which can occur 
after an IMI and can be detected in milk (Zanetti, 2004; Cubeddu et al., 2017). Recent 
research on these peptides gave them extra relevance in the development of new 
antimicrobial drugs and potential application in mastitis diagnostics (Young-Speirs et al., 
2018). They are highly correlated with SCC, can be eliminated in milk before leukocyte 
influx and SCC rise is detected, and are generally not detected in milk produced by healthy 
quarters. Therefore, they are recognized as highly sensitive and specific mastitis biomarkers 
(Smolenski et al., 2014; Pongthaisong et al. 2015; Addis et al., 2016).  
Studies in vivo and in vitro allowed the discovery of seven different bovine 
cathelicidins molecules, with variable structures, modes of action and distinct antimicrobial 





profile studies in naturally occurring CM and in experimentally induced infections by 
different bacteria showed different fold increases in the concentration of the seven 
cathelicidins between different studies and causative pathogens. Cathelicidin-1, -2, -3 and -
4 have been detected in studies in infections with gram-positive and gram-negative bacteria 
(Ibeagha-Awemu et al., 2010; Huang et al., 2014; Mudaliar et al., 2016), however, 
cathelicidin-5, -6 and -7 have been associated with gram-positive mastitis only (Reinhardt 
et al., 2013; Huang et al., 2014; Mudaliar et al., 2016). Cathelicidin-2 was detected in severe 
CM but not in moderate CM cases caused by E. coli (Yang et al., 2015). 
 A study examined the abundance of cathelicidin in an experimentally induced IMI 
using S. uberis as well in naturally occurring mastitis caused by diverse pathogens, found 
that cathelicidin increases after IMI, to be correlated to SCC, but its abundance may vary for 
different stages of infection or different clinical presentations (Smolenski et al., 2011). In 
another study, cathelicidin median levels were particularly increased in mastitis caused by 
Strep. agalactiae, followed by Staph. aureus, and non-agalactiae streptococci. Clinical 
mastitis caused by gram-negative bacteria, or coagulase negative staphylococci and culture 
negative CM were associated with lower median cathelicidin values (Addis et al., 2017). 
Despite the variations in cathelicidin concentrations, it was concluded that cathelicidin levels 
did not show enough discriminatory power to guide treatment decisions. Neither Smolesnki 
et al. (2011) nor Addis et al. (2017) described severity levels of CM. A study that included 
both severity levels and CM-causing pathogen information demonstrated that cathelicidin 
abundance in CM cases was not influenced by severity or the bacteriological result, despite 
reporting some significant differences in cathelicidin levels in quarters with SCM caused by 
coagulase negative Staphylococci, Staph. aureus and S. uberis (Wollowski et al., 2021). All 
these studies agree that cathelicidin abundance is not the same for all mastitis cases. 
However, is still not clear whether these variations reflect the severity of inflammation or 
the MCB or other potential factors. In all these studies, bacteriological identification with 
broad categories, to differentiate gam-positive CM from other CM cases was never done and 
in most of these studies, information about CM severity was lacking, which are known as 
relevant and enough to inform CM treatment decisions (Malcata et al., 2020). 
Based on this knowledge gap, the aim of this study was to investigate if a culture-





positive CM from other forms of CM, which includes severe CM and/or CM caused by non-
gram-positive pathogens. 
 
4.2 Material and Methods 
4.2.1 Regulatory compliance 
This research was approved by the Ethics and Welfare Committee of the School of 
Veterinary Medicine of The University of Glasgow, UK (Ref 50a/16). 
 
4.2.2 Sample collection 
Seven dairy farms in Scotland were selected for participation based on herd size, 
location, and willingness to cooperate in the study (for participating farms’ information 
please refer to Table 3-1 in section 3.2. Material and Methods). Farm staff, including milkers 
and herd managers, were recruited to participate in the study and trained by me on how to 
identify CM cases, how to classify each CM case for severity, and how to collect milk 
samples aseptically as explained in Chapter 3. One farmer was asked to sample additional 
milk samples from clinically healthy cows, with no signs of CM and SCC < 200.000 
cells/mL. 
Samples were collected in two periods: from January to May 2018 and from 
September to November 2020. The first sampling period included seven farms, the second 
sampling period included just 4 farms, based on farm location and willingness to cooperate 
in the study.  
Samples were stored frozen on-farm (-20°C), and once a week I transported them to 
Glasgow University’s Veterinary Diagnostic Services laboratory where they were stored 







4.2.3 Milk microbiology  
Samples were thawed at ambient temperature for up to 8 hours and were processed 
using standard bacteriological culture methods (NMC, 2017), with subsequent determination 
of species identity using MALDI-ToF MS as the reference test. Sheep blood agar (5% 
vol/vol; SBA) and MacConkey agar number 3 plates (E&O Laboratories Limited, 
Bonnybridge, Scotland) were inoculated with 0.01 mL of milk each using disposable sterile 
calibrated plastic loops. After processing the plates for bacteriology aliquots from the milk 
samples were taken for molecular biology and stored frozen (-20°C). Plates were incubated 
at 37°C in aerobic conditions and examined after approximately 48 hours. Samples that did 
not yield growth of visible colonies were considered negative for mastitis-associated 
pathogens. Samples that yielded three or more colony types were considered contaminated 
and excluded from data analysis in accordance with NMC guidelines. For the remaining 
plates, each morphotype was identified by standard laboratory methods (NMC, 2017) 
including colony morphology, growth on MacConkey, catalase test, haemolysis, coagulase 
test and gram-staining. For each non-contaminated sample, each colony type was sub-
cultured onto half of an SBA plate for purification. From each pure culture, a colony was 
selected and grown in 2 mL of Brain Heart Infusion broth for 24 hours at 37°C in aerobic 
conditions without shaking. The isolates were preserved with 15% glycerol (v/v) in cryovials 
at -80°C and submitted to two external laboratories for species identification by MALDI-
ToF MS. Isolates from the first sampling period, January to May 2018, were submitted to 
the Laboratoire de Microbiologie, (Vétoquinol SA, Lure, France) and identified using Vitek-
MS and V3.1.0 database (bioMérieux, Marcy-l'Étoile, France). Isolates from the second 
sampling period were submitted to the Laboratory of Quality Milk Management Services 
(QMMS, Easton, Wells, Somerset, United Kingdom) and identified using Microflex - Flex 
Control Version 3.4 (Bruker Daltonics, Billerica, Massachusetts, USA) and MBT IVD (DB-
5989 MSP) and MBT Compass (DB-5989 MSP) databases, respectively. 
 
4.2.4 Milk molecular biology – cathelicidin measurement 
4.2.4.1 Protein quantification 
Total protein concentrations for a subset of CM samples with no growth, or growth 





milk samples that were not contaminated were determined using the bicinchoninic acid 
(BCA) protein assay kit (Thermo Life Science Ltd, UK). Aliquots of the original milk 
samples taken for bacteriological culture were thawed at ambient temperature for less than 
1 hour and subsequently homogenized on a vortexer. Each sample was diluted in purified 
water (Milli-QTM) at a proportion of 1/40 (v/v), using 10 µL of milk and 390 µL of purified 
water. BCA standards were prepared using the same diluent as the samples in accordance 
with the manual of the Pierce BCA Protein Assay Kit (Thermo Life Science Ltd, UK) (Table 
4-1). The buffer solution was created by mixing Pierce BCA protein assay sample Reagent 
A with Reagent B (1/40) prior to adding to each well. Each diluted sample (25 μL) and 
standards (25 μL) were pipetted into the appropriate wells on the microplate, with 200 μL of 
buffer solution. The microplate was agitated at 350 rotations per minute (rpm) on an orbital 
microplate shaker for 30 seconds and incubated for 30 minutes at 37°C. After incubation, 
the plate was cooled at room temperature for 3 minutes and then read at 562 nm on a 
microplate reader, using Ascent software (Multiskan Ascent, MTX Lab Systems). Data was 
analysed using Microsoft Excel, (2010) and GraphPad Prism software, version 5 for 
Windows (GraphPad Software, San Diego, California, USA. The average 562 nm 
absorbance measurement of the blank standard was subtracted from the 562 nm absorbance 
measurements of all other standards and unknown samples, and a standard curve was 
generated by plotting the average blank-corrected 562 nm measurement for each BSA 
protein standard against its concentration in µg/mL. Comparison of absorbance against this 
standard curve allowed the determination of the protein concentration of each sample. 
Table 4-1 Preparation of diluted BSA standards 
Dilution Scheme for Standard Test Tube Protocol and Microplate Procedure 
(Working range = 20-2,000 µg/mL) 
Vial Volume of Diluent (µL) Volume and Source of BSA (µL) Final BSA Concentration (µg/mL) 
A 0 150 of Stock 2000 
B 62.5 187.5 of Stock 1500 
C 162.5 162.5 of Stock 1000 
D 87.5 87.5 of Vial B dilution 750 
E 162.5 162.5 of Vial C dilution 500 
F 162.5 162.5 of Vial E dilution 250 
G 162.5 162.5 of vial F dilution 125 
H 200 50 of vial G dilution 25 






4.2.4.2 Detection of cathelicidin presence in clinical mastitis milk samples 
The cathelicidin presence was assessed using two Western blot techniques (A and B) 
using aliquots from original CM milk samples. For these assays, a commercial human 
primary polyclonal antibody was used, i.e. anti-human cathelicidin (Antibody 16135, HuCal 
BioRad Ltd, UK), which had previously been investigated, along with 14 other human 
primary anti-human cathelicidin antibodies, in Glasgow University’s Proteomics laboratory 
(N. Brady personal communication). To produce these antibodies, a CTHL2-
7_Pep1_Transferrin peptide (SSEANLYRLLELD-Ttds-C) was used because it was 
common to all seven bovine cathelicidins (Smolenski et al., 2011). Therefore, these 
antibodies are polyclonal against this region and should have cross-reactivity towards all 
bovine cathelicidins. Antibody 16135 was selected because it generated the cleanest and 
most consistent signal at the expected molecular weights (17 and 28 kDa) with minimum 
nonspecific background, using aliquots from bovine CM samples from this project. 
 
4.2.4.2.1 Western blot technique A 
This method was previously described in bovine milk (Smolenski et al., 2011) and 
was implemented here with slight modifications. Samples from CM cases where the culture 
results were known (culture negative samples and samples that yield a single morphotype 
that was identified as gram-positive or gram-negative) were chosen to evaluate my 
biomarker.  Aliquots of milk samples were diluted to 2 mg/mL of protein with purified water 
(Milli-QTM) to give a sample volume of 50 µL. Diluted samples were mixed 1:1 with sample 
buffer. To prepare a 1:1 (vol/vol) mixture of diluted milk and sample buffer, 50 µL of sample 
buffer (prepared by combining 950 µL of 2x Laemmli sample buffer (BioRad Ltd, UK) and 
50 µL β-mercaptoethanol) was mixed with 50 µL of diluted milk (2 mg protein/mL). 
Samples were vortexed for 6 seconds at 9000 rpm, incubated at 95°C for 4 minutes, and 15 
µL were loaded on an 18-well gel (Criterion TGX precast midi protein gel, BioRad Ltd, 
UK). 
In the first well, 7.5 µL protein molecular weight ladder (PageRuler Plus prestained 
ladder, ThermoFisher Scientific Ltd, Renfrew, UK) was added on its own in the gel. Samples 
were then separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) in gel running buffer (10x Tris/Glycine/SDS buffer Ltd, UK; diluted 1:10 with 





nitrocellulose membranes using an electrophoretic transfer at 70 V for 60 minutes through a 
blotting tank (Figure 4-1) and adding ice packs to the tank to keep the transfer cool while 
running.  
 
Figure 4-1 Electrophoretic transfer using a blotting tank. 
 
 
After the transfer, the membranes were blocked overnight at 4°C in 5% semi-
skimmed milk solution, with Tris-buffered saline (pH 7.4) containing 0.5% Tween 20 (TBS-
T), at 300 rpm on an orbital microplate shaker. Blots were washed three times for 10 min at 
a time with 0.5% TBS-T solution and then incubated with the primary antibody diluted 
1:1587 in 1% semi-skimmed milk solution with TBS-T, with gentle shaking at 300 rpm on 
an orbital microplate shaker at room temperature for 60 min. 
After incubation with the primary antibody, blots were washed three times for 10 
minutes at a time with 0.5% TBS-T solution. Blots were then incubated with a secondary 
antibody, i.e. Goat anti-Human IgG F(ab')2 antibody (BioRad Ltd, UK) diluted 1:5000 in 
1% semi-skimmed milk solution with TBS-T, with gentle shaking at 300 rpm on an orbital 







4.2.4.2.2 Western blot technique B and optimisation 
This technique was previously used in canine cerebrospinal fluid proteomics (Shafie 
et al., 2013) and adapted to milk samples with some modifications as described here. Sample 
selection criteria were similar to those for technique A, however, the sample set differed in 
terms of size and proportions of gram-positive and other than gram-positive samples, i.e. 
gram-negative bacteria and culture-negative samples. The technique used milk samples that 
were prepared as described under 4.2.4.2.1 Western blot technique A, by increasing 
concentrations of β-mercaptoethanol by 25%, 50%, 75% and 100% before addition to the 
sample buffer. An increase of 100% implies that twice the baseline concentration of β-
mercaptoethanol was used. Samples were homogenized for 6 seconds at 9000 rpm by 
vortexing, incubated at 95°C for 4 minutes as previous (4.2.4.2.1 Western blot technique A), 
and by increasing heating times by 25%, 50%, 75% and 100%, i.e. 5, 6, 7 and 8 minutes. 
Then 15 and 10 µL of the 1:1 mixture of the sample with sample buffer were loaded on a 12 
and 15 well gel (NuPAGE Novex 4-12% Bis-Tris Protein Gels, Invitrogen, ThermoFisher, 
Scientific Ltd, Renfrew, UK), using a ladder as described in technique A, a positive and 
negative controls, respectively, in each of the three first wells of the gel. 
Electrophoresis was run in an XCell SureLock (Invitrogen, ThermoFisher Scientific 
Ltd, Renfrew, UK) electrophoresis tank using gel running buffer (NuPAGE MES SDS 
Running Buffer, Invitrogen, ThermoFisher Scientific Ltd, Renfrew, UK) 1:20 with distilled 
water at 150 V for 45 min (Figure 4-2). 






  After the electrophoresis, the gel was blotted to nitrocellulose membranes using a 
dry electrophoretic iBlotTM chamber (Invitrogen, ThermoFisher Scientific Ltd, Renfrew, 
UK) (Figure 4-3).  
Figure 4-3 Electrophoretic transfer using semi-dry blotting chamber. 
 
 
Selected gels were run and stained with Coomassie Brilliant Blue, to allow 
visualisation of protein bands and confirm loading consistency across wells. When outliers 
were noticed, such as the absence of protein bands or unequal size of protein bands the SDS-
PAGE process was repeated. 
After the transfer, all the membranes were stained with Ponceau S to allow 
visualisation of protein bands and to confirm equal loading across wells and transfer 
consistency across the electrophoresis tracks. When outliers were apparent, lack of sample 
migration from the gel to the membrane, the correspondent samples were repeated or not 
considered for the analysis.  
After de-staining (three 10-minute washes with 0.5% TBS-T), the blots were blocked 
at room temperature for 60 minutes using 5% semi-skimmed milk solution, with Tris-
buffered saline (pH 7.4) containing 0.5% Tween 20 (TBS-T), at 300 rpm on an orbital 
microplate shaker. Blots were washed 3 times as described and incubated with anti-human 
cathelicidin diluted 1:1587, 1:3000, 1:5000 and 1:10000 in 1% semi-skimmed milk solution 
with TBS-T, with gentle shaking at 300 rpm on an orbital microplate shaker at 4°C for 60 
minutes. After incubation with the primary antibody, washing was repeated as before and 
blots were then incubated with goat anti-human antibody (BioRad Ltd, UK) diluted 1:5000 
in 1% semi-skimmed milk solution with TBS-T, with gentle shaking at 300 rpm on an orbital 





secondary antibody the blots were washed again every 10 minutes for three times with 0.5% 
TBS-T solution. 
4.2.4.2.3 Enhanced Chemiluminescence and film development 
This procedure was the same for both techniques A and B. To detect the 
immunocomplexes, the enhanced chemiluminescence (ECL) reagent (Pierce ECL, 
ThermoFisher Scientific Ltd, Renfrew, UK) was prepared according to manufacturer’s 
guidelines, mixing equal volumes of ECL reagents A and B. Then the nitrocellulose 
membrane was immersed in ECL solution and incubated for 5 min. After that, the ECL 
reagent was drained and the membrane was gently blotted with 3MM paper to remove the 
excess of ECL. Then, the membrane was wrapped in cling film and placed inside of a 
radiographic cassette. 
To determine optimal exposure times for radiographic films, different exposure times 
were selected and trialled. Films were exposed to the blot, following ECL contact, for 30 
seconds, 3 minutes and 5 minutes. Protein band density and background interference were 
assessed on radiographic films to determine the optimal exposure times and interpreted as 
presence or absence of cathelicidin in the corresponding CM sample. 
 
4.2.5 Data analysis 
Protein quantification results (response variable) were analysed using repeated-
measures ANOVA, at the genus and species level, for broad categories, such as growth and 
gram-levels, and by severity level groups (explanatory variables). Pairwise t-test analysis 
using Bonferroni-error correction to adjust for multiple comparisons was employed using 
the Anova package in R (Harrell Jr and Dupont, 2019). 
To evaluate cathelicidin performance, the reference test results were used to classify 
CM with presence of bacterial growth or presence of gram-positive bacteria and compared 
with western blot results for presence or absence of cathelicidin. Based on this comparison, 
cathelicidin results were classified as true positives (TP), true negatives (TN), false positives 
(FP) and false negatives (FP) as follows: CM samples with bacterial growth in the reference 
test and presence of cathelicidin in the western blot were considered TP and if cathelicidin 





cathelicidin bands in the western blot they were considered FP, or TN if cathelicidin was 
absent in western blot. Likewise, gram-positive cases in the reference test with the presence 
of cathelicidin in the western blot were considered TP and if cathelicidin was absent, they 
were considered FN. For samples that yielded other results than gram-positive, i.e. gram-
negative or culture-negative, if samples yielded cathelicidin bands in the western blot they 
were considered FP, or TN if cathelicidin was absent in western blot. From those 
classifications, sensitivity (Se), specificity (Sp), accuracy (Ac), positive predictive value 
(PPV) and negative predictive value (NPV) were calculated as follows: Se = TP/(TP+FN), 
Sp = TN/(FP+TN), Ac = (TP+TN)/n, PPV = TP/(TP+FP), NPV = TN/(FN+TN). 
To evaluate the potential of the culture-independent biomarker to support treatment 
decision, the calculations were repeated using a subset of samples, originated from non-
severe CM cases only, that yielded gram-positive results in the reference test. For this 
comparison, the outcome was expressed as “treatment”.  
Biomarker performance statistical analysis was performed in Excel (Microsoft Corp., 
Redmond, USA) using tabular methods and in R (R Core Team, 2019). Epidemiological 
parameters were expressed as percentages with 95% Wilson type confidence intervals (CI), 
calculated using the Hmisc package in R (Harrell Jr and Dupont, 2019). Statistical 
significance was declared at P < 0.05. Agreement was expressed as Cohen’s kappa 
coefficient (κ) and considered almost perfect (κ > 0.8), substantial (0.61 ≤ κ ≤ 0.8), moderate 
(0.41 ≤ κ ≤ 0.6), fair (0.2 ≤ κ ≤ 0.4), or slight (κ < 0.2) (Dohoo et al., 2009). 
 
4.3 Results 
4.3.1 Milk sample microbiology 
A total of 208 milk samples were collected across both periods (156 from January to 
May 2018, and 52 from September to November 2020). In total, 31 (14.9%) samples were 
contaminated, and three samples yielded growth but could not be identified by the reference 
method, therefore they were excluded from the study. From the remaining 174 non-
contaminated samples 24 (13.8%) samples showed no growth, and 150 (86.2%) showed 
growth of one or two colony types that could be identified by the reference method. From 





similar (42.5 vs 48.9%). At the species level, the most identified species were E. coli, and S. 
uberis, followed by non-aureus Staphylococci, Klebsiella spp. and Strep. dysgalactiae. 
Comparing the results of first and second sampling periods, the second period had a higher 
proportion of samples that yielded no growth, and fewer samples that yielded gram-positive 
results (Table 4-2). 
Table 4-2 Test results of 177 milk samples from bovine clinical mastitis based on a reference test consisting 
of standard bacteriological culture and species identification by matrix-assisted laser desorption ionisation 
time-of-flight mass spectrometry (Maldi-ToF MS) 
Result 1st period1 (%) 
(n = 130) 
2nd period1 (%) 
(n = 44) 
Total sample set1 (%) 
(n = 174) 
No growth 14 (10.8) 10 (22.7) 24 (13.8) 
Growth 116 (89.2) 34 (72.3) 150 (86.2) 
Gram-positive only 54 (41.5) 9 (20.5) 63 (36.2) 
Gram-negative only 53 (40.8) 21 (47.7) 74 (42.5) 
Mixed (gram-positive & gram-negative) 7 (5.4) 4 (9.1) 11 (6.3) 
Gram-negative 60 (46.2) 25 (56.8) 85 (48.9) 
Escherichia coli 51 (39.2) 16 (36.4) 67 (38.5) 
Klebsiella spp. 6 (4.6) 9 (20.5) 15 (8.6) 
Other gram-negative 4 (3.1) 0 (0) 4 (2.3) 
Gram-positive 61 (46.9) 13 (29.5) 74 (42.5) 
Staphylococcus spp. 22 (16.2) 7 (15.9) 29 (16.7) 
Staphylococcus aureus 7 (5.4) 1 (2.3) 8 (4.6) 
Non-aureus staphylococci 15 (11.5) 6 (13.6) 21 (12.0) 
Streptococcus spp. 32 (24.6) 4 (9.1) 36 (20.7) 
Streptococcus dysgalactiae 10 (7.7) 0 (0) 10 (5.7) 
Streptococcus uberis 21 (16.2) 3 (6.8) 24 (13.8) 
Other Streptococcus spp. 1 (0.8) 0 (0) 1 (0.6) 
Enterococcus spp. 3 (2.3) 1 (2.3) 4 (2.3) 
Other gram-positive 13 (10.0) 1 (2.3) 14 (8.0) 
Prototheca zopfii 2 (1.5) 0 (0) 2 (1.1) 
1The total number of species/genera listed exceeds the number of samples because more than one species/genus 
was detected in some samples that were not contaminated based on the NMC standard definition of 3 or more 
colony types (the percentage shown is related to the proportion of samples). 
 
When assessing sampling results at farm level, both gram-positive and gram-
negative isolates were identified in each farm, with variations between farms between the 
two periods. Some farms had a preponderance of gram-positive results (Farms 4 and 5; 
Table 4-3), others had a preponderance of gram-negative results (Farms 2 and 6; Table 4-3) 
and the remaining farms an even balance between gram-positive and gram-negative (Farms 
1, 3 and 7; Table 4-3) in the first sampling period. The proportion of contaminated samples 
per farm ranged from 0 to 33%, indicating heterogeneity in the quality of sampling (Table 
4-3). When comparing the two sampling periods, for farms that participated in both periods, 





Some farms showed a shift towards gram-negative results (Farms 1, 3). On the other farms 
(Farms 2 and 5), the number of samples was small and prevalence estimates may be subject 
to random fluctuation (Table 4-3).  
Of 12 samples collected from clinically health quarters, nine yielded no bacterial 
growth and three were contaminated. 
Table 4-3 Sampling results for bovine milk samples (n = 208) from quarters with clinical mastitis by 
participating farm and sampling period 
 







mixed Prothotheca spp. unidentified mild moderate severe total 
1st 
period 
1 6 4 22 20 3 2 1 23 26 9 58 
2 4 3 6 14 1 0 2 7 16 7 30 
3 1 11 13 6 2 0 0 16 17 0 33 
4 1 0 2 1 1 0 0 1 2 2 5 
5 1 1 4 2 0 0 0 3 5 0 8 
6 1 4 2 5 0 0 0 3 7 2 12 
7 0 0 5 5 0 0 0 3 4 3 10 
2nd 
period 
1 5 3 6 13 2 0 0 4 17 8 29 
2 0 1 1 1 0 0 0 2 0 1 3 
3 3 3 1 7 2 0 0 6 8 2 16 
5 2 1 1 0 0 0 0 4 0 0 4 
Total 24 31 63 74 11 2 3 72 102 34 208 
 
 
4.3.2 Milk molecular biology – cathelicidin measurement 
4.3.2.1 Protein quantification 
Protein concentration results from 104 milk samples, including 95 CM samples that 
yield just one gram-positive or gram-negative isolate or no growth, and 9 healthy quarter 
milk samples that had no growth were calculated and are shown below. Protein concentration 
varied between 10 and 67 mg/mL. Except for other gram-negative than E. coli and Klebsiella 
spp. and other gram-positive than Staphylococci and Streptococci, median protein values per 
sample group were between 25 and 35 mg/mL. Healthy quarter milk samples showed a lower 
interquartile range, therefore fewer protein concentrations variations than in CM samples, 
and particularly less than CM that yielded E. coli, Klebsiella spp. or no growth results 
(Figure 4-4). 
Bacterial growth were significantly associated with overall protein concentration (P-
value = 0.031), however, for pairwise comparisons between each bacterial group at genus 
and species level no differences were found (P-value > 0.05). At broad category level, i.e. 
when differentiating bacterial growth at gram level, no growth and clinically healthy quarter, 





mg/mL), median (28.05 mg/mL) and in CM they were positively skewed (average higher 
than the median, with differences of 1.65, 1.97 and 1.82 mg/mL for CM with gram-negative, 
gram-positive and no growth, respectively) and had higher interquartile range (13.4, 12.95, 
15.95 and 4.66 mg/mL for gram-negative, gram-positive, no growth and healthy quarter, 
respectively) (Figure 4-5). Broad category had no significant effect on overall protein 
concentration and in pairwise comparisons between each broad category group no 
differences were found. Comparing healthy quarter milk samples with CM samples of 
different severities, severity was significantly associated with protein concentration (P-value 
= 0.015). In pairwise comparisons between severity levels, protein concentration was 
significantly different between mild and moderate CM (P-value = 0.033). For the other 
pairwise comparisons, differences were not statistically significant (Figure 4-6). 
 
Figure 4-4 Distribution of protein concentration in mg/mL measured through bicinchoninic acid protein assay 
in healthy quarter and clinical mastitis milk samples, with bacterial identification at species and genus level 
based on a reference test consisting of standard bacteriological culture and species identification by matrix-
assisted laser desorption ionisation time-of-flight mass spectrometry (Maldi-ToF MS). The black horizontal 
line inside each box is the median; the bottom and top of the boxes are the 1st and 3rd quartiles; vertical lines 






Figure 4-5 Distribution of protein concentration in mg/mL measured through bicinchoninic acid protein assay 
in healthy quarter and clinical mastitis milk samples The black horizontal line inside each box is the median; 
the bottom and top of the boxes are the first and third quartiles; vertical lines end at the minimum and maximum 
values; the cross is the average. 
 
 
Figure 4-6 Distribution of protein concentration in mg/mL measured through bicinchoninic acid protein assay 
in healthy quarter and clinical mastitis milk samples with different severity levels (mild, moderate, and severe). 
The black horizontal line inside each box is the median; the bottom and top of the boxes are the first and third 








4.3.2.2 Detection of cathelicidin presence in clinical mastitis milk samples 
4.3.2.2.1 Western blot technique A 
A subset of 60 samples was used in technique A, however, 14 samples were just run 
once in one gel, and therefore were excluded from the analysis. To evaluate consistency and 
repeatability the assay required that all the samples analysed were run twice. The remaining 
46 samples included samples with no growth, and evenly balanced proportions of gram-
negative and gram-positive bacteria (45.7 vs 41.3%). This subset included different gram-
negative and gram-positive bacterial genera and species, and samples from different 
severities: mild (30.4%), moderate (58.7%) and severe (10.9%) CM (Table 4-4). These 
samples were used to evaluate the potential of the biomarker to be used as a proxy of 
pathogen presence. 
 
Table 4-4 Clinical mastitis milk samples used in Western blot technique A to evaluate cathelicidin as 
biomarker for growth. Culture results based on the reference test consisting of standard bacteriological culture 
and species identification by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry 
(MALDI-ToF MS). 
Result Severity Total (%) Mild (%) Moderate (%) Severe (%) 
No growth 0 (0) 6 (13.0) 0 (0) 6 (13.0) 
Growth 14 (30.4) 21 (45.7) 5 (10.9) 40 (87.0) 
Gram-negative 9 (19.6) 7 (15.2) 5 (10.9) 21 (45.7) 
Escherichia coli 6 (13.0) 5 (10.9) 4 (8.7) 15 (32.6) 
Klebsiella spp. 3 (6.5) 1 (2.2) 1 (2.2) 5 (10.9) 
Other gram-negative 0 (0) 1 (2.2) 0 (0) 1 (2.2) 
Gram-positive 5 (10.9) 14 (30.4) 0 (0) 19 (41.3) 
Staphylococcus spp. 1 (2.2) 4 (8.7) 0 (0) 5 (10.9) 
Staphylococcus aureus 1 (2.2) 3 (6.5) 0 (0) 4 (8.7) 
Non-aureus staphylococci 0 (0) 1(2.2) 0 (0) 1 (2.2) 
Streptococcus spp. 4 (8.7) 10 (21.7) 0 (0) 14 (30.4) 
Streptococcus dysgalactiae 2 (4.3) 6 (13.0) 0 (0) 8 (17.4) 
Streptococcus uberis 2 (4.3) 4 (8.7) 0 (0) 6 (13.0) 







When using the technique, A, the biomarker had low to moderate sensitivity for 
growth (range 22.0-55.0%). Specificity was higher than sensitivity, but with a more marked 
variation of values between gels (A1 and A2) and both exposures (range 33.3-100%). 
Accuracy was poor for this outcome (< 54.3%). Positive predictive values were moderate to 
high (> 69.2%) but NPV were low (< 18.8%), explained by the high prevalence of bacterial 
growth (87%) in the sample set used. The ability of cathelicidin as a biomarker to detect 
gram-positive bacteria was better than for detection of growth, showing moderate sensitivity 
(range 31.26-68.4%) and specificity (range 55.6-81.55%), translating into moderate 
accuracy for gram-positive organisms (>56.5%) (Table 4-5). 
When assessing different exposure times in different gels, sensitivity and specificity 
were affected differently, which is a common trade-off, i.e. when the sensitivity increased 
the specificity decreased for increased exposure times. The different gels showed 
inconsistencies in the results with the same exposure and running the same samples. For the 
samples from non-severe CM cases (n = 41), the potential of cathelicidin to be used as a 
treatment decision support tool was evaluated. Sensitivity for the subset of non-severe CM 
cases was similar to Se for all CM cases (47.7 vs 47.4%), but specificity was slight decreased 
(68.2 vs 74.1%). Predictive values for gram-positive results and treatment were low to 





Table 4-5 Performance of the culture-independent biomarker under evaluation, cathelicidin, using western blot 
technique A for detection of mastitis pathogens (n = 46 samples), using different exposure times (30 seconds 
and 5 minutes), and running the gels twice (A1 and A2). Results are based on comparison with a reference test 
consisting of culture and species identification based on matrix-assisted laser-desorption ionisation time-of-
flight mass spectrometry (MALDI-ToF MS). Values represent point estimates expressed as percentage with 
95% confidence intervals in brackets. 
 30 seconds exposure 5 minutes exposure 
 A1 A2 A1 A2 
Sensitivity 

































































Positive predictive value 





















Negative predictive value  






















Repeatability of the technique, measured as the agreement between gels using 
technique A, and expressed in Cohen’s κ, was slight for exposure of 30 seconds (κ = 0.109) 
and moderate for exposure of 5 minutes (κ = 0.572). An example of inconsistencies is shown 
in Figure 4-7. 





Figure 4-7 Western blot technique A with 5 min exposure demonstrating the appearance of the cathelicidin 
forming multiple bands, a monomer seen in the low molecular weight band (17 kDa, examples illustrated by 
the stars), and potential multiple dimer bands seen for the other molecular weight bands (> 18 kDa examples 
illustrated by the arrows) (gels A1 and A2). This figure shows inconsistency between gels. Ct: negative control. 
Consistent results 1-9, 11, 13-14 and 16-17. Inconsistent results: 10, 12 and 15. Interpreted as samples positive 
in both gels 1, 3, 12-14 and 16. Samples interpreted as negative in both gels: 4-9 and 15, 17. 
 
 
4.3.2.2.2 Western blot technique B 
The improved technique was achieved after several trial-and-error assays, when 
consistencies in the signal, bands size, absence of outliers and minimum non-specific 
background were achieved after several technical repeats, including multiple lanes with the 
same sample in a single gel, and multiple gels with the same samples. The optimum 
conditions for gel loading included 10 μL of the solution with a protein concentration at 2 
mg/mL, 4 µL of protein molecular weight ladder in the first well of the gel, and positive and 
negative controls in second and third wells, respectively. Ideal sample incubation conditions 
included heating at 95°C for 4 min. Sample buffer with standard β-mercaptoethanol 
concentration as in technique A resulted in presence of cathelicidin monomer and dimer 
(Gels B3 and B4) (Figure 4-9) and sample buffer with an increase in β-mercaptoethanol 
concentration of 50% resulted in disruption of the dimer formation (Gels B1 and B2) (Figure 
4-8). Both concentrations were used to evaluate the potential of the biomarker as a proxy of 
pathogen presence. 
A subset of 35 samples was used in technique B, including samples with no growth 





and samples from different severities: mild (23.5%), moderate (58.8) and severe (17.6%) 
(Table 4-6). 
Table 4-6 Clinical mastitis milk samples used in Western blot technique B results based on the reference test 
consisting of standard bacteriological culture and species identification by matrix-assisted laser desorption 
ionisation time-of-flight mass spectrometry (MALDI-ToF MS) 
Result Severity Total (%) Mild (%) Moderate (%) Severe (%) 
No growth 1 (2.9) 4 (11.8) 0 (0) 5 (14.7) 
Growth 7 (20.6) 16 (47.1) 6 (17.6) 29 (85.3) 
Gram-negative 4 (11.8) 11 (32.4) 6 (17.6) 21 (61.8) 
Escherichia coli 4 (11.8) 9 (26.5) 5 (14.7) 18 (52.9) 
Klebsiella spp. 0 (0) 1 (2.9) 1 (2.9) 2 (5.9) 
Other gram-negative 0 (0) 1 (2.9) 0 (0) 1 (2.9) 
Gram-positive 3 (8.8) 5 (14.7) 0 (0) 8 (23.5) 
Staphylococcus spp. 1 (2.9) 0 (0) 0 (0) 1 (2.9) 
Staphylococcus aureus 1 (2.9) 0 (0) 0 (0) 1 (2.9) 
Non-aureus staphylococci 0 (0) 0 (0) 0 (0) 0 (0) 
Streptococcus spp. 2 (5.9) 5 (14.7) 0 (0) 7 (20.6) 
Streptococcus dysgalactiae 1 (2.9) 3 (8.8) 0 (0) 4 (11.8) 
Streptococcus uberis 1 (2.9) 2 (5.9) 0 (0) 3 (8.8) 
Total 8 (23.5) 20 (58.8) 6 (17.6) 34 (100) 
 
 
Sample buffer that disrupts cathelicidin dimer in the gels (B1 and B2): 
When using the higher β-mercaptoethanol concentration for the sample buffer (gels 
B1 and B2) there was a total or partial suppression of the higher molecular weight 
cathelicidin bands, disrupting cathelicidin dimer formation limiting cathelicidin appearance 
in a gel to a single monomer band with lower molecular weight (17 kDa) (Figure 4-8). In 
technique B using an increase in the β-mercaptoethanol concentration of 50%, the biomarker 
had moderate to high sensitivity to detect bacterial growth (sensitivity range 62.1-79.3%), 
however, specificity for growth was inferior to sensitivity (range 40.0-80.0%), which was 
reflected in moderate accuracy (range 61.8-73.5%) (Table 4-7). Positive predictive values 
were high (>88.5%) in contrast to negative predictive value (< 30.8%), explained by the high 
prevalence of bacterial growth (85.3%) in the sample set used. Regarding the ability of the 
biomarker to detect gram-positive bacteria using this technique and the mentioned reducing 
agent concentration in the sample buffer, the biomarker performance was lower than for 
detection of growth, showing low to moderate sensitivity (range 37.5-75.0%) and even lower 





As for technique A, when assessing different exposure times in different gels, 
sensitivity increased, and specificity decreased for increased exposure times. Using this 
protocol, the agreement between gels was better than for technique A, with a substantial and 
perfect agreement for exposure of 30 seconds (κ = 0.693) and 5 minutes (κ = 1.0), 
respectively. 
  For the samples from non-severe CM cases (n = 28), the potential of cathelicidin to 
be used as a treatment decision support tool was evaluated. Sensitivity for gram-positive in 
the subset of non-severe CM cases had the same results as when severe CM cases were 
included in this sample set. Specificity improved but was still poor (< 45.0%). Predictive 
values had a wide range for growth, gram-positive and treatment, ranging from 15-95.2% 
(Table 4-7).  
 
Figure 4-8 Western blot technique B with 5 min exposure, demonstrating appearance of a single cathelicidin 
band monomer with low molecular weight (17kDa) (gels B1 and B2) and example of consistency in 
cathelicidin detection. 1: Protein molecular weight ladder, Ct+: positive control and Ct-: negative control, 
consistent results for all the tested samples 4-15. Interpreted as samples positive in both gels 4, 6-11, 13 and 







Table 4-7 Performance of the culture-independent biomarker under evaluation, cathelicidin, using western blot 
technique B for detection of mastitis pathogens (n = 35 samples), using different exposure times (30 seconds 
and 5 minutes), and running the gels twice using a sample buffer that disrupts cathelicidin dimer (B1 and B2). 
Results are based on comparison with a reference test consisting of culture and species identification based on 
matrix-assisted laser-desorption ionisation time-of-flight mass spectrometry (MALDI-ToF MS). Values 




 30 seconds exposure 5 minutes exposure 
 B1 B2 B1 B2 
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Sample buffer that shows cathelicidin dimer in the gels (B3 and B4): 
When using the lower β-mercaptoethanol concentrations (gels B3 and B4) it showed 
two cathelicidin bands between 17-28 kDa (Figure 4-9). Using this sample buffer, the 
sensitivity of the biomarker to detect growth increased compared to the sample buffer used 
in the gels presented before (B1 and B2) (range 75.9-89.7% vs 62.1-79.3%), but the 
specificity decreased (range 40.0-60.0% vs 62.1-79.3%), resulting in moderate to high 
accuracy for growth (range 73.5-82.4%), which was better than for gels B1 and B2. For 
detection of gram-positive bacteria, sensitivity was much higher than specificity (range 75.0-
87.5% vs 15.4-30.8%), resulting in poor accuracy (range 29.4-41.2%) (Table 4-8). 
As before, sensitivity increased, and specificity decreased for increased exposure 
times. The agreement between gels B3 and B4 as expressed in Cohen’s κ revealed the 
repeatability of the technique was almost perfect for exposure of 30 seconds (κ = 0.9) and 
substantial for exposure of 5 minutes (κ = 0.7), which was higher than repeatability in 
technique A which was slight (κ = 0.109) and moderate for (κ = 0.572) for 30 seconds and 
5 minutes exposures, and similar to the agreement between gels B1 and B2, which had a 
substantial and perfect agreement for exposure of 30 seconds (κ = 0.693) and 5 minutes (κ 
= 1.0), respectively. 
Sensitivity for gram-positive in the subset of non-severe CM cases (n = 28) was the 
same as for severe CM cases in this sample set. Specificity improved but was still poor (< 
50.0%).  
Figure 4-9 Western blot technique B with 5 min exposure, demonstrating the appearance of the cathelicidin 
forming two bands,  a monomer seen in the low molecular weight band (17 kDa shown by the star), and a 
dimer seen in the high molecular weight band (28 kDa shown by the arrow) (gels B3 and B4) and showing 
consistency in cathelicidin detection. Ct+: positive control and Ct-: negative control. Consistent results 4-15. 






Table 4-8 Performance of the culture-independent biomarker under evaluation, cathelicidin, using western blot 
technique B for detection of mastitis pathogens (n = 35 samples), using different exposure times (30 seconds 
and 5 minutes), and running the gels twice using a sample buffer that does not interfere with cathelicidin dimer 
(B3 and B4). Results are based on a comparison with a reference test consisting of culture and species 
identification based on matrix-assisted laser-desorption ionisation time-of-flight mass spectrometry (MALDI-






 30 seconds exposure 5 minutes exposure 
 B3 B4 B3 B4 
Sensitivity 
Growth  75.9 [61.5; 90.2]  
79.3 
[65.7; 92.9]  
86.2 
[74.6; 97.8]  
89.7 
[79.4; 99.9]  
Gram-positive  75.0 [60.4; 89.6]  
75.0 
[60.4; 89.6]  
75.0 
[60.4; 89.6]  
87.5 
[76.4; 98.6]  
Treatment  75.0 [60.4; 89.6]  
75.0 
[59.0; 91.0]  
75.0 
[59.0; 91.0]  
87.5 
[75.3; 99.8]  
Specificity 
Growth  60.0 [43.5; 76.5]  
60.0 
[43.5; 76.5]  
40.0 
[23.5; 56.5]  
40.0 
[23.5; 56.5]  
Gram-positive  30.8 [15.3; 46.3]  
26.9 
[12.0; 41.8]  
15.4 
[3.3; 27.5]  
15.4 
[3.3; 27.5]  
Treatment  50.0 [33.2; 66.8]  
30.0 
[13.0; 47.0]  
20.0 
[5.2; 34.8]  
20.0 
[5.2; 34.8]  
Accuracy  
Growth  73.5 [58.7; 88.4]  
76.5 
[62.2; 90.7]  
79.4 
[65.8; 93.0]  
82.4 
[69.5; 95.2]  
Gram-positive  41.2 [24.6; 57.7]  
38.2 
[21.9; 54.6]  
29.4 
[14.1; 44.7]  
32.4 
[16.6; 48.1]  
Treatment  55.9 [39.2; 72.6]  
42.9 
[24.5; 61.2]  
35.7 
[18.0; 53.5]  
39.3 
[21.2; 57.4]  
Positive predictive value 
Growth 91.7 [82.4; 100]  
92.0 
[82.9; 100]  
89.3 
[78.9; 99.7]  
89.7 
[79.4, 99.9]  
Gram-positive 25.0 [10.4; 39.6]  
24.0 
[9.6; 38.4]  
21.4 
[7.6; 35.2]  
24.1 
[9.8; 38.5]  
Treatment  31.6 [16.0; 47.2]  
30.0 
[13.0; 47.0]  
27.3 
[10.8; 43.8]  
30.4 
[13.4; 47.5]  
Negative predictive value 
Growth 30.0 [14.6; 45.4]  
33.3 
[17.5; 49.2]  
33.3 
[17.5; 49.2]  
40.0 
[23.5; 56.5]  
Gram-positive 80.0 [66.6; 93.4]  
77.8 
[63.8; 91.8]  
66.7 
[50.8; 82.5]  
80.0 
[66.6; 93.4]  
Treatment  86.7 [75.2; 98.1]  
75.0 
[59.0; 91.0]  
66.7 
[49.2; 84.1]  
80.0 





4.3.2.2.3 Cathelicidin results by pathogen and severity 
From the gels and exposures that yield perfect agreement (B1 and B2, 5 minutes 
exposure) and almost perfect agreement (B3 and B4, 30 seconds exposure) cathelicidin 
results were analysed by genus and species level, severity level and broad categories when 
differentiating bacterial growth at gram level and no growth. Results in each pair of tests 
were similar, except for one sample in B3 and B4 gels with 30 seconds exposure 
(corresponding to lane 5 in Figure 4-8 and Figure 4-9), which was a mild case of E. coli. 
From a total of 34 samples, cathelicidin was detected in most of the samples (76.1%). It was 
detected in samples that had no growth and growth, and in a similar proportion of gram-
positive and gram-negative samples (Figure 4-10). At species and genus level, cathelicidin 
was not detected in the only Staph. aureus and only “other gram-negative” samples, which 
was Pasteurella multocida. For the remainder of samples with growth, cathelicidin was 
detected in more than half of the samples of E. coli and Strep. dysgalactiae and in all the 
samples that yielded Klebsiella spp. and S. uberis (Figure 4-10). In the tested sample set the 
proportion of samples where cathelicidin was detected increased with severity (Figure 
4-11).   
 
Figure 4-10 Cathelicidin detection using western blot technique B, gels B1 and B2 with 5 minutes exposure, 
using clinical mastitis samples results where there was perfect agreement between gels (n = 34). Bacterial 
identification at species and genus levels based on a reference test consisting of standard bacteriological culture 


























Figure 4-11 Cathelicidin detection using western blot technique B, gels B1 and B2 with 5 minutes exposure, 
using clinical mastitis samples with different severity levels (mild, moderate, and severe) where there was 




4.3.3 Agreement between techniques A and B 
The agreement between Techniques A and B on the same samples (n = 18) as 
expressed in Cohen’s κ, revealed poor reproducibility of the biomarker with κ values varying 
from slight, fair and moderate for one comparison (A1 and B2 for 5 minutes exposure) 
(Table 4-9). 
 
Table 4-9 Cohen's κ agreement between gels of different technique A and B using the same samples (n = 18) 
and two different exposures of 30 seconds and 5 minutes. The values represent κ Cohen's agreement. NA: not 
available. 
Exposure Technique and gels B1 B2 B3 B4 
30 seconds 
A1 0.40 0.36 0.25 0.25 
A2 0.14 0.12 0.16 0.16 
5 minutes 
A1 0.36 0.48 0.17 NA 




















4.3.4 Milk protein profiles 
The healthy quarter milk samples had similar milk protein profiles (samples with 
numbers 3-8 Figure 4-12) and generally differed from milk protein profiles of CM (Ct and 
9-15 Figure 4-12). In healthy quarter milk samples, the dominant proteins are caseins 
(represented by the arrows in 28-40 kDa). In CM samples (CT and 9-15), there is an 
alteration in casein profile, whereby bands often seemed of smaller size and there is an 
increase of other proteins of higher molecular weight (72-80 kDa) (Figure 4-12). 
 
Figure 4-12 Ponceau S staining of the blot, and protein profiles of different clinically healthy quarter milk 
samples (3-8) and clinical mastitis samples with no growth (Ct, 9-15). L: protein molecular weight ladder, Ct: 







In the present study, I evaluated if cathelicidin could be used to differentiate gram-
positive CM from other causes of mastitis and if this biomarker could be used to inform 
treatment decisions in non-severe CM. Cathelicidin in the present study was detected in CM 
milk samples using two different western blot techniques adapted from previous studies 
(Smolenski et al., 2011; Shafie et al., 2013). 
A good biomarker must exhibit good sensitivity, specificity, accuracy, be repeatable 
and reproducible (Boehmer, 2011). Cathelicidin in the present study showed to be a poor 
biomarker to inform treatment decisions, because it had limited capacity to differentiate 
gram-positive CM from other causes of CM, regardless of methodology. To detect gram-
positive bacteria technique A showed variable sensitivity (< 68.4%) and specificity (< 
81.5%), with moderate accuracies for different gels and exposures (< 67.4%), which is not 
sufficient for diagnostic use. In addition, repeatability was considered an issue using this 
technique, probably due to extra and more skilled steps needed when using the transfer in a 
blotting tank than when the transfer used a semi-dry blotting chamber. The fact that both 
techniques A and B were not performed simultaneously also can explain why technique A 
performed poorly, as it was done first, and it requires time to acquire consistency in each 
step. There may be a learning effect for the person conducting the experiments. Technique 
B was performed to overcome repeatability issues, which was demonstrated by having 
almost perfect and perfect agreement between two gels using the same samples in two 
different exposures. In these conditions, it was possible to evaluate biomarker performance, 
showing moderate-high sensitivity (75%) but poor specificity (23.1%) for detecting gram-
positive CM. When excluding severe cases, specificity increased slightly (30%), however, 
not enough to be considered an accurate test (35% accuracy) and capable to inform treatment 
decisions. For use in an automatic milking system, sensitivity and specificity requirements 
are  80% and 99%, respectively (ISO, 2017). It can be argued that techniques were applied 
to distinct sample sets, with different bacterial prevalence and different sample sizes, 
however, sensitivity, specificity and accuracy, in contrast to predictive values, are not 
influenced by bacterial prevalence (Dohoo et al., 2009). The low sample size in this study 
decreases its power and explains the wide confidence intervals around the point of estimate. 





might become significant, but there would still be too many false-positive and false-negative 
results to make this an accurate diagnostic test. 
Other studies that investigated the abundance of the biomarker at the genus and 
species level using ELISA techniques also demonstrated that the biomarker has limited 
discriminatory power to differentiate CM caused by different bacteria at the genus and 
species level  (Addis et al., 2017; Wollowski et al., 2021). This supports the results in the 
present study, where specificity was considered the main issue. In one study cathelicidin 
abundance could discriminate only between Strep. agalactiae and coagulase negative 
staphylococci, which demonstrated the maximum and the minimum levels of cathelicidin, 
respectively (Addis et al., 2017). In another study, cathelicidin levels in CM were not 
influenced by the mastitis-causing pathogen, and the significant differences detected for 
cathelicidin levels were limited to SCM cases caused by S. uberis, Staph. aureus and Staph 
non-aureus (Wollowski et al., 2021). These previous studies used quantitative methods to 
quantify cathelicidin concentrations in each CM sample, which have been reported to be 
more sensitive than western blot techniques (Addis et al., 2017). Cathelicidin in the present 
study was not quantified, as repeatability was identified as an issue even when cathelicidin 
detection was just considered. The disruption of cathelicidin dimers was achieved in my 
study by increasing reducing agent concentration in the sample buffer, as previously 
observed for cathelicidin dimer (Storici et al., 1996) and for transthyretin protein in CSF 
samples (Shafie et al., 2013). This was done in the present study in an attempt to quantify 
both cathelicidin forms, but quantification was not done because of the poor repeatability of 
results, even for qualitative reading. The use of a numerical reading would have allowed the 
determination of a cut-off to optimise both sensitivity and specificity or to maximise one of 
them (Watson and Petrie, 2010). 
Reproducibility of the assay is also an important characteristic when evaluating a 
biomarker. Reproducibility can be assessed when there is satisfactory repeatability of a 
procedure and assesses whether two different individuals using the same methodology 
obtain similar results or whether two different techniques performed under similar 
circumstances produce the same results, evaluating thus between-method or between-
observer agreement (Watson and Petrie, 2010). In the present study, the between method 
agreement was assessed (technique A vs technique B) when aliquots of the same samples 





technique A reproducibility of the biomarker in the conditions evaluated was low but 
reproducibility assessment under these circumstances is unreliable (Watson and Petrie, 
2010). In the current study, assessment of reproducibility using the between-observer 
agreement, i.e. technique B performed by two different people in the same samples, would 
have been a reliable way to assess it. Due to time constraints, this was not performed. 
Because of time restrictions caused by Covid lockdowns, the sample set used for 
technique B was smaller than in technique A, with uneven distributions of gram-positive 
CM samples. The uneven prevalence’s used explains the differences in positive and negative 
predictive values. As seen in Chapter 3, predictive values regarding treatment decision are 
more important for on-farm application of the biomarker in a specific population than other 
point estimates, as they inform about targeted treatment decisions performance. A high 
positive predictive value is associated with an optimal reduction of AMU and a high negative 
predictive value means that treatment is only withheld when cows truly do not need it 
(Malcata et al., 2020). Unfortunately, these interpretations cannot be done in the present 
study. Other limitation of the sample set used, was that it did not allow investigation of the 
potential of the biomarker to differentiate major and minor mastitis pathogens. This could 
have been of relevance for implementing targeted treatment decisions, as CM caused by 
NAS generally do not require antimicrobial treatment  (McDougall, 1998; Wilson et al., 
1999). 
The biomarker showed limited specificity to detect gram-positive CM. High 
specificity for this outcome would have meant that cathelicidin would not be detected in 
gram-negative cases and culture-negative cases. This low specificity is not an unexpected 
result as the biomarker has been used as indicator of mastitis in general rather (Smolenski et 
al., 2014; Pongthaisong et al., 2015; Addis et al., 2016). The present study supported this 
notion, as none of the healthy quarter milk samples tested were positive for the presence of 
cathelicidin, demonstrating 100% specificity of this peptide as a mastitis biomarker. These 
results agree with previous studies where cathelicidin in healthy quarters was not detected 
(Smolenski et al., 2011; Addis et al., 2017), and supports the knowledge that there is a need 
for udder tissue inflammation for the biomarker to be released in milk (Cubeddu et al., 2017). 
This can be caused by IMI, which are generally detectable in culture, but is not infrequent 
that bacteriological culture yields no growth results, e.g.13.6% in the present study, which 





intrinsic characteristics of bacterial culture that also explain in part the poor specificity of 
the biomarker for gram-positive bacteria, as a false negative result in the reference test would 
erroneously explain a false positive result for the biomarker (Addis et al., 2016).  
A strategy to increase the specificity of this biomarker as an indicator to inform 
targeted CM treatment would be to use monoclonal antibodies for several specific subtypes 
of cathelicidin (Young-Speirs et al., 2018) rather than a polyclonal antibody that has affinity 
to all subtypes of cathelicidins This may be possible by using antibodies specific to 
cathelicidins -5, -6 and -7 as they have been detected in naturally occurring gram-positive 
mastitis (Ibeagha-Awemu et al., 2010; Huang et al., 2014) or experimentally induced IMI 
with this type of bacteria (Reinhardt et al., 2013; Mudaliar et al., 2016). Cathelicidins-5 and 
-7 have are increased in S. uberis infections (Mudaliar et al., 2016) and cathelicidin-6 and -
7 are increased in Staph. aureus infections (Reinhardt et al., 2013; Huang et al., 2014). By 
contrast, mastitis caused by E. coli or lipopolysaccharide challenge have increased 
cathelicidin-1, -2, -3 and -4 (Boehmer et al., 2008; Danielsen et al., 2010; Ibeagha-Awemu 
et al., 2010; Yang et al., 2015), but none of these studies reported an increase in cathelicidin 
-5, -6 and -7. However, these results are often reported in experimental challenge studies. 
Therefore, there is a need to investigate if similar effects occur in naturally occurring CM 
caused by the same MCB or other gram-positive and gram-negative bacteria that have not 
been investigated yet. Differences between challenge infections and natural occurring CM 
studies in Staph. aureus, report differences in types of cathelicidins detected, with 
cathelicidin-2, -6, -3, -4 in one study (Huang et al., 2014) and cathelicidin-1, -2, -4, -6 and -
7 in the other (Reinhardt et al., 2013). Different studies also reported differences in the fold 
increase for the same cathelicidin, for example from 1.4 fold (Huang et al., 2014) to -20-fold 
(Reinhardt et al., 2013) for cathelicidin-6.  
The present method detected cathelicidin in most of the CM samples tested (26/34, 
76.47%), which demonstrate that different CM cases yield different cathelicidin responses, 
despite the presence or absence of bacterial growth in bacteriological results all these 
samples were from cases of CM. Cathelicidin levels may have been influenced by the 
bacterial numbers at the time of sampling. In an experimentally induced IMI with S. uberis, 
using proteomic analysis at multiple time points pre- and post-challenge, the cathelicidin 
peak coincided with the highest decrease of bacterial numbers (Mudaliar et al., 2016). In the 





where cathelicidin was detected. The only other study that evaluated this association showed 
no effect (Wollowski et al., 2021). Host factors may contribute to the variation in 
cathelicidin, as it was shown in an experimental challenge with the lipopolysaccharides that 
cathelicidin results varied among the three challenged animals (Danielsen et al., 2010). 
Bacterial strain effects may also contribute to cathelicidin levels, as hypothesized in a 
previous study in other biomarkers (Thomas et al., 2018). 
Other relevant outcomes of this study were that both bacterial presence and severity 
were significantly associated with increased protein concentration in milk. This is not an 
incidental finding but supports the purpose of this research in how severity and bacteria can 
affect cathelicidin. In this study, protein expression differed between CM and healthy quarter 
milk samples, which was shown by significant differences in protein concentrations in mild 
and moderate CM, and differences in CM milk profile detected through electrophoresis. 
Whey from healthy quarter milk samples is characterized by the abundance of casein (80% 
of total protein) and whey proteins (10-37 kDa) which represent about 16% of total milk 
protein. In CM samples protein profile is characterized by the increased abundance of serum 
albumin and other vascular-derived proteins such as serum albumin, serotransferrin, 
fibrinogen, etc., due to break down of blood milk barrier (60-100 kDa) (Boehmer et al., 
2008, 2010). These proteins that leak in the milk from systemic circulation are large 
glycoproteins. As reported by Mudaliar et al. (2016), concentrations of some of these 
proteins can be increased or decreased during the process of inflammation and at different 
periods after challenge. Increase of some of these proteins can be more than 25000-fold, 
others can decrease more than 5000-fold. In the present study, CM samples were collected 
when farm-staff detected the CM, which will have occurred at different stages of infection. 
This can potentially explain the high variability of protein concentrations presented for the 
CM cases. The discrepancy of protein concentrations being due to the preparation method 
seems unlikely as the median and average protein concentration in healthy quarter milk 
samples (28.88 and 28.05 mg/mL, respectively) were comparable to the reported average 
milk protein concentration in normal milk (32 mg/mL) (Mudaliar et al., 2016). 
Other important point of discussion is that the proportion of culture-negative samples 
in the present study was 13.6%, which was within the reported ranges but probably on the 
lower side. For example, in a previous study in the UK, the proportion of culture-negative 





found in the present study. However, studies from North America reported prevalence’s 
from 10-40% (Roberson, 2003). The thawing step of up to 8 hours as discussed in Chapter 
3 might have had an impact in my results acting as a pre-incubation step. The IMI definition 
used (100 colony-forming unit/mL) is other factor that may have influenced the proportion 
of no growth samples as a more lenient or strict IMI definitions would have had yielded 
different results (Dohoo et al., 2011). Prudence is required when comparing present 
prevalence results to other studies as bacteriology techniques and IMI definitions may also 






5. Chapter 5. General discussion 
Knowledge development has always been a synonym for opportunity and change. 
Knowledge regarding technological development, demonstrated by examples of 
sophisticated computers, mobile phones, almost ubiquitous available network, or by recent 
DNA-sequencing technologies, allowed impressive changes in our lives and in our 
perception of the world. The biology of CM, however, did not change as much and certainly 
not at the same speed. Regarding udder health, there have been improvements and changes 
in genetics and husbandry, and new ways to harvest milk. Some of these changes were 
subsequently responsible for important shifts in mastitis pathogens’ prevalence in some 
countries (Zadoks and Fitzpatrick, 2008). 
Societal concerns regarding AMU have also changed and they influence the 
availability and AMU for CM treatment. However, more reluctant to change is human 
behaviour, which drives the need, the development and uptake of diagnostic tools and 
implementation of targeted selective treatment. Whilst the previous two chapters have 
focussed on technical or scientific aspects of new point-of-care diagnostics, social or 
convenience aspects of diagnostic tests are equally as important to their use. In this section, 
I discuss farmers’ behaviour and mindset and the drivers and barriers for behavioural change 
towards targeted treatment decisions and uptake of on-farm diagnostics. 
 
5.1 Drivers of diagnostic test uptake  
5.1.1 Current practices – farmers’ behaviour 
As seen in previous chapters, knowledge to support CM targeted treatment decisions 
is available. However, it is well recognised from previous udder health studies that farmers 
infrequently implement them, even though they know that they would benefit from the 
adoption of new management practices (Barkema, et al., 1999), and their udder health 
management decisions are sometimes not fully understood (Vaarst et al., 2002). Farmer 
behaviour can explain, to some extent, differences in the occurrence of mastitis problems 
between farms (Jansen et al., 2009). Clinical mastitis treatment approaches differ in different 





CM practices and promote prudent AMU. In France, it is still very common to treat all cases 
of CM with antimicrobials (Samson et al., 2016). In the Netherlands, just 50% of the farmers 
reported using blanket treatment of all CM (Griffioen et al., 2016). In Wales and England, 
CM with “watery milk” or “clots” was described as the health condition where the farmers 
are most likely to use antimicrobial (Jones et al., 2015). Despite these differences, it seems 
broadly accepted that farmers do not treat all the animals in the same way. Farmers tend to 
treat severe cases differently than first or repeat cases (Samson et al., 2016), and they tend 
to extend the treatment in moderate compared to mild CM cases (Pinzón-Sánchez and 
Ruegg, 2011b). Some farmers limit antimicrobial treatment to severe CM (Griffioen et al., 
2016), and most farmers are more likely to use antimicrobial to treat high yielding animals 
or younger animals (Gussmann et al., 2018). This demonstrates that treatment decisions are 
cow- (Griffioen et al., 2016; Samson et al., 2016) and farm-specific (Oliveira and Ruegg, 
2014; Gussmann et al., 2018). Clinical signs, milk conductivity or a failure of an alternative 
treatment have been reported as the most common sources of information to underpin 
farmer’s antimicrobial treatment decision (Griffioen et al., 2016). Some farmers follow 
antimicrobial label instructions or a protocol agreed with the veterinarian (Griffioen et al., 
2016); others routinely extend treatment beyond the label instructions, built on a social norm 
belief of “being a good farmer” (Swinkels et al., 2015). These heterogeneities of behaviours 
are probably associated with feelings of “insecurity” or “uncertainty” that farmers 
experience regarding CM treatment (Swinkels et al., 2015). These feelings may motivate 
farmers to seek social approval that “extended treatment is better”, which makes it 
emotionally rewarding (Swinkels et al., 2015). Diagnostic tests can reduce this insecurity 
and allow for the implementation of evidence-based treatment approaches. Despite this only 
one third of farmers in the Netherlands reported sending samples to the laboratory and just 
2% of the farmers base their treatment decisions on these results (Griffioen et al., 2016). As 
presented and investigated in previous sections, multiple diagnostics can be used on the farm. 
However, some of their characteristics do not meet farmers’ expectations and preferences. 
Farmers are interested in advice about treatment and in a result to be delivered in less than 
12 hours (Griffioen et al., 2016) as they do not like to postpone treatment decisions (Neeser 
et al., 2006). 
Test characteristics may hinder uptake; however, it seems that farmers are also 





behaviours and practices is not entirely dependent on the development of new tools, such as 
those described in Chapters 2 and 3, or on the development of more knowledge, but probably 
related to other socio-psychological aspects and concepts, where policy development can 
potentially influence farmers’ behaviour to reduce AMU. 
 
5.1.2 Changing practices – behavioural change 
To be effective, the available knowledge needs to be communicated and applied. 
Regarding udder health, communication has been reported as an important tool (Lam et al., 
2011; Jansen and Lam, 2012), and if managed ingeniously and tailored to different types of 
farmers it can allow veterinary practitioners to better support farmers to improve udder 
health (Lam et al., 2011). In udder health programs, two strategies of communication have 
been previously identified (Jansen et al., 2010). The central route is supported by different 
science-based educational tools, but its success depends on farmer’s internal motivation (see 
following section) (Petty and Wegener, 1999). By contrast, peripheral communication is not 
a science-based strategy, but it can be very effective as a step-by-step approach to change 
farmer’s behaviour (Lam et al., 2011). Both communication types work better in 
combination and both should be considered to train farmers to implement targeted selective 
treatment for CM and thereby reduce AMU. 
Firstly, farmers need to consider this approach and philosophy relevant (Noar, 2006). 
A recent study in 71 dairy farms in Wales and England reported that 70% of the farmers 
consider that reducing AMU would be a “good thing to do” (Jones et al., 2015). To make 
sure that intentions lead to actions, socio-psychological concepts such as farmers’ motivation 
and mindset are important in the behavioural change process. Motivation can lead to 
voluntary or involuntary change. Voluntary change can be driven by external motivators, 
such as economic means such as the application of penalties or premiums with milk price 
based on milk quality and composition (Múnera-Bedoya et al., 2017). Curiously, penalties 
for decreased milk quality seemed to work better than premiums in motivating farmers to 
behavioural change (Valeeva et al., 2007; Huijps et al., 2010). Therefore, the creation of 
financial penalties regarding AMU above a certain threshold or market restrictions could be 
a potential way to decrease AMU. Internal motivators can arise from different sources of 
information, and this type of motivation generally leads to long-term behavioural change. 





impacts of AMU in human and animal health. Compulsory behavioural change is known to 
be very effective, though it has the limitation that it only works while restrictions are in place 
(Lam et al., 2011). Implementation of new policies could also work to reduce AMU, for 
example limiting the number of treatments per animal or per farm. Work from The 
Netherlands has shown that good udder health can be maintained when restricted 
antimicrobial use policies are in place (Santman-Berends et al., 2016). 
Advisors and veterinarians are in a privileged position to motivate farmers internally 
through communication. Farmer-led approaches rather than traditional passive knowledge 
transfer methods have recently been proposed as a good strategy and probably the best way 
to motivate change (Bard et al., 2017). Motivational interviewing is a communication 
strategy designed to facilitate clients’ internal motivation to change and has been described 
as an effective way to improve uptake of veterinarian’s advice (Bard et al., 2019). 
Demographic factors and affective attributes, such as a veterinarian’s age, respectfulness and 
dominance, or farmers’ education level also influence farmers’ satisfaction and willingness 
to adopt veterinary advice (Ritter et al., 2019). Such insights could be implemented to 
promote uptake of on-farm diagnostics, targeted treatment and reduce AMU. The regular 
contacts between veterinarians and farmers build up a relationship of trust and recognise 
veterinarians as a valuable source of knowledge and advice, therefore veterinarians can be 
useful to help to detect and understand farmers’ mindset which may also influence farmers’ 
behaviour regarding AMU and on-farm diagnostics uptake.  
 
5.1.3 Current mindset  
Farmers’ mindset involves several psychological concepts such as personality, 
attitudes, beliefs, values, intentions, skills, knowledge, perceived norms, and perceived self-
efficacy. It has been demonstrated that these factors influence farmers’ decisions, and are 
believed to explain to some extent the lack of management changes uptake that would result 
in noticeable benefits for the farm (Jansen and Lam, 2012). As a result, mindset can affect 
farm performance (Meek et al. 1984; Tarabla and Dodd, 1990; O’Leary et al., 2018), 
including udder health (Jansen et al., 2009). In the Netherlands, a favourable mindset with 
regards to the reduction of AMU impacted positively on shifting from a blanket DCT 
approach to selective DCT (Scherpenzeel et al., 2016), demonstrating the importance of this 





important to motivate farmers to change and to potentially implement targeted selective 
treatment of CM. Two characteristics of farmers’ mindset have been described as 
fundamental. The first is farmers’ need to acknowledge the existence of a problem and their 
responsibility to take an action. The second is farmers’ perception that the recommended 
strategy is feasible and will be successful on the farm (Ritter et al., 2017). These two 
characteristics have been described as the main determinants in mastitis management (Jansen 
and Lam, 2012).  
Farmers’ perception that the amount of AMU on-farm is high can be a starting point 
to implement new approaches to control CM with less AMU but does not mean that farmers 
see it as a problem. Farmers’ “normative frame of reference”, i.e. the threshold of when an 
issue becomes a problem, differs between farmers (Jansen and Lam, 2012). It is influenced 
by their descriptive norms, e.g. how the other farmers treat CM or by injunctive norms, e.g. 
what practice is approved by other farmers. The use of benchmarking tools to compare AMU 
between farms (RUMA, 2020) and farm annual AMU reviews with the prescribing 
veterinarian, as used in food standard schemes in the UK (Red Tractor Assurance, 2018), 
are examples of strategies to raise farmers’ perception of responsibility regarding AMU. 
These perceptions obviously vary among farmers and are associated with farmers’ goals and 
reasons to reduce AMU. Farmers generally want to reduce AMU to reduce medicine costs 
(Jones et al., 2015). However, setting a nationwide target to reduce AMU allows the farmer 
to assess their own reduction against the national benchmark (RUMA, 2020). This is a way 
to encourage the farmers’ sense of being part of a nationwide reduction campaign, as farmers 
are more likely to assume their responsibility as a joint effort (Brennan and Christley, 2013). 
Only when farmers identify the amount of AMU as a problem (Jansen et al., 2009), or if 
they feel responsible for AMR, will they action (Ritter et al., 2017). 
The second characteristic is farmers’ beliefs in the effectiveness of new mastitis 
management practices, which is influenced by perceived benefits and barriers to execute 
them (Jansen and Lam, 2012). Perceived benefits in these situations can be, for example, 
cows’ welfare, economic improvement, compliance with sector-specific AMU targets, long-
term job satisfaction, good reputation, consumers’ demands, social recognition, pride or 
desire to conform with perceived standards of “being a good farmer”. Perceived barriers can 
be, for example, extra labour, lack of time, extra economic investments with no financial 





that raising farmers’ awareness related to CM blanket treatment costs and consequences and 
building up farmers’ self-confidence and beliefs in the success of a diagnostics-based 
targeted approach may lead to its implementation and the associated reduction of AMU.  
 
5.1.4 Changing mindset 
To change farmers’ mindset and behaviour towards the application of a targeted 
selective treatment, new technical knowledge, new standards, or new perceived norms need 
to be strong enough to create social pressure, capable to motivate farmers to adopt the desired 
behaviour. Communication, as stated previously, is a powerful way to inform and diffuse 
new knowledge and to generate new norms or perceived standards. There are multiple 
information sources with differences in accessibility, credibility, relevance, practicality, or 
consistency. Mass media, for example, can reach a broad group of farmers. Tailored 
approaches, such as participatory learning and one-on-one communication, are very 
effective in leading to on-farm change (Ritter et al., 2017). One-on-one communication, 
particularly when done by veterinarians, can be a very powerful way of communicating 
(Jansen and Lam, 2012). Another important and powerful tool of information is research 
because evidence-based knowledge can be a way to update beliefs (Higgins et al., 2017), 
which are another aspect of farmers’ mindset. If the new evidence is strong enough, it can 
result in a belief update to be used for behavioural change, but if the new data differs from 
present beliefs it may lead to uncertainty and may result in farmers drawing insufficient 
strength from the evidence or even create scepticism (Higgins et al., 2017). There is evidence 
that an integrated approach involving stakeholders, udder health specialists, experts in 
communication, social sciences and marketing can facilitate change of current AMU 
practices and increase the uptake of diagnostic tests. In addition, creating a new institutional 
context e.g. milk buyers or food assurance authorities, supported by programs and policies, 
subsidies, regulations or penalties (Jansen and Lam, 2012), can support and allow a mindset 
and behavioural change with more prudent AMU. Whilst there is a plethora of new point-
of-care diagnostics available (Malcata et al., 2020), their limited uptake to date suggests that 
more work needs to be done on farmer motivation and behaviour if we want to promote 
targeted CM treatment and prudent AMU. The specific tests considered in Chapter 3 and 





treatment decisions (Chapter 3) and turn-around time (Chapter 4), which are recognized 
barriers to test uptake (Griffioen et al., 2016). 
Conclusion 
In this project, I investigated the laboratory-based performance of different tools to 
support targeted treatment of bovine CM based on differentiation of gram-positive bacteria 
from other causes of mastitis, using two different approaches. 
Using a culture-dependent approach, I evaluated the performance of a simplified test, 
and I demonstrated that it performs similar to a commercially available on-farm test that was 
used for benchmarking in terms of sensitivity or accuracy, whilst performing better in terms 
of specificity. Social science research has shown that farmers are more interested in 
treatment recommendations than in the knowledge of mastitis pathogens when using on-
farm diagnostics, and the simplicity of the slide test can make it an attractive tool for farmers 
to target antimicrobial treatment of non-severe CM cases caused by gram-positive organisms 
with good diagnostic accuracy. However, users’ willingness, and ability to collect high- 
quality milk samples were identified as issues that need to be understood and supported. In 
addition, further work to evaluate the test’s user-friendliness and accuracy in on-farm 
settings, as opposed to the laboratory setting, I used for this initial evaluation, followed by 
an assessment of uptake, economic impact, and AMU reduction are needed. 
To overcome the major limitation of culture-based testing, i.e. it’s relatively long 
turn-around time, I also evaluated a culture-independent approach using a biomarker. The 
biomarker investigated, cathelicidin, failed to support targeted treatment decisions based on 
differentiation of gram-positive and other causes of CM. The biomarker showed moderate 
sensitivity, i.e. it gave a positive result when gram-positive organisms were present, but poor 
specificity, meaning that it also gave positive results when gram-negative organisms or no 
growth were present. This combination was responsible for its poor accuracy. In this study, 
cathelicidin presence was detected using a polyclonal antibody that showed high specificity 
for mastitis, as cathelicidin was not detected in any of the healthy quarter milk samples. To 
inform targeted treatment decisions, however, some degree of specificity to differentiate 
different types of CM is required. Additional work using antibodies that are specific to a 





would be a logical next step, as detection of cathelicidin subtypes may be able to inform CM 
treatment decisions.  
In the general discussion, I provided insight into farmers’ behaviour and mindset 
regarding current CM treatment practices and the barriers and drivers for uptake of on-farm 
diagnostics. Current CM treatment practices vary between countries, and are herd- and cow- 
specific, and despite the evidence available to support targeted treatment of CM and 
available on-farm diagnostic tests, its uptake is limited or unquantified in most countries. 
Several barriers such as test characteristics, farmers’ routine practices, labour shortages, lack 
of time, cost and uncertainty regarding the tests’ financial benefit, were identified as possible 
barriers that limit diagnostics uptake. On the other hand, potential economic benefits, social 
recognition, pride, improved cow welfare, and the perception of being a good farmer were 
identified as potential drivers for their uptake. Mindset, which includes farmer’s attitudes, 
beliefs, perceived norms and perceived self-efficacy, influences behavioural change and has 
been recognised as an important feature in the implementation of mastitis control programs. 
An integrated approach with multiple stakeholders, supported with potential policies, 
subsidies, strategies of AMU benchmarking and communication, may help to raise 
knowledge and awareness about AMU and may help to change farmer’s mindset and 
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Appendix 1: Laboratory-based evaluation of a simplified point-of-care test 
intended to support treatment decisions in non-severe bovine clinical mastitis 
 













To limit the use of antimicrobials in dairy cattle, farmers are increasingly encouraged 
to adopt targeted treatment decisions based on knowledge of the pathogens causing clinical 
mastitis (CM), whereby treatment of non-severe CM is generally recommended for gram-
positive mastitis but not for gram-negative or culture-negative mastitis. The objectives of 
this study were to conduct a laboratory-based evaluation of the performance of a simplified 
slide test as a tool to differentiate gram-positive CM from other cases of CM, and to compare 
its performance against a commercially available on-farm test that is commonly used in our 
area (VétoRapid). Test outcomes after 24-48 hr incubation were compared to results from 
bacteriological culture and matrix-assisted laser desorption/ionisation time-of-flight mass 
spectrometry. Milk samples (n = 156) were obtained from cases of severe and non-severe 
CM on seven farms and collected by farm personnel. After removal of contaminated samples 
(n = 23) and organisms with unknown species identity (n = 3), the simplified slide test 
showed high sensitivity and accuracy (> 80%), similar to the comparator test. For most 
outcomes of interest (culture positive, Escherichia coli, or gram-positive growth), the 
specificity of the slide test (85.7, 97.5 and 76.8% respectively) was higher than the 
specificity of the comparator test (57.1, 92.4 and 58% respectively). When considering non-
severe cases of CM only, and interpreting detection of gram-positive organisms as indicative 
of the need for antimicrobial treatment, the simplified test had higher specificity (77.4% vs 
60.4%) and higher positive predictive value (79.7% vs 70.0%) than the comparator test and 
similar sensitivity (83.9% vs 87.5%). The proportion of sampled CM cases, contaminated 
samples and gram-positive mastitis cases - which affects the positive and negative predictive 
value, the economic value of diagnostic testing and its potential to reduce antimicrobial use 
- differed between farms. The simplicity and accuracy of the slide test could make it an 
attractive tool for farmers to target antimicrobial treatment of non-severe clinical mastitis. 
  
Keywords: point-of-care test, bovine clinical mastitis, treatment, antimicrobial use 
 
Mastitis control is the most frequent reason for antibiotic use in lactating and non-
lactating dairy cows (Pol & Ruegg, 2007). Because of concerns that antibiotic usage may 
lead to antimicrobial resistance (WHO, 2015), strategies are needed to promote and ensure 
prudent use of antimicrobials for mastitis control. Selective treatment for CM in lactating 
cows, based on differentiation between gram-positive pathogens and other causes of mastitis, 
has the potential to reduce antibiotic use significantly without negative impact on udder 
health, production or culling (Lago et al. 2011a, b; Mansion-de Vries et al. 2014).  This has 
led to development of an array of diagnostic tools for on-farm classification of mastitis 
pathogens to support selective treatment. 
Numerous culture-based detection kits for classification of mastitis pathogens have 
been reviewed, and new tests are becoming commercially available (Malcata et al. 2020). 
There are diagnostic tests based on Petrifilm, agar plates, or tube-test based systems. Some 
identify bacteria as gram-positive or gram-negative, whereas other tests identify bacteria to 
genus or species-level (Malcata et al. 2020).  Some assays also include antibiotic 
susceptibility testing (Jones et al. 2019). All tests are more reliable when used for diagnosis 
of broad categories, such as growth, gram-positive and gram-negative species, rather than at 
genus or species level (Lago & Godden, 2018). The performance of diagnostic assays can 
be evaluated using scientific characteristics such as sensitivity, specificity and accuracy, and 
convenience aspects such as cost, ease of use and turn-around time. For example, most 





Mastatest (Jones et al. 2019) costs more but provides automated reading to increase ease of 
use.  
Although many tests were designed to identify pathogens to genus or species level, 
farmers are more interested in advice on antibiotic use than identification of causative agents 
of CM (Griffioen et al. 2016). A simplified test to differentiate gram-positive organisms 
from other causes of mastitis could be sufficient to decide whether antimicrobial treatment 
of non-severe CM is needed. In a different context, namely bacteriuria in pregnant women, 
a similar need for reliable and simple testing to differentiate gram-positive, gram-negative 
and culture-negatives samples led to development of the Uricult dip-slide (Van Dorsten & 
Bannister, 1986). The dip-slide is a plastic paddle with two selective media that can be 
dipped in a liquid sample such as urine or milk, allowing for growth of either gram-positive 
or gram-negative organisms.  
The aim of our study was to evaluate the laboratory performance of a simplified slide 
test for bovine mastitis, to determine whether it differentiates gram-positive from other forms 
of mastitis with similar accuracy as a commercially available comparator test commonly 
used in our practice. 
 
Material & Methods 
Regulatory compliance 
This research was approved by the Ethics and Welfare Committee, School of 
Veterinary Medicine, University of Glasgow, UK (Ref 50a/16). 
 
Sample collection 
Seven dairy farms in Scotland were selected based on herd size, location, and 
willingness to cooperate in the study (Supplemental Table S1). Farm staff, including milkers 
and herd managers, were trained to identify CM and to classify cases as mild (abnormal 
milk, e.g. clots, flakes or serous milk), moderate (abnormal milk and signs of udder 
inflammation: hardness, swelling, redness, heat or pain) or severe (presence of additional 
systemic signs of disease, e.g. fever, tachycardia, tachypnea, dehydration, or anorexia) 
(Pinzón-Sánchez & Ruegg, 2011). They were taught how to collect milk samples aseptically 
according to National Mastitis Council recommendations (NMC, 2017). CM cases were 
sampled regardless of mastitis severity. If multiple quarters of a cow were affected 
simultaneously, each affected quarter was sampled. Any CM episode in a quarter occurring 
>14 days after the previous episode, or caused by a different etiological agent, was 
considered a new CM case. Animals were eligible for inclusion in the first week after calving 
but no animals included were within 14 days of administration of antimicrobial products. 
Samples were collected from January to May 2018. They were stored on farm at -
20°C, and transported once a week to Glasgow University’s Veterinary Diagnostic Services 
laboratory where they were stored at -20°C until processing. All samples were cultured 
within 4 weeks from CM detection. 
 
Reference test  
Samples were thawed at ambient temperature for up to 8 hours and processed 
simultaneously using the reference test, the simplified slide test, and the commercially 
available plate-based comparator test as described in the following two sections. For 





test. Bacteriological culture (NMC, 2017) with subsequent determination of species identity 
using MALDI-ToF MS was used as the reference test as detailed in the supplementary file.  
 
Slide test  
Media of the simplified slide test (VétoSlide, Vétoquinol, Lure, France) were 
inoculated by applying milk directly to each side using cotton wool swabs (approximate 
volume 0.1 ml) to moisten the entire surface of the media, as per manufacturer’s instructions. 
The inoculated slides were incubated aerobically at 37° and examined after 24-48 hours. 
When at least one colony was visible, the sample was considered positive (Dohoo et al. 
2011). Based on the manufacturer’s guidelines, any growth on the green media was 
considered to indicate presence of gram-negative bacteria and red colonies on the green 
media were considered Escherichia coli. Growth on the red media was considered to indicate 
presence of gram-positive bacteria (Supplemental Figure S1). When there was growth on 
both media, it was considered to indicate mixed infection with gram-positive and gram-
negative bacteria. Guidelines to identify contaminated samples were not given, so samples 
were never classed as contaminated based on the slide test.  
 
Comparator test 
Plates for the comparator test (VétoRapid, Vétoquinol, Lure, France) were chosen 
for benchmarking because it is the most commonly used on-farm test in the dairy community 
of the authors and was previously evaluated in similar study settings (Viora et al. 2014). 
These plates were inoculated with 0.01 ml of milk per sector using disposable sterile 
calibrated plastic loops, incubated aerobically at 37°C and examined after 24-48 hours, as 
detailed in the supplementary file.  Results were summarized as gram-positive, gram-
negative, E. coli and no growth for comparison with the reference and slide tests results. 
Samples not yielding visible colonies on the comparator test were considered negative for 
mastitis-associated pathogens. As for the slide test, a contaminated category was not 
specified by the manufacturer. 
 
Data analysis 
Samples that were contaminated or contained non-identifiable isolates by MALDI-
ToF MS were excluded from evaluation of diagnostic test performance. All other culture-
positive and culture-negative samples (n = 130) were used to calculate sensitivity, 
specificity, accuracy, positive predictive values (PPV) and negative predictive values (NPV) 
for growth, gram-positives, gram-negatives and E. coli. The reference test was used to 
classify results from the slide test and comparator test as correct or incorrect. To evaluate 
the potential of the test kits as treatment decision support tools, the calculations were 
repeated using a subset of the 130 samples, namely those from non-severe CM cases (n = 
109), and the outcome was expressed as “treatment”. This outcome is equivalent to gram-
positive growth or no gram-positive growth. The latter category includes gram-negative 
bacteria, non-bacterial growth, and culture-negative results. 
Statistical analysis was performed in Excel (Microsoft Corp., Redmond, USA) using 
tabular methods, and in R. If the 95% confidence interval for the difference between tests 
excluded zero, test performance was considered significantly different. Full details are 








Per farm, 5 to 58 samples were collected (Supplemental Table S1). Of 156 samples, 
23 (14.7%) were contaminated. Among 133 non-contaminated samples, 14 (10.5%) showed 
no growth, and 116 (87.2%) showed growth of one or two colony types that could be 
identified by the reference method (Table 1). Three samples with growth of organisms that 
could not be identified by the reference method, were excluded from further analysis. Within 
each farm’s sample set, gram-positive and gram-negative isolates were identified, with a 
preponderance of gram-positive results for some farms (Farms 3, 4 and 5), mostly gram-
negative results for others (Farms 2 and 6) and an even balance for the remainder (Farms 1 
and 7; Figure 1). The proportion of contaminated samples per farm ranged from 0 to 33%, 
indicating considerable differences in sample quality. The most common species were E. 
coli and S. uberis, followed by other major mastitis pathogens, including S. dysgalactiae, S. 
aureus and Klebsiella (Table 1). (Figure 1 near here) 
 
Slide test 
After excluding contaminated samples and those with unidentified organisms, 130 
samples were used to evaluate the performance of the slide test. A milk sample could be 
culture negative or culture positive, contain a single colony type or two colony types (two 
gram- positive morphotypes, two gram-negative morphotypes, or mixed gram-positive and 
gram-negative growth). The latter were considered gram-positive in the gram-positive 
analysis and gram-negative in the gram-negative analysis. The proportion of culture negative 
results was considerably higher for the slide test (20%) than for the reference test (10.8%). 
Of 26 culture-negative samples in the slide test, 12 (46.2%) were correctly classified. Of 14 
false negative slide test results, seven were from samples with gram-positive growth in the 
reference test and seven from samples with gram-negative growth.  
Mixed gram-positive and gram-negative growth was more common in the slide test 
(12.3%) than in the reference test (5.4%) (Table 1). (Table 1 near here) 
The sensitivity of the slide test was similar for gram-positive and gram-negative 
organisms, but specificity was higher for the latter, resulting in higher accuracy for gram-
negative organisms (89.2%) or E. coli (92.3%) than for gram-positive organisms (79.2%), 
(Table 2). For the samples from non-severe CM (n = 109), the potential of the slide test to 
be used as treatment decision support tool was evaluated. Sensitivity and specificity for this 
subset were similar to those for all CM cases (Table 2).  
Mean PPV of the slide test was high (between 92.6 and 98.1%) for growth, gram-
negative results, and E. coli and moderate (between 75 and 80%) for gram-positive results 
(all based on 130 samples) and treatment (based on 109 samples). The mean NPV was less 
than 50% for growth and between 82 and 90.6% for all other outcomes (Table 2). (Table 2 
near here) 
 
Benchmarking against the comparator test 
Despite using a higher inoculum, the slide test gave fewer false positive results for 
growth than the comparator test, resulting in significantly higher specificity. Low specificity 
of the comparator test was partly due to moderate specificity in the detection of S. aureus 
and S. uberis (70.7% and 82.6%, respectively; Supplemental Table S2), which was 
accompanied by high sensitivity for the same pathogens (100% and 90.5%, respectively). 
For sensitivity, there were no statistically significant differences among tests for any of the 
outcomes (Table 2). Despite the greater specificity of the slide test, overall accuracy of the 
two tests was not significantly different. In our study population, the slide test had 
significantly greater PPV than the comparator test for growth, gram-positive, E. coli and 







We evaluated the laboratory performance of a simplified culture-based slide test, 
VétoSlide, which was developed as a potential point-of-care tool to support farmers’ CM 
treatment decisions. Its accuracy for gram-positive organisms in samples from non-severe 
CM (80.7%) is in the same range as commercially available point-of-care tests, including 
the comparator test (VétoRapid) (74.3%, this study), the Minnesota Easy Culture System-
Triplate (81.3%) (Ferreira et al. 2018), Minnesota Easy Culture System-biplate (81 to 84%) 
(Royster et al. 2014), Petrifilm (80.2%) (Mansion-de Vries et al. 2014) and MastDecide 
(58.6 to 85.3%) (Leimbach & Krömker, 2018), although comparisons between studies are 
complicated by differences in study design, populations, and methods of analysis. Such 
differences make comparison of predictive values problematic because they are highly 
dependent on pathogen prevalence, which are farm-specific. Benchmarking of the new slide 
test against a commercially available comparator in a single study allowed us to compare 
predictive values, which are more important in practice than sensitivity, specificity, or 
accuracy. A high PPV means that unnecessary treatment is minimised whereas a high NPV 
means that treatment is withheld only when cows truly do not need it. The slide test 
outperformed the comparator test in PPV and had similar NPV, meaning that the reduced 
risk of over-treating was not accompanied by an increased risk of under-treating. Whether 
positive or negative predictive value is considered more important in informing treatment 
decisions differs between regions. In some areas, such as southern Europe, it is generally 
assumed that antimicrobial treatment of mastitis is needed until proven otherwise (Busani et 
al. 2004). Conversely, in northern Europe, it is assumed that treatment is not needed until 
proven otherwise (Persson Waller et al. 2016). Within countries, this balance may shift over 
time, as illustrated by work from The Netherlands on selective dry cow treatment (DCT). 
Two split-udder trials conducted two decades apart (Schukken et al. 1993; Scherpenzeel et 
al. 2014) in the same country both showed that blanket DCT prevents CM when compared 
to selective DCT. However, the first study concluded that blanket DCT should be used to 
prevent CM despite the need to “eliminate unnecessary use of antibiotics”; whereas the 
second study emphasized the reduction in antimicrobial use that could be achieved by 
abandoning blanket DCT.  
Whether the price of the diagnostic test is worth paying in terms of financial benefit 
is a matter of debate. On farms with a single dominant pathogen, the value of information 
may be limited (Cha et al. 2016), but our data showed that several farms did not have clear 
predominance of gram-positive or gram-negative mastitis over other types of mastitis. Some 
authors argue that even with just 20% of gram-positive mastitis, use of on-farm diagnostics 
would not be cost-effective (Down et al. 2017). Hence, the value of information would be 
farm-specific and no blanket statements around cost-benefit or reductions in antimicrobial 
use can be made based on our results. It is clear, however, that some farms will need further 
training in sample collection and handling to reduce the number of contaminated samples 
and to make investment of time and money into diagnostic testing better value for money. 
Moreover, before uptake of the slide test can be recommended on-farm, evaluation under 
on-farm conditions will be needed, as our laboratory-based analysis included freezing and 
thawing of milk, which would not be part of its on-farm use. Reading of plates at 24 and 48 
hrs, as done here to allow for comparison with VétoRapid results, would cause considerable 
delay in treatment decisions, and shorter incubation times would need to be considered, with 
growth of gram-negative organisms often visible well within 24 hrs (data not shown).   
The reference test used in our study included species identification by MALDI-ToF 





pathogens, e.g. Bacillus and Lysinibacillus species. Although both genera are gram-positive, 
it is debatable whether they should be targeted with antimicrobial treatment because little is 
known about their role as pathogenic agents or their response to treatment. None of the 
currently available point-of-care tests for mastitis have the ability to differentiate such 
organisms from recognized mastitis pathogens. When information at species or subspecies 
level is required for advanced investigations or decision making at herd or animal level, 
laboratory-based microbial diagnostics continue to be important (Mansion-de Vries et al. 
2014). For on-farm treatment decision making, however, the simplified slide test appears to 







  Using laboratory-based evaluation of farmer collected milk samples, we 
demonstrated that a simplified slide test performs similar to the commercially available on-
farm test that was used for benchmarking in terms of sensitivity or accuracy, whilst 
performing better in terms of specificity. The simplicity of the slide test can make it an 
attractive tool for farmers to target antimicrobial treatment of non-severe CM cases caused 
by gram-positive organisms with good diagnostic accuracy. Further evaluation of user-
friendliness, and test accuracy in on-farm settings is needed, followed by assessment of 
uptake, economic impact, and reduction in antimicrobial use. In addition, users’ willingness 
and ability to collect high quality milk samples needs to be understood and supported.  
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Test results of 130 milk samples from bovine clinical mastitis based on a reference test 
consisting of standard bacteriological culture and species identification by matrix-assisted 
laser desorption ionisation time-of-flight mass spectrometry (MALDI-ToF MS) in 
comparison with the simplified slide test under evaluation (VétoSlide, Vétoquinol, Lure, 




Performance of the simplified slide test under evaluation (VétoSlide, Vétoquinol, Lure, 
France) and a commercially available plate-based comparator (VétoRapid, Vétoquinol, 
Lure, France) for identification of mastitis pathogens (n = 130 samples) and as a treatment 
decision support tools for non-severe clinical mastitis (n = 109 samples). Results are 
based on comparison with a reference test consisting of culture and species identification 
based on matrix-assisted laser-desorption ionisation time-of-flight mass spectrometry and 
the difference compares the two tests while correcting for dependence. Values are point 
estimates expressed as percentages, with 95% confidence intervals in brackets. 
 
Supplemental Table S1: 
Farms participating in sample collection to evaluate potential on-farm diagnostics for clinical 
mastitis in dairy cattle. 
 
Supplemental Table S2: 
Performance of the commercially available plate-based comparator (VétoRapid, Vétoquinol, 
Lure, France) for identification of mastitis pathogens (n = 130 samples) based on 
comparison of results at species, genus or group level with a reference test consisting of 
non-selective culture and species identification based on matrix-assisted laser-desorption 
ionisation time-of-flight mass spectrometry. Values are point estimates expressed as 




Sampling results for bovine milk samples (n = 130) from quarters with clinical mastitis by 
participating farm. The number of samples for each farm were, from farm 1 to 7 
respectively, 58, 30, 35, 5, 8, 12 and 10. 
 
Supplemental Figure S1: 
Simplified slide test (VétoSlide, Vétoquinol, Lure, France) and commercially available 
plate-based comparator (VétoRapid, Vétoquinol, Lure, France) for on-farm mastitis 
diagnostics. (A) The green media on the slide allow for detection of gram-negative 
bacteria. (B) Escherichia coli forms red colonies (right panel) and other gram-negative 
bacterial species form white colonies (left panel). (C) The red media allows for detection 
of gram-positive bacteria. (D) Bacterial growth on red media. E. Commercially available 
plate-based comparator (VétoRapid, Vétoquinol, Lure, France) with 3 selective indicator 
media. (F) Growth in the sector selective for gram-negative bacteria. (G) Growth in the 














No growth 14 (10.8) 26 (20.0) 17 (13.1) 
Growth 116 (89.2) 104 (80.0) 113 (86.9) 
Gram-positive only 54 (41.5) 50 (38.5) 55 (42.3) 
Gram-negative only 53 (40.8) 38 (29.2) 30 (23.1) 
Mixed (gram-positive & gram-negative) 7 (5.4) 16 (12.3) 28 (21.5) 
Gram-negative 60 (46.2) 54 (41.5) 58 (44.6) 
Escherichia coli 51 (39.2) 45 (34.6) 50 (38.5) 
Klebsiella spp. 6 (4.6) n/a 16 (12.3) 
Other gram-negative 4 (2.8) n/a 2 (1.5) 
Gram-positive 61 (46.9) 66 (50.8) 83 (63.8) 
Staphylococcus spp. 21 (16.2) n/a 56 (43.1) 
Staphylococcus aureus 7 (5.4) n/a 43 (33.1) 
Non-aureus staphylococci 15 (11.5) n/a 21 (16.2) 
Streptococcus spp. 32 (24.6) n/a 50 (38.5) 
Streptococcus dysgalactiae 10 (7.7) n/a 11 (8.5) 
Streptococcus uberis 21 (16.2) n/a 38 (29.2) 
Other Streptococcus spp. 1 (0.8) n/a 6 (4.6) 
Enterococcus spp. 3 (2.3) n/a 2 (1.5) 
Other gram-positive 13 (10.0) n/a 1 (0.8) 
Prototheca zopfii 2 (1.5) n/a n/a 
1The total number of species/genera listed exceeds the number of samples because more than one species/genus was detected in some samples 
that were not contaminated based on the NMC standard definition of 3 or more colony types (the percentage shown is related to the proportion 
of samples). n/a = not applicable. 
 
Table 2:  
 VétoSlide VétoRapid Difference 
Sensitivity 
Growth 87.9 [80.8; 92.7] 92.2 [85.9; 95.9] 4.3 [-2.2; 10.8] 
Gram-negative  83.3 [72.0; 90.7] 83.3 [72.0; 90.7] 0.0 [-9.2; 9.2] 
Gram-positive (n = 61) 82.0 [70.5; 89.6] 88.5 [78.2; 94.3] 6.6 [-3.5; 16.6] 
E. coli (n = 51) 84.3 [72.0; 91.8] 86.3 [74.3; 93.2] 2.0 [-9.6; 13.5] 
Treatment (n = 56) 83.9 [72.2; 91.3] 87.5 [76.4; 93.8] 3.6 [-6.3; 13.4] 
Specificity 
Growth  85.7 [60.1; 96.0] 57.1 [32.6; 78.6] -28.6 [-52.2; -4.9]* 
Gram-negative  94.3 [86.2; 97.8] 88.6 [79.0; 94.1] -5.7 [-13.5; 2.1] 
Gram-positive  76.8 [65.6; 85.2] 58.0 [46.2; 68.9] -18.2 [-30.4; -7.3]* 
E. coli  97.5 [91.2; 99.3] 92.4 [84.4; 96.5] -5.1 [-9.9; -0.2]* 
Treatment  77.4 [64.5; 86.5] 60.4 [46.9; 72.4] -17 [-30.6; -3.4]* 
Accuracy  
Growth  87.7 [80.9; 92.3] 88.5 [81.8; 92.9] 0.8 [-5.8; 7.3] 
Gram-negative  89.2 [82.7; 93.5] 86.2 [79.2; 91.1] -3.1 [-9.1; 2.9] 
Gram-positive  79.2 [71.5; 85.3] 72.3 [64.1; 79.3] -6.9 [-15; 1.1] 
E. coli  92.3 [86.4; 95.8] 90.0 [83.6; 94.1] -2.3 [-7.7; 3.1] 
Treatment  80.7 [72.3; 87.0] 74.3 [65.4; 81.6] -6.4 [-15; 2.1] 
Positive predictive value   
Growth 98.1 [93.3; 99.5] 94.7 [88.9; 97.5] -3.4 [-6.7; -0.03]* 
Gram-negative 92.6 [82.4; 97.1] 86.2 [75.1; 92.8] -6.4 [-15.2; 2.4] 
Gram-positive 75.8 [64.2; 84.5] 65.1 [54.3; 74.4] -10.7 [-18.9; -2.55]* 
E. coli 95.6 [85.2; 98.8] 88.0 [76.2; 94.4] -7.6 [-14.8; -0.3]* 
Treatment  79.7 [67.7; 88.0] 70.0 [58.5; 79.5] -9.7 [-18.5; -0.86]* 
Negative predictive value 
Growth 46.2 [28.8; 64.5] 47.1 [26.2; 69.0] 0.9 [-18.7; 20.5] 
Gram-negative 86.8 [77.4; 92.7] 86.1 [76.3; 92.3] -0.7 [-7.3; 5.8] 
Gram-positive 82.8 [71.8; 90.1] 85.1 [72.3; 92.6] 2.3[-7.3; 11.9] 
E. coli 90.6 [82.5; 95.2] 91.3 [83.0; 95.7] 0.7 [-5.8; 7.2] 
Treatment  82.0 [69.2; 90.2] 82.1 [67.3; 91.0] 0.1 [-10.7; 10.8] 
*Outcomes where VétoSlide and VétoRapid are significantly different 





Supplemental Table S1: 
Farm Lactating cows (n) Samples collected (n) 
Bulk tank SCC 
(×1000 cells/ml) 
Clinical mastitis incidence per 100 
cows per year 
Milking 
Frequency (/day) Milking parlor type Bedding 
1 795 58 140 28 3 52-point rotary sand 
2 549 30 180 30 3 24 x 48 SwingOver herringbone oat husks and lime 
3 496 33 230 60 3 48 x 48 herringbone sawdust and lime 
4 607 5 145 40 3 24 x 48 SwingOver herringbone recycled manure solids 
5 304 8 195 45 2 24 x 24 herringbone oat husks and lime 
6 296 12 280 65 2 24 x 48 SwingOver herringbone sawdust and lime 
7 276 10 190 45 2 44-point rotary sawdust and lime 
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Figure 1:  
 












Appendix 2: Point-of-care tests for bovine clinical mastitis: What do we have 
and what do we need? 
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Mastitis, inflammation of the bovine mammary gland, is generally caused by 
intramammary infection with bacteria, and antimicrobials have long been a corner stone of 
mastitis control. As societal concern about antimicrobial use in animal agriculture grows, there 
is pressure to reduce antimicrobial use in dairy farming. Point-of-care tests for on-farm use are 
increasingly available as tools to support this. In this Research Reflection, we consider available 
culture-dependent and culture-independent tests in the context of ASSURED criteria for low-
resource settings, including convenience criteria, scientific criteria and societal criteria that can 
be used to evaluate test performance. As tests become more sophisticated and sensitive, we may 
be generating more data than we need. Special attention is given to the relationship between test 
outcomes and treatment decisions, including issues of diagnostic refinement, antimicrobial 
susceptibility testing, and detection of viable organisms. In addition, we explore the role of 
technology, big data and people in improved performance and uptake of point-of-care tests, 
recognising that societal barriers may limit uptake of available or future tests. Finally, we 
propose that the 3Rs of reduction, refinement and replacement, which have been used in an 
animal welfare context for many years, could be applied to antimicrobial use for mastitis control 
on dairy farms.  
 
Keywords: Dairy, clinical mastitis, point-of-care, antimicrobial, diagnostics 
 
 
Setting the Scene: Background and Aim  
Mastitis is an inflammation of the mammary gland, frequently caused by intramammary 
infections (IMI), and occasionally by mechanical or chemical trauma (through teat or udder 
trampling for instance), or when cleaning liquids are mistaken for teat disinfectants. Mastitis 
and IMI are different biological processes that require different diagnostic tools and treatments. 
Mastitis is characterized by physical and chemical changes in milk and, in moderate or severe 
cases, by pathological changes in the mammary gland or systemically. Clinical mastitis (CM) 
can be detected using human senses (vision, touch, and taste, although the latter is discouraged), 
whereas detection of subclinical mastitis (SCM) requires additional tools. With no one-to-one 
relationship between clinical severity and causative agent, the cause of mastitis can rarely be 
detected without further testing. Ideally, mastitis treatment is based on knowledge of severity, 
causative agent and prognosis so that anti-inflammatory, antimicrobial and supportive 
treatments can be selected for maximum efficacy and minimal side effects, which include 
potential selection for antimicrobial resistance (AMR). The contribution of antimicrobial use 
(AMU) to selection for AMR has become of concern due to actual or predicted adverse effects 
in human and veterinary health (O’Neill, 2016). Both quantity and “quality” (or type) of 
antimicrobials are important. The World Health Organization (WHO) has identified Highest 
Priority Critically Important Antimicrobials (HP-CIA) for human medicine (WHO, 2019), and 
suggested that HP-CIA “should not be used for treatment of food-producing animals with a 
clinically diagnosed infectious disease” (WHO, 2017). Quinolones, macrolides and ketolides, 
polymixins and 3rd and 4th generation cephalosporins are all HP-CIA used for mastitis treatment 
and we can do better in this area (Turner et al. 2018; Doehring & Sundrum, 2019). 
Selective treatment is the practice of restricting AMU to cases most likely to benefit 
from treatment and may help to reduce AMU. The phrase “targeted treatment” is also used and 





the default option, which is modified by selecting cows for treatment. Targeted treatment 
suggests no treatment to be the default option, with targeting of treatment to those cows that are 
most likely to benefit. Whilst selective dry cow treatment has been or become the norm in 
several countries (Vanhoudt et al. 2018), selective treatment of lactational mastitis is a more 
recent development (Lago & Godden, 2018). Principles underpinning this approach include the 
notion that AMU must be reduced in livestock; the suggestion that HP-CIA should be avoided 
in veterinary medicine; the recognition that mild to moderate CM caused by gram-negative 
pathogens does not necessarily need antimicrobial treatment; evidence that narrow-spectrum 
antimicrobials are effective against most gram-positive mastitis; and the maxim that  “lack of 
an indication is a contra-indication”, whereby absence of viable bacteria may be interpreted as 
lack of an indication. Each of these principles is subject to debate, to individual differences in 
weighing of available evidence, and to technical or societal opportunities and constraints, which 
explains the wide range of AMU practices on dairy farms. Central to targeted treatment of 
lactational CM is the ability to differentiate mild-to-moderate gram-positive mastitis from other 
forms of mastitis. Point-of-care (POC) testing can make this distinction. For the sake of this 
paper, we interpret “point-of-care” as a tool to inform treatment decisions. Generally, this 
requires on-farm testing, although some commercial diagnostic laboratories or veterinary 
practices may offer a 24-hr turn-around time (TAT) or service.  
In this paper, we reflect on characteristics of POC tests with a focus on CM diagnostics 
that can inform treatment decisions. Specifically, we focus on how such tests succeed or fail in 
addressing professional and societal needs, and how future developments might change this. 
 
What do we need? 
We need to detect CM cases, which is usually done during milking, by people or by 
equipment (reviewed by Hogeveen et al. 2010). Where broad-spectrum antimicrobials are 
advocated for treatment of CM, one could argue that there is no need for further diagnostics. To 
reduce AMU, however, treatment would need to be targeted to a subset of CM cases based on 
severity and causative agent. In addition to reduction in AMU, refinement may be possible, e.g. 
by avoidance of HP-CIA antimicrobials, by use of narrow-spectrum antimicrobials, or possibly 
based on antimicrobial susceptibility of pathogens. Many professionals and scientists accept that 
pathogens such as Mycoplasma spp. and non-bacterial organisms such as algae, (Prototheca 
spp.) and yeast (e.g. Candida spp.) will not respond to antimicrobial treatment and that mild to 
moderate gram-negative mastitis does not need to be treated with antimicrobials (Lago & 
Godden, 2018). Some will also argue that culture-negative mastitis cases are unlikely to respond 
to antimicrobial treatment because there are no viable bacteria to treat, whereas others 
emphasise that culture results may be false negative. Conversely, detection of gram-positive 
bacteria is not necessarily indicative of IMI as it may result from contamination of samples or 
tests, or from presence of clinically non-significant organisms (Nyman et al. 2016). Here, we 
discuss ways to assess diagnostic test performance in relation to diagnostic needs before 
presenting detail of available tests in subsequent sections. 
 
Convenience criteria 
In terms of diagnostic capability, farms are resource-constrained settings. To evaluate 
POC test performance in resource-constrained human health care settings, The ASSURED 
criteria (Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free and 





(sensitivity, specificity) and convenience criteria (“cheap”, “easy”, “quick”), and will be used 
here as framework for discussion of POC tests for CM.  
Dairy production is a sector which often has low profit margins, which might seem to 
argue for tests with low costs, but price is not necessarily a priority (Griffioen et al. 2016). Cost 
may need to be balanced against ease of use, whereby some of the cheapest systems may require 
significant user training and hence staff retainment. More expensive systems may have higher 
ease of use due to automated sample processing, reading or interpretation and may be more 
robust to changes in environment or personnel. There may also be trade-offs between cost and 
time. For example, culture-based diagnostics inherently have a slow turn-around due to the time 
needed for bacterial growth, but they can be very affordable. Conversely, currently available 
DNA-based diagnostics are fast but require expensive instrumentation. The relative costs of 
reagents, equipment and labour may be quite different between countries, a phenomenon that is 
also reflected in the predominance of milking systems (hand milking, milking parlour, or 
automated milking system) in different parts of the world. Whether low-tech or high-tech, good 
diagnostic tests cannot compensate for poor quality samples. Any test applied to a contaminated 
sample is a waste of resources. Surprisingly, not every POC test has “contamination” as a 
recognized outcome. This may mask the presence of false positives and give high test sensitivity 
at the expense of test specificity, potentially leading to “justification” of AMU based on 
detection of contaminants rather than mastitis pathogens. Sample quality, although rarely 
discussed, may be more important than test characteristics. 
 
Scientific criteria 
Diagnostic tests are routinely judged based on the scientific criteria of sensitivity 
(“ability to recognise positives”) and specificity (“ability to recognise negatives”). Tests should 
be validated in the host species and under the conditions where they are intended to be applied 
but most published POC test evaluations are laboratory-based rather than farm-based (Table 1). 
Estimates of scientific criteria are often obtained by comparing the test results with a reference 
test or “gold standard”. Because no test is perfect, no-gold standard comparison or latent class 
analysis is also used (Nyman et al. 2016). Outcomes of interest can be presence versus absence 
or quantitative thresholds, such as counts of colony forming units in plate-based tests, Ct values 
in PCR-based analysis, or optical density in colorimetric analyses. When comparing test 
characteristics across studies, critical interpretation of the results is required as study designs 
(e.g. definitions, reference tests, thresholds used), study populations (animal and pathogen 
populations), and methods to calculate confidence intervals may vary and make estimates for 
scientific criteria study-specific. The summary of POC tests provided in the online 
Supplementary Table S1 should be read with those cautionary notes in mind. For on-farm 
application, predictive values are more important than sensitivity and specificity, but they are 
rarely reported because they are dependent on pathogen prevalence and hence population-
specific. A high positive predictive value means that no unnecessary treatment is given (“treat 
as little as possible”), which achieves the aim of reducing AMU, whereas a high negative 
predictive value means that treatment is only withheld when cows truly do not need it (“treat as 
much as needed”), so that cow welfare is not compromised. 
 
Level of differentiation 
A crucial question is how POC test results inform decision making. Several plate-based 





What do we have?), but the rationale for use of selective treatment for mild to moderate CM is 
largely based on differentiation of gram-positive versus other forms of mastitis. Hence, one 
could argue that a POC test only needs to give information about presence of gram-positive 
organism. In addition, it needs to distinguish between contamination and IMI. If genus or species 
level information influences treatment decisions, however, for example by differentiating 
Streptococcus spp. from Staphylococcus aureus or S. aureus from non-aureus Staphylococci, 
this is relevant at POC level. In some countries, narrow spectrum penicillins are the 1st line of 
treatment for CM, in which case differentiation of penicillin-susceptible and penicillin-resistant 
isolates may be useful, particularly for S. aureus (Barkema et al. 2006). Some POC tests now 
include antimicrobial susceptibility testing (Jones et al. 2019). When susceptibility testing is 
conducted at sample level rather than isolate level, without the ability to differentiate between 
pure cultures, mixed cultures and contamination, the value of such testing to inform treatment 
decisions is unknown. In addition, its value may differ between farming systems and regions.  
For example, predominance of Strep. uberis without presence of Escherichia coli as a major 
cause of CM is uniquely associated with the pasture-based system in New Zealand and 
predictive values from that system may not translate to other dairy-production systems or 
regions (Bates et al. 2020). A recent study suggested a 24% reduction of AMU could be 
achieved when using a POC test with susceptibility testing, yet no change in milk withhold was 
observed, which is surprising as milk of treated cows should be withheld (Bates et al. 2020). 
  
Societal criteria 
Like convenience criteria (cost versus ease of use) or scientific criteria (sensitivity versus 
specificity), societal drivers for POC test use may be at odds with each other. For animal welfare 
reasons, a “security blanket” of broad-spectrum antimicrobials for all CM cases may be 
preferred, but this does not sit well with calls to reduce and refine AMU. From an economic 
point of view, the value of diagnostic tests is situation-specific. Like predictive values, the value 
of information depends on pathogen prevalence. If most CM is caused by a single species, the 
cost of testing may not be outweighed by its financial benefits (Cha et al. 2016). This line of 
reasoning does not account for the potential introduction of AMU quota, which, like milk quota, 
extend the impact of decisions at individual level to other cows in the herd. 
 Societal concerns may also exist around work health and safety. On-farm bacteriology 
by non-experienced people is forbidden is some countries because of concerns about 
propagating pathogens, including hazard group 2 pathogens which can infect and kill people. 
Several major mastitis pathogens belong to this category, including E. coli, Klebsiella spp., S. 
aureus, and Streptococcus agalactiae (Zadoks et al. 2011). In addition to concerns about 
hazardous waste, environmental implications of POC testing may need to be considered. Ideally, 
POC tests would use materials that are bio-degradable or come from renewable sources. 
 
What do we have? 
We currently have POC tests that detect mastitis (inflammation) or pathogen presence 
(Adkins & Middleton, 2018). Inflammation is an indirect measure of infection whereas 
pathogen detection is a direct measure of infection, with the caveat that pathogen detection 
without evidence of inflammation may not be sufficient evidence for IMI nor adequate 
justification for AMU (Nyman et al. 2016). All currently available on-farm diagnostics for 
pathogen identification are culture based (online Supplementary Table S1, whilst culture-






Culture-dependent pathogen information 
Several formats are available for culture-based POC tests, including petrifilm, agar 
plates, and tube-based systems. Some identify bacteria as gram-positive, gram-negative, or 
absent, e.g. MastDecide, Petrifilm, Point-of-Cow, and VétoSlide. Others identify bacteria to 
genus and species-level, e.g. VétoRapid, Minnesota Easy Culture Tri-plate, Accumast, SSGN 
plate, Hardy Diagnosis Triplate, Micromast, Dip-Slide Mastitis, Selma and Selma Plus. Some 
assays include antibiotic susceptibility testing, e.g. Mastatest, Point-of-Cow and Speed Mam 
colour. All tests are more reliable when used for diagnosis of broad categories (growth, gram-
positive, gram-negative) than at genus or species level (Lago & Godden, 2018). Broad 
categories may suffice to inform treatment decisions but for culling decisions, more detail or 
accuracy can be desirable. For such decisions, however, TAT is often less critical, and 
laboratory-based testing may be more appropriate than on-farm testing. 
Reported sensitivities for gram-positive bacteria range from 58.6% (MastDecide; 
Leimbach & Krömker, 2018) to 98% (Minnesota easy culture system Bi-plate; McCarron et al. 
2009a), and specificities from 48% (Petrifilm; MacDonald, 2011) to 97% (MastDecide). The 
inherent trade-off between sensitivity and specificity tends to limit accuracy, although 
exceptions exist, e.g. for E. coli (online Supplementary Table S1). Low pathogen prevalence in 
POC test evaluation studies will result in wide confidence intervals around point estimates for 
test characteristics. Interestingly, Strep. agalactiae is a major pathogen in many emerging dairy 
industries but almost no information is available on accuracy of POC tests for this organism 
(online Supplementary Table S1). The market that is currently targeted for POC testing 
presumes a certain standard of farm management, which would generally be associated with 
successful control of Strep. agalactiae. Accuracy also depends on observer skills. For example, 
the ability to detect S. aureus based on haemolysis depends on the population under 
investigation and the experience of the reader (McCarron et al. 2009b). Petrifilm or agar-based 
tests tend to involve relatively cheap equipment and reagents. However, they require 
considerable user training, as well as sufficiently high throughput to maintain user skills. Agar-
based tests often allow for easy visual identification of sample contamination, which is 
important to monitor sample quality. Unfortunately, not all user manuals provide guidance on 
the distinction between positive and contaminated samples, or its importance.  In recent market 
introductions, such as Point-of-Cow and Mastatest (Jones et al. 2019), consumables and 
equipment are more sophisticated and more expensive to increase ease of use. Although the test 
is run on-farm, data interpretation may happen off-farm, using cloud-based computing systems. 
Issues around data confidentiality and data ownership in such systems may need further 
consideration, especially if test data is combined with data at cow or farm level. Culture-based 
tests all have similar TAT of up to 24 hrs. Although this is fast enough to inform decision 
making, farmers would prefer less delay with turn-around from one milking to the next 
(Griffioen et al. 2016). 
 
Culture independent pathogen information 
Commercially available culture-independent pathogen detection systems are currently 
based on polymerase chain reaction (PCR), a method to selective amplify target DNA of 
interest. Targets may be genus specific, species specific, or indicative of AMR, as in the case of 
the blaZ gene encoding penicillin resistance in Staph. aureus. DNA amplification is possible 





pathogen detection in culture-negative samples. This is probably more relevant for samples that 
are shipped to a laboratory than for POC testing and use of PCR is largely limited to professional 
laboratories. Whether detection of bacterial DNA in culture negative samples provides 
justification for AMU is an open question (Nyman et al. 2016). Growing recognition of the 
existence of a mammary microbiota, and descriptions of mastitis as a “dysbiosis”, suggest that 
presence of DNA in low quantities may be normal. Studies on associations between treatment 
and cure have historically been culture based. If or how treatment impacts on the outcome of 
CM cases with PCR-positive, culture-negative results is untested. 
 To combine the scientific characteristics of DNA-based testing with the convenience 
characteristics of on-farm testing, loop-mediated isothermal amplification (LAMP) of DNA is 
explored. This test uses different chemistry than PCR, requires less sample preparation, and is 
less sensitive to inhibitory substances present in biological samples (Bosward et al. 2016). It 
can be configured as a pregnancy test-like lateral flow device, which could be a rapid and cost-
effective on-farm diagnostic (Cornelissen et al. 2016). LAMP has received attention in the 
scientific literature as a means to make molecular diagnostics feasible and affordable in low 
resource settings. Its implementation as on-farm POC test for CM is hampered by heterogeneity 
of mastitis pathogens and resistance determinants and the limited ability for multiplex testing. 
The latter may be addressed through developments in microfluids (see Future developments). 
 
Future developments 
Technological development progresses extremely quickly, demonstrated by 
revolutionary changes in computing, mobile phone technology, and DNA-sequencing over 
recent decades. The biology of CM in dairy cattle has not changed as much over the same period, 
although developments in genetics and husbandry have led to significant shifts in milk 
production and predominant pathogen populations in developed countries. Societal attitudes 
towards AMU have changed more recently and influence availability and use of antimicrobials 
for CM treatment. Possibly most resistant to change is human behaviour, which drives the need 
for as well as the development and uptake of diagnostics. In this section, we discuss 
opportunities to harness the power of the technological revolution, the data revolution, and the 
people that milk or manage cows (Figure 1). 
 
Harnessing the power of technology 
Advances in microfluidics allow development of technologies that can be incorporated 
into automatic monitoring systems and portable devices for sensitive and rapid mastitis 
diagnostics (Viguier et al. 2009). After somatic cell count, perhaps biomarkers such as acute 
phase proteins (APPs) are the most widely studied inflammatory biomarkers in milk. 
Haptoglobin (Hp) and milk-amyloid A (MAA) are especially prominent members of this group 
in dairy cattle and both are synthesised locally in mammary tissue. To inform treatment 
decisions, biomarker patterns would need to be pathogen-specific. Whilst there is some evidence 
to support this approach, which could be enhanced by multiplex assays linked to machine 
learning technology (see next section), it is not always clear whether APP profiles reflect 
severity of inflammation or causative agents and concerns exist about sensitivity and specificity 
(Pyörälä et al. 2011). Small inflammatory mediators such as cytokines and chemokines have 
shown significant promise with proteomic platforms differentiating the host response to 
different pathogens (Kusebauch et al. 2018), and progress is being made in the development of 





line between biomarker detection and pathogen detection is blurred, as culture-free pathogen 
detection becomes feasible on microfluidic devices popularly known as “lab on a chip”. One of 
the key challenges in the development of such devices is the need to detect multiple targets. We 
are not aware of developments aimed at differentiating gram-positive and other causes of 
mastitis, although identification of a few major gram-positive mastitis pathogens might suffice 
to support on-farm treatment decisions. If so, paper-based multiplex LAMP assays may provide 
a low-cost option that is fast, microbiologically safe (no pathogen amplification, paper can be 
burned after use) and environmentally sustainable (Reboud et al. 2019). 
   
Harnessing the power of data 
Technological developments should be accompanied by developments in data analysis 
to maximise the benefit from increasingly sophisticated biomarker or pathogen detection 
systems. 
Machine learning methods became popular for many applications in which predictive 
performance is the main aim. This type of narrow artificial intelligence has been applied to 
mastitis diagnosis, focusing on real-time detection from milking data. Artificial neural networks 
(ANN) and tree based models perform best in this context (Ebrahimie et al. 2018; Ebrahimi et 
al. 2019), linking parameters such as milk yield, electrical conductivity, and lactose level to 
SCM. This black-box type of model is optimised for prediction at the cost of interpretability, 
which is a good trade-off for real-time mastitis diagnosis. Adding more layers of weights to 
ANNs gives rise to the “deep learning” models that are successful in many fields. Dhoble et al. 
(2019) recommends neural networks also for label-free flow cytometry data to routinely screen 
for mastitis. 
By contrast, simple classification tree models are easy to interpret, and cut-off values 
calculated from them are easily applicable in POC tests such as lateral flow immunoassays. 
More complex models (random forests, gradient boosted trees) gain predictive accuracy at the 
cost of interpretability (Ebrahimi et al. 2019). Like neural networks, complex tree models are 
mostly black boxes to the user. Machine learning methods are more flexible than classic 
multivariate statistical methods, requiring fewer assumptions about the data generating 
mechanisms and independence of various measurements. They can combine multiple data types 
into a single prediction model, making them useful for mastitis diagnosis based on a 
combination of demographic, epidemiological, milking, flow cytometry, and biomarker data. 
However, the lack of human oversight in the model specification process is also the drawback 
of many machine learning models. Biases in the data on which these models are trained tend to 
get reinforced in the model fitting process, reducing the applicability of the model to the wider 
animal/farm population. Training data sets should therefore be representative of the target 
population, and also relatively large to avoid overfitting.  
In the era of cheap sensors, the goal will be to develop rapid (semi-)automated diagnostic 
systems that apply artificial intelligence to real-time data streams (e.g. from automated milking) 
and biomarker information to distinguish between gram-positive and gram-negative pathogens. 
Differences in baseline parameters between farms will pose a challenge, which can be overcome 
by either standardising the machine learning models, or retraining them for use on new farms 
(Ebrahimi et al. 2019). Ideally, data from diagnostic systems would be combined with 
prognostic factors, such as duration of infection (SCC and CM history), parity, as well as 
measures of cow value (genetic merit and lactational performance) to weigh the probability of 





are limited but suggest the importance of similar factors across multiple gram-positive 
organisms (Barkema et al. 2006, Samson et al. 2016). 
 
Harnessing the power of people 
Scientific research has generated sufficient knowledge to support targeted treatment of 
non-severe CM based on pathogen identification and cow factors. However, this knowledge is 
hardly implemented and farmers frequently experience “insecurity” and “uncertainty” about 
mastitis treatment (Swinkels et al. 2015). Such feelings may motivate farmers to seek social 
approval and emulate peer behaviour, for example by extending treatment where increased 
AMU is perceived to be “better” (Swinkels et al. 2015). Ideally, the same social phenomenon 
would be harnessed to reduce AMU, e.g. by training “champions” of antimicrobial stewardship 
and using peer networks to spread prudent AMU. Farmer-led approaches rather than traditional 
passive knowledge transfer methods may be the best way to motivate change in AMU or POC 
test use (Bard et al. 2017). In addition, communication approaches like motivational 
interviewing, which are designed to facilitate clients’ internal motivation to change may 
improve uptake of veterinarian advice (Bard et al. 2019; Svensson et al. 2019). Demographic 
factors and affective attributes, such as a veterinarian’s age, respectfulness and dominance, or a 
farmer’s education level also influence farmers’ satisfaction and willingness to adopt veterinary 
advice (Ritter et al. 2019). Such insight could be implemented to promote POC tests uptake and 
targeted treatment approaches. 
Farmers and veterinarians are part of food production and health care systems that may 
provide barriers or incentives for behaviour change. Perceived barriers at farm level include lack 
of time, economic investment with no financial short-term benefits and labour shortages (Ritter 
et al. 2017). Drivers for uptake may include improvement of cows’ welfare and farm 
profitability, long-term job satisfaction, reputational benefits in relation to consumer demands, 
social recognition and pride, and the desire to conform to perceived standards of “being a good 
farmer” (Swinkels et al. 2015). In some countries AMU quota have been implemented 
successfully or recommended to reduce AMU (Bos et al. 2015; O’Neill, 2016). Benchmarking 
of individual AMU against average AMU of peers or at national level can provide a sense of 
being part of a nationwide reduction campaign and may encourage POC test uptake, as farmers 
are more inclined to assume their responsibility as a part of joint effort (Ritter et al. 2017). It 
would be naïve, however, to ignore the role of commercial drivers in uptake of selective 
treatment to reduce AMU. Many veterinarians generate income from sales of antimicrobials, 
and this may serve as a disincentive for promotion of targeted treatment. In many countries, 
antimicrobial use and sales are not under veterinary control, which makes the issue even more 
complicated. Contracts and demands from milk processors and retailers may override 
preferences or recommendations from farmers and veterinarians. The balance between “stick” 
(forced reduction in AMU) and “carrot” (financial and reputational benefits from reduction in 
AMU) will differ between countries and production systems and change over time.  
 
Final thoughts 
The 3Rs of Reduction, Refinement and Replacement are well known in the context of 
experimental animal research. The same concepts could be applied to antimicrobial treatment 
of mastitis. Reduction can be achieved if AMU for non-severe CM is targeted to gram-positive 
IMI only. As reviewed here, this may require further improvements in convenience 





behaviours among veterinarians and dairy farmers. Behaviour change should also include 
refinement, whereby we should abstain from the use of HP-CIA in dairy cattle (Turner et al. 
2018). Professionals in the dairy industry, processors, retailers, pharmaceutical companies and 
regulators all have a role to play in reduction and refinement as they buy milk, or produce, 
approve and market antimicrobial products. Ideally, refinement of herd management practices 
would reduce the incidence of mastitis and the need for treatment. The concept of replacement 
is used in dry cow treatment, where internal teat sealants increasingly replace antimicrobials as 
tools for infection prevention. To some extent, anti-inflammatory and supportive therapy can 
act as replacements in treatment of lactational CM. They are not causative in removing the 
infectious agent but contribute to a successful host response. Alternatives that target mastitis 
pathogens, such as biocins and phage therapy, require further development (reviewed by 
Angelopoulou et al. 2019).  
Regardless of the need for further research on replacement, we already have the tools 
and the knowledge to reduce and refine the use of antimicrobials in treatment of lactational 
mastitis. The onus is on the veterinary profession, the farming industry, and associated industries 
and regulators to decide how best to incentivise and implement them. 
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Point-of-care tests for bovine clinical mastitis. What do we have and what do we need. 
 
Table legends: 
Supplemental Table S1: 
 What do we have as point-of-care (POC) tests for bovine clinical mastitis? 









Table S1. What do we have as point-of-care (POC) tests for bovine clinical mastitis? Characteristics summary of point-of-care tests available on 
the market for pathogen identification. (Table 1 near end section “3.1 Culture-dependent pathogen information”) 
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Table S1. (Cont.) 
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Using Aerobic Count & 
Coliform Count together: 




Staph. aureus (Staph Express 
Disk) 
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Table S1. (Cont.) 
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 aGram+ve, bGram-ve/coliform, cE. coli, dS. aureus, eS. uberis. NA: Information not available, NV: not validated 
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